Resveratrol and Its Effects On Human Health and Longevity

Resveratrol and its Effects on Human Health and Longevity - Myth or Miracle?
JaMEs BETz Founder and CEO of Biotivia Bioceuticals, LLC
Truth Publishing International, Ltd ? P. O. Box 29-99 Taichung, Taic hung City 40899 Taiwan ----------------------- Page 3----------------------All information contained in this book is copyright 2011 by Truth Publishing, In c. All rights reserved. All information contained in this publication may not be copied , published, distributed, broadcast, posted on the internet, or otherwise used for any purpos e whatsoever without the prior written consent of Truth Publishing, Inc.
CAT 217381
For information regarding this and other Truth Publishing books, please contact Truth Publishing International, Ltd: www.TruthPublishing.com/Contact
Disclaimer: This book is offered for information purposes only and is protected under freedom of speech. It is not medical advice nor should it be construed as such. Nothing in this book is intended to diagnose or treat any disease. Always work with a qualified health p rofessional before making any changes to your diet, prescription drug use, lifestyle or exer cise activates. This information is provided as-is, and the reader assumes all risks from the us e, non-use or
misuse of this information. The information in this book is not suppo rted by conventional medicine or most physicians. It is, however, the truth. ----------------------- Page 4----------------------Contents
Introduction 1
Resveratrol
versus penicillin 3
The l
scientific
community
recognizes
resveratrol s
potentia
Vintage wine
versus a 6
lowly
weed
Can a humans?
molecule
that
protects
plants also
protect
Why
smaller is 12
better
Resveratrol
and
aging, life 13
spanversus
health span
Most wrong
of
what
you
think
you 15
know
about
aging
is
Why
are
we
aging 22
faster but
living longer?
prescription
for 24
longevity
What
the
science says 27
Resveratrol
human clinical 27
trials
A nt
guide
to
selecting
a 33
quality resveratrol
suppleme
Gimmicks
to
watch
our 39
for
Five essential provider
criterion
to
41
pick
resveratrol
Future Prospects 44
Scientific
studies confirming 47
statements
and
claims
----------------------- Page 5----------------------acle? Resveratrol and its effects on human health and longevity - Myth or mir
Distributed by www.NaturalNews.com
Introduction
Is resveratrol, as breakthrough discovery destined health and vention and ics; or to the make pre-
many a of
scientists
believe, to
a human antibiot
greater contribution age-related
treatment is it
disease than
only another false dollars and talent away world needs now to from treat
promise which the an
is
taking scarce research of pharmaceuticals the
development aging
population?
With r s
obesity, disease and
diabetes,
coronary
disease, levels in the
Alzheime develope and
cancer reaching near d world, surely a compound treatment with the powers
pandemic putative
disease prevention dismissed
of resveratrol cannot be scientific investigation. Only and pharmaceutical , companies and only five had a years
without extensive scientists natural compound any effects.
ago
physicians, of this
barely heard and
handful of scientists real knowledge of the molecule s
physicians health and
possessed wellness
potential
The was on shown
first not the the
high-strength even consumers potential in
resveratrol radar. A life at span,
supplement, few and
Bioforte,
animal studies had a in few hundred
for increases investigations primarily and
by researchers China elucidated
universities
Japan, India with could that only respect be had to
resveratrol s to cancer and said for of at other one
chemoprotective properties, diabetes. hundreds However,
particularly the same drugs lab,
phytochemicals and time or
synthetic the
another shown promising be shuttled off
results in to
oblivion the same mammals,
when scientists effects in especially humans.
were
unable to
replicate
One that
intriguing caught the
and
rather unique aspect of and the
resveratrol public was
attention of its ability to
both researchers extend
the rol,
lifespan of for example, the
some lived same
animals. 59
Fish
fed
resverat Obese of
percent longer than mice lived the mally
species without resveratrol. managed to and obesity. avoid all
31 percent longer and diseases norassociated with aging
The big however,
missing element in was a human Very
the clinical
resveratrol
equation, major also what bioavail
lack of published medical schools and research about the tial might institutions. potenof a
trials by then known
little was in about about
toxicity constitute
resveratrol correct concerns questions Some
humans or the its low possible
dose; and ability of ratrol, as estrogenic
there were resvewell as effects.
scientists to avoid veratrol y the
speculated resfor this opposite has a and as this
that
women
might now in
be know a agent are life
best that
advised precisel
reason. We is been shown powerful chemotherapeutic
true. Resveratrol studies to be chemoprotectorant cancer. It the seems study that, of new light
wealth of against breast devoted to applications
more resources potent quality of
molecule, come to a
medical and on
regular basis.
As the replicated,
results of and
the research critical
earlier studies were teams
successfully world
new investigations by uncovered a virtual laundry list of signaling pathways and small cule, in other moleimportant in US 2010, a were
around the factors, this
transcription
pharmacokinetic effects of resveratrol and there were increased over 4,000
very
interest Asia, the late resand only
exponentially published was developi
Europe. By studies on veratrol ng. Not scientists positive as one molecule approaches and modes of rate.
remarkable
consensus and examined
finding unusually results, institution after using different and technologies, being these of and
consistent the but other
replicable the new effects
fundamental at have of an
action were Many of
discovered resveratrol treatment
astonishing huge
diverse properties implications for the prevention
potentially human disease.
Only time antibiotics the to at In top human this terms
will to
tell take
if the
resveratrol most
manages to
unseat
spot as health, but point of in its
important cannot be
contributor counted out. such as
time it beneficial to
properties diabetes, cular is
relative cardiovas-
chronic conditions fitness, race has
diseases, many a strong confor
cancers and the
resveratrol just begun.
tender and
resveratrol
Resveratrol
versus penicillin
In an technology in March opinion, the space regarded scientific on I ring ly
interview magazine 2009, I resveratrol of as 20 a
with told will, or more than
a the in
well-known journalist;
international In to this to human my be predicti positive race. at
30 years, come important penicillin. In
development was refer-
to this impact the
small molecule s health, quality of my scientist took life
potential of the
longevity, and Seven months after interview, a Harvard University
researching
resveratrol
this prediction resveratrol will more important
one be than
step all
further by antibiotics.
proclaiming
that
Penicillin credited many rol from has
was with
discovered saving if not isolated source in as a in was Asia first
in
1928
and of the than a
has
been
thousands, was first a been plant used
millions, 1940 in tradifor more
lives. Resverat West, 2,000 but years.
tional medicine In 1970 it characterized as that protects human such poor a tissue from as
a chemopreventive, healthy the
substance various agents example of protect
disease-causing effects of viruses and of low aging. An dose
diet, bacteria, chemopreventive the use attacks.
would be against heart
aspirin to
Both a cacy, from
penicillin and long history of are a derived from common
resveratrol, effinatural sources; found
like
most
drugs
with comes
penicillin in a
fungus, and resveratrol is plants including grapes,
variety of
peanuts and
cranberries,
but
most
importantly
in
the
Japanese Knotweed knotweed has medicine disorders, acquired
Giant plant, also been to used treat known as Polygonum-cuspidatum. as a Giant
in Asia immune neurological as its
traditional The plant
cancer, and a
conditions. a
rather unsavory ut Southeast Asia the and ago for on
reputation
foreign invader througho survive in years articles
and Japan, owing to harshest conditions to a giant how crowd out other Google search knotweed would to exterThe same studies its
ability to
plants and return hundreds would
crops. Five of be
minate it. scientific elucidating
search today
filled with
astonishing
medical and
health applications.
The scientific
community resveratrol s
recognizes potential
In of
September resveratrol
2010 re-
the about
first a
international one-hour event, over institutions
conference train 120 in findings to I the am ride of the
searchers outside of
was held Copenhagen,
Denmark. At this the world s leading scientists from US, Asia, prestigious India,
milestone research met to and
Europe and Australia on resveratrol. After attending presentations this of
present their listening scientists, of
conference these
distinguished and now convinced that, with
highly accomplished my ex-
if anything, penicillin was
comparison
resveratrol
tremely conservative.
Resveratrol functional foods , that will
and
the
drugs, treatments, tiny but
supplements
and
contain this eclipse importance some propits 2010, 800
incredibly generation. studies on From 2005
potent molecule From 1940
penicillin s until 2005, there were biological erties and middle of have and
within one published
resveratrol s until the
health benefits. there than 3,000 new
been more humans.
studies on are being
cells, animals, announced
New and surprising almost weekly
revelations
now by organizations to
the
leading universities, of of on of
medical schools and these discoveries
research add
around the world. All our knowledge of range ideas good
resveratrol s remarkable on effects and gives knowledge mankind. us for new the
health and how to
disease preventi apply this
The reservations science journal-
expressed
by
some
physicians
and
ists or
a over
few years estimation of new
ago of
about
possible have are been being
side
effects,
the benefits refuted; and previously as more devoted to remarkable
resveratrol, benefits human clinical when an
almost entirely revealed this
unimagined funding is animal and natural
trials of we of face
chemical. At drug resistant explosion levels of bilitating forms of and that
a time bacteria,
multiple pandemic other clear
in the obesity, increases dementia,
incidence dein
diabetes, disease and is
Alzheimer s
many other resveratrol whose
diseases is a time has
of aging, it chemocome.
preventive
No has
single molecule shown the of life
or potential of
drug
known
to
medical science and been extend
wide range quality of enhancement shown to cancer, kill life span animals, free
preventative, resveratrol.
therapeutic, It has
properties inhibit bacteria, in
viruses and
fungal infections, in
improve energy production
cells, quench damaging in diabetics, concentration, and
radicals, increase improve cardiac function, enhance physical repair damaged DNA, much more. prevent cell
glucose tolerance and
mental fitness and
damage from
nuclear radiation,
Penicillin has combat bacterial
been shown infec-
to
have
one
use:
to
tions. Its the past years as resistance Time as will a
effectiveness twenty many to
has
been
greatly diminished have fulfill its
over acquired promise
strains of it.
harmful bacteria does
tell if so-called but the
resveratrol miracle only
molecule, percent of
if it health and
proves to attributed
possess 10 to it
medical benefits so far, it
researchers have will indeed
make in,
a and
greater contribution all antibiotics.
to
human
health then
penicill
perhaps even
Vintage wine
versus a
lowly
weed
Given all benefits wine and naturally that the scientists ment skin does is too this
of of
the recent publicity drinking French Paradox,
about
the one used
health would by the
the so-called assume
principal source of and supplethe red grapes amounts of make wine
resveratrol
makers is of red contain small much low to compound.
grape. Although the
resveratrol,
concentration source of
grapes an
economical
Another problem with grapes is the difficulty in es, fungicides,
the
extraction the
of residues
resveratrol from fruit only to by
from pesticid while poses reduce the
removing and other
agricultural chemicals it ripens. The
needed to
protect the not tends
application of agricultural a serious problem from the contamination natural proby
chemicals also
toxins, but and other is
duction of grape. The concentration that are by much
resveratrol highest
antioxidants found too also of in
of resveratrol stressed weather, lack
organic grapes too wine quality.
fungus, unfavorable water and a
little or lower the
of pesticides. These production levels but often result in
conditions a wine
outstanding
If the inadequate
amount of resveratrol to explain the what is the the
in
red
wine
is
French Paradox then 40 percent less heart anyone who spent is fats a time high
reason the
French suffer As diet from
disease than has in in
average westerner? typical French urban
France knows, the other this
and salt and health standspite far of lower
less-than-ideal ingredients fact, the
point. In to have rates s. of Even
French people tend do American tobacco-
cancer and are
cardiovascular disease than relatively low
lung cancer rates loving French
amongst the
citizens. age of any other believe that full range accounts
Furthermore, 100 than European it is of for
France has country. the not
more Many only wine.
people over scientists resveratrol,
the now which
polyphenols, the drinking
chemopreventive effects of
There is Paradox. American Americans
another paradox, The Paradox refers to are fed rate and
which the most
is fact
called the that even
American though
amongst the best the world, their of more tes high other US low heavy mortality recently, and the compared
affluent heart disease, is consumption and UK and and with heavy
people in and extraordinarily in diet other the is chemical laden little exercise on
from cancer and diabeeffects of to many obesity, Wine
developed countries. is relatively and on the bad
typical American fats, red meat growth hormones foods along a
raised on s, high tose corn burgers and fast ,
antibiotics, fruc-
syrup, processed other factors, stress, sleep, and
chemical too reliance
foods. These too much
not enough sound pharmaceuticals to
treat chronic conditions, serious diseases in health span. the US.
surely account for They also
much
of a
the shorter
result in
Health span free of diseases age of avoid ns
is the of 85
the number of so-called
years
a dies
person lives at the conditio longer of life
aging. A person who who manages to heart disease and has age impaired after
cancer, diabetes, such and a
neurological a many far years
as Alzheimer s health span than who dies intensive ment due and and to
dementia person
at the same medical treata dramatically chronic disease
quality of
incapacity.
So, of
if grape resveratrol,
skins then
are what the were would Giant
not Japanese a
the
preferred Giant Knotweed of
source
is? The plant, aka
answer is Polygonumthere it
cuspidatum. If plant kingdom, surely be Japanese
master ninja
the
Knotweed.
This and
voracious predator most aggressive
is
one
of
the
toughest
plants in be much
existence. like any
Above green
the
ground it but can of this hot
appears to under the
other docile flowering surface its roots tell a gnarly, hard, brown oak good like. in and mass tree, idea It high in different dense, thick that you
perennial you roots of
story. If the roots well
imagine a a plant and in in mature look cold, more an is
resembles have a the as
of what thrives just and wet low or
altitudes, in arid climates. grow once stronger
It seems to hostile environments. an area,
actually It is
aggressive invader and, will overwhelm vegetation it has up
established few building
existing so tough to grow
within a been known
years. It
through concrete
foundations.
In waged local it.
Japan by
and parts farmers and
of
Europe, a
fierce battle is at least control
councils to In mid-2010, the the of the
eliminate or the governthe to
ment of approving importation roots of
United Kingdom took a worm Polygonumin invasive of if a known
extreme measure of thrive on the
cuspidatum plant rid England and Wales who to will even is plant or of have the tried
rather desperate weed. Japanese root British and Giant of
attempt to Asian Knotweed one plant year farmers
remove infestations tell you that one left will two. centimeter in the return with
of the ground the a
vengeance
within a
This the
obnoxious resveratrol of a
plant used
is in
the
principal
source of humans. It and Tibet.
thousands is also year-old
studies on 2,000medicine
cells, animals and in China
traditional
Resveratrol for this and many peanuts, and is
functions plant others. Although blueberries,
as
the
immune and is of rich names
defense systems found in
resveratrol concentration the plant source of with
many other highest in Not is
plants, the only also is a
resveratrol in like are resverat polydati only analogs
Knotweed. rol, it other n,
natural protective pterosand to Some be
compounds
tilbene, beginning vestigate. appear to
emodin, which inof even these
western scientists so-called
resveratrol
more potent than diseases and ing health.
resveratrol improv-
in
fighting
specific
Pterostilbene, for chemically to resveratrol, has
example, been shown
a to
compound
closely related mental
reverse decline in
function rats than whose res-
in cerebrums or any lowering were chemically damaged even also the has better potent
veratrol cholesterol
pharmaceutical. It believe that
properties. Many and medical effects will chemopreventive plant polyphenols,
scientists
optimum health with other
follow from extracts and
combining such one as
resveratrol
pterostilbene, fruit-based and researcher as
other phytochemicals. As recently stated, Antioxidants players in symphony are a
physician acts, they
not solo diverse
perform best
orchestra.
Can
a also
molecule
that protect humans?
protects
plants
In to as e in , much or The also
2006, scientists resveratrol a that response insects, sunlight, infection. theory of provide proearly
working at
Harvard began is plant as plant these
referring a substanc
hormetic. A is produced to heat, which
hormetic by a such the is that
stresses and too protects
fungus, bacteria against damage substances the
zenohormesis warning of who in
tection and animals in their whole the plant as
environmental
threats to
vicinity plant or, case of compounds, in a
consume them,
either by form
eating the of the
humans, a such supplement.
concentrated
Hormetics, such act directly illness or They do
as on
resveratrol, the
do as
not do
normally most drugs.
biological stressor, not function like such as
conventional medicines cancer drugs, and y
antibiotics, nor do
painkillers, they generall
blood pressure regulators; possess the toxic-
ity s
of work
synthetic by processes
drugs. These within the
natural plant-derived animals stress and own
compound cells and
kick-starting organs, which
attack disease or ental factors.
protect against the
harmful environm
One example of animals is its ability to certain pro-
way
in
which
resveratrol by
protects
prevent and
reduce inflammation the other body in
suppressing to
teins produced by infection, injury, and stresses.
response
It is simply being symptom of
now a
well
known once
that thought,
inflammation, is
rather then itself the
disease as
cause
of
many We that
human have very inflamcompelling evidence, diseases as many for
afflictions. example, mation plays such as gies other heart
a key arthritis,
role in aller-
autoimmune as well
and multiple sclerosis, illnesses including disease, diabetes and
Alzheimer s
disease.
When resveratrol reduce inflammation. cells
is
consumed activates that This
it
does
not the
directly body s
Instead, it and proteins
systems in is not proteins why a
reduce inflammation is called a lator or regulator or genes treat its a works
naturally. regu-
resveratrol drug. and A even
potentiator, and by activating
deactivating various enzymes, to prevent or the cause symptoms. of a
problem,
not
simply mask
When c
is drug
the that
last time actually Resveratrol of that
you cured inhibits are and
heard
of
syntheti by anti-inf
any disease? activating many the same lammatory
inflammation activated precisely by targeted
processes drugs, but
in a more manner. Comparing veratrol with is analogous to Resveratrol flammation processes the not
sophisticated res-
NSAIDS, non-steroidal a
anti-inflammatory a the It bread
drugs, knife.
comparing reduces inwithout also that
scalpel to with
interfering inhibit.
beneficial also does
anti-inflammatory drugs have the unwanted
0 ----------------------- Page 15----------------------acle? Resveratrol and its effects on human health and longevity - Myth or mir
side and
effects of the more next
drugs such recently generation
as
aspirin,
ibuprofen, drugs.
released
anti-inflammatory
The manner in example of its rol selective, inhibits
which
resveratrol
attacks cancer is effects on
another
almost intelligent the cells insmall
cells. Resverat differen a areas side a
growth of cancerous t actions. It hibits the tumor, but stimulate of the referred effect of drugs, which cancerous also such works as growth of does not the body, to the
through a blood
number of feed other one to
vessels that tumor which to is blood
spread of the a process as metastasis, anti-cancer
also inhibit the tumor. It by Tumor activating an
supply of or
deactivating
certain proteins
Necrosis that characterizes protein which linked to
Factor, TNF, many is
important by
immune system molecule NF-kB, a
tumors, and
suppressing humans.
almost all
cancers in
Many the
of same
these anti-cancer effects
effects of
resveratrol
are
that of
the pharmaceutical companies dollars to in more new ef-
are
spending
billions
reproduce of the fective drugs to the as death the the well race
pharmaceuticals. today are also
Unfortunately, many highly poisonous it is a
being used patient as for to the
the tumor. Often patient between the
drugs toxic cancer.
effects and
growth and
spread of
One oncologist Hospital in Very days. sive most few With
I spoke Houston said; actually as they
to
at dying
M.D, of
Anderson cancer these and surgery
people are aggressuch the if the
treatments die of
chemo, radiation are lucky they
therapy first, or the cancer and treatment.
survive both
This as or more
is a
not to treatment
propose the use for cancer, that
of
resveratrol need much
any other actual human data 4000
disease for and plus
matter. We of the
clinical in the studies, we can with as
confirmation
results seen before
trials and say
investigations already completed resveratrol studies is as
confidence that the laboratory
effective
indicate It may that some effective drugs know the their will for case ef-
it well
should be turn out of best in
against any resveratrol strategy
specific and to the
disease. more
combination anti-cancer be the example that, of and It that be some
pursue. We improves side Pterosti presentl
chemotherapy severity
agents, resveratrol of their as is
fectiveness effects. turn out lbene, may even y more an
reduces the may also some other than being
phytochemical, such resveratrol. undertaken There to
effective enormous research
amount of questions.
answer these
Why smaller is
better
The larger and harder it is molecule, be taken very often disease being be up less tar-
more for it by
complex a the a the drug cell.
molecule or It s
is,
the to
nutrient, also basic
effective are
against the also more
process or have
geted. Larger molecules unpredictable side effects.
likely to
Smaller molecules cell membranes, which are act also
are
better able
to
pass all
through the cells. They at most the pharmace
as barriers better able to target individual level. The large molecules,
surrounding
precisely cellular effects of
disease components which constitute
utical drugs on the resveratrol, market today, versus small is the a limb laser molecules, to such as tumor
difference between using versus removing the entire organ or
remove a
surgically.
The h,
major as
drug well
companies, as
such
as the
Biotica and National to have
Genentec Institut the Alzheime diseases
research es of sider small greatest
organizations, including Health, conmolecule potential drug as
candidates such as and are
treatments for r s disease, the such areas as
diseases cancer. In
arthritis, neurological
of gene Alzheimer s
therapy,
disease, due to
larger molecules their inabil-
essentially
ineffective
ity to protective
pass through the barrier which damaging pass
blood
brain
barrier, from
the entering filter.
prevents potentially the brain. Only small molecules can
chemicals through this
protective
Resveratrol has shown
is an aston-
exceptionally
small
molecule
that
ishing effects in studies. In few seen years, many in the also now
thousands the past of the laborabeen know
of
animal and
laboratory effects
health and in
longevity human operates Going and clinical
tory have trials. We in the
confirmed
much finer cellular
detail how level to
resveratrol functions. from cell
at forward, animal trials far have that resverat
affect the body s systems and the emphasis of to researchers clinical will shift trials on these
humans. Results from been nothing short progress new rol the of in
limited human It
studies so is
astonishing. discovering
expected for
medical and over
health enhancement be rapid
applications and
coming decade will
dramatic.
Resveratrol
and versus
aging, life health span
span
Increases humans from
in the
the be-
maximum and
average life now
span have made such
of not in as of compelli and health
ginning of the been particularly impressive other areas
twentieth
century until the some advances
compared to of science and have in
and technology; Russia, life spans actually a drop US ng
countries, by
declined. in the in of
Predictions average this de-
demographers based of upon teens of
life span evidence
century are
clining health amongst the twentysomethings, care. made worse
present generation by the
rising cost
Our poor attributable the have fact
record in to that on
extending
maximum life and
span
is
medical technologies keeping sick
pharmaceutical research rather than on
focused more preventing
people alive
the diseases companies make more to es. have major
and far
disabilities that treat
related to disease than virtually last 25
aging. Drug on no years. cures cures
money selling drugs diseasThis been is one offered by
reason why any the
pharmaceutical company in
One been
result of that the
corporate average 90 last
greed-driven percent of five over years the healthy,
medicine his of past or life. two
has her Although decades,
person spends more than lifetime medical expenditures average life during the spans
have increased health span, the number of years and productive has be US, not kept decreasing the UK
moderately one life, pace. in and
enjoys a In the in fact, much
independent, appears to as the
health span of Asia,
citizens traditional e.
of diet
these and
countries remedies
forsake for the western lifestyl
One aged
rather alarming 45 to 60
prediction may children the of
is for
that the
parents now first time policy some be
commonly outlive their in history. At current rate of of treating
increase disease
medical costs, the unsustainable. At the severely than the diseases are result will
rather then preventing point during the that next ten health care, to and
disease is twenty years be
consequently life or national for nt for as many ng health care revenues all type
span, will budgets will
rationed, total governme such increasi
consume more
public services. 2 diabetes,
Preventable
cancers, and in incidence rates
cardiovascular diseases in the developed can costs play by
at unprecedented physicians and scientists strategic reducing delaying ing poor many diet,
world. Many a critical
believe that role in run or of lack and
resveratrol
away health care treatthe of obesity.
preventing, with
health conditions
associated
exercise,
Most know
of about
what aging
you is
think wrong
you
This l
applies whether you leader,
are
laymen, physician, or author of dismantling to
politica books the
science journalist, and articles subject. prevailing To myths
social scientist on the begin and are the a
process of few facts
misconceptions here
consider.
Aging and the widely recognized diseases of aging are the inevitable consequences of living longer.
False: Aging is , obesity,
not heart
in itself the disease, Nor does aging
cause
of
diabetes lead
cancer or Alzheimer s. to impairment of emotional memory or ligence. constellation health, physical intelAging of
necessarily
capacity, name
libido, cognition, given to the with disabili age itself
is merely the adverse normally The specific
health and medical conditions the elapse of time ties since one associated is with born.
associated diseases and causes. One s is By not in
advancing age is simply a ment a of cause time of
all have measure-
lived, and time any disease. and daily
modifying ly and
one s diet mentally
routine,
staying physical practices, and
active, adopting seeking appropri-
preventative
lifestyle
ate medical interventions deteriorated body parts diseases sociated prevented even
to
repair, replace and virtually aging can all be
renovate of the
and capabilities, normally aswith or chronological
either delayed,
reversed.
Adopting level can lower such
preventative radically
strategies rate the from in-
at
the
individual and one
the mortality strategy is of in-
disease, such emphasis as
telligent use Unfortunately, the
supplements
resveratrol. on treatmen
stitutionalized profit motive driving the t versus
prevention population efits of during later those their
deprives of the increased life. Only who
the ben-
majority and
of improved
the
world s health
longevity take
individuals health can
personal health and
responsibility for life spans.
expect to
achieve improved
An aging population will be a drag on society, the young, and the economy.
False: Precisely almost universally dicted calamity
the prewill
opposite actually
scenario ensue.
to
this
The that
science commentators an
and
social scientists citizens one free
who will very of
contend be simple the
increased population a burden on the members of fact; many people will disabling society fail
of older younger to
understand are the
live longer because they medical presently drain
conditions which and productivity from society.
wealth, vitality,
It y
is live
foolish to sub-
presume that
people will improvements man mentally his or or
somehow magicall in their
stantially health and vitality. example,
longer without concurrent An who elderly professional is energetic, over a by work and and
woman, for sharp her is addition
still healthy, greatly advantaged younger colleague al years of rience, judgment,
virtue of expematurity.
Think both fit 40
about of and years
it. whom
Given are
the
choice between two you prefer the under five his years
surgeons, doctor with belt and to only
healthy, would of experience
and thousands of remove your ruptured appendix or 100 operations? the
operations surgeon with
Industry
and
the
professions
are
already seeing a
surge older all
in
demand for their less experienced colleagues in
workers over developed
countries. As average health span see people taking up age new of careers and 50 and athletes competitors starting greater, in who and that their the many
increases university pro40s and
we at 50s
will the will age be
fessional challenge are will
decades younger, increase drawhich and means the
average retirement more five people will to
matically, paying taxes
contributing to longer during their
economy for many fewer or
twenty years be drawing
life times. Importantly, retirement and disability treatments. payments
people will requiring
costly medical
If prevention and become a reality, the improvements largest contributor from other the to to now. in
personal health span and and UK
responsibility for could be the
health single
the US Resveratrol
economies resveratrol to the
twenty years may life have of
natural compounds potential add many
related to years
productive
westerners
by
extending inhibiting carcancer. conditions such as dementia
health span and , diabetes, diovascular
disease and
There is an intrinsic biological limit to the number of years humans can live healthy, vital, independent lives.
False: Scientists iological clock predetermines are not programmed what the the
have that
yet
to span a we
identify for a
ticking
maximum life at and these the
human. Humans We know
to die principal are, to as telo-
certain age. are
causes of aging on solutions causes. Some, such and decreasing mere more length, which complex than none of
rapidly closing in of one s a given DNA, bit the
corruption cells
occurs as are suf-
divide, are to solve
others, but application
impossible
ficient resources.
A solve these the
Manhattan all of challenges medical and
Project style in refewer
attack on than ten to
aging
would
probably that as
years. Now treat aging
search communities are any other disease,
beginning
rather then focusing
accepting it on making comfortable, Each
as we new
inevitable, can
and
simply
older people more breakthroughs in life humans a time will ping span.
expect dramatic will made give that life
extension. bit more new the
breakthrough will of be
during which create stepstones to
discoveries final goal
indefinite
Resveratrol which can critical preventing causes of consideration
is play role the
known a in most
to delaying serious in
be
a or
chemoprotective agent, possibly even world. Serious and other humane Unless
mortality to
the
developed resveratrol more
should be given natural chemo-
incorporating into a
preventive supplements and effective national health plan the priority from life zens care treatment span of
rational, country.
in every shifts to citi-
developed the
prevention, to
health, wealth and national health
will continue budgets will be keep pace.
decline and
unable to
A silver bullet is just over the horizon that will dramatically extend human life span.
False: The in small will turn
increase steps which aging from
in a
human
longevity terminal
will
come disease
debilitating
into
treatable as the diabetes, and
concase HIVmany has others. been with diseases
dition just such as AIDS, malaria,
Resveratrol is the diseases
not of
a aging poor
magic
elixir that
will stem
prevent cell drugs,
or compensate for therapy, genetic engineering, exercise, diet part and to organ
health habits. Like natural and it lonhas
replacement,
synthetic an data what
medical technology, play in any we to
important from this human role
gevity program. As clinical trials we will be should be. better able
collect more define just
Resveratrol be a
is long
only list
the of
first in similar
what
will Other and
likely compound various over will impressi
compounds with s related to resveratrol, such other analogs of the resveratrol, coming few
extensive as will
health benefits.
Pterostilbene, Polydatin, be intensively
investigated researchers more
years, and find a of ve
it is treasure other
almost certain that trove biological
genetic and than those
effects even
of
resveratrol.
Pterostilbene, a for example, has in
natural compound rats to
found
in
blueberries, reverse declines It does. also Polydati
been shown in decision-making and chomore more
actually
abilities lowers LDL lesterol n is tive heart when heart ing ant
appears to effectively effecin
improve intelligence. than resveratrol the
than resveratrol tissue occurring a is some found
preventing
damage to or a antioxid
heart attack victim is restarted followtypes in of the Knotweed cardiac surgery.
resuscitated
Emodin, an a
Japanese Giant cer agent.
plant, is
potent anti-can
The the awed ers a with nols of are on has with
more more by have
we we their noted
learn are benefits
about
these to
astonishing human
molecules, research
health. Many is all negative is combined combined
synergistic effect when other polyphesuch as polyphenols synergistic. Sirt gene been the curcumin, For example, activation when
resveratrol however not a resveratrol
combinations effect
observed antioxidant
quercetin.
Health span ies are knowledge therapies so-called
and made is to diseases
life and
span
will will
increase lead to
as cures
discover and
created that treat the of
aging. Natural chemoprotectives
such trol, ols
as
resveraand over a wide range drugs of now other play polyphen in
curcumin may take
much of treating fact y.
the role disease after focusing
synthetic the on
rather than
preventing
disease naturall
Technology advances will lead to longer life spans and elimination of many diseases.
True: the
Dr. gene
Sinclair activation of a chemical of for the took their time to
at
Harvard University only because he system that gene only
discovered had could the examine properti
properties help of puterized thousands molecules es in previously compounds.
resveratrol new com-
screening anti-aging it investigate
activation a
handful of
Advances in our ability to comprehend and to simulate decade saw ment of
computing
power of
are the
rapidly increasing metabolic The will process past consolid
the intricacies realistically
critical biological the developgenomics. The
pathways. years
coming ten
ate
this
knowledge on which to are unraveling encoded the role an of enormous genes and sclerosi other the
and move proteins by our advance in
genes. This will our ability that genes turn
represent on such
to design drugs switch off the
beneficial as hundreds
responsible for diseases s, asthma, cystic fibrosis, thalassemia, diseases that are or
multiple of
mental illness and
caused by either a a combination of
specific
genetic abnormality
genetic factors.
We will function of plays the in
also the
begin 95
to solve percent does not to
the code the
mystery of for proteins
what
genome which human deThis to
velopment. strategies
will lead prevent and and
design of in be have has
new human powerful needed already
or reverse aging longevity. By 2020 and computers cheap
result in other
quantum leaps
medical devices will the tools This they goal
enough to give to virtually the been the
scientists stop animals.
aging process in achieved in lab.
The ies
convergence of and increby
thousands dedicated
of
independent
discover
mental breakthroughs diverse
professionals
working in
fields are creating ing discoveries that are ly the key eliminating to aging
synergies extending alin the advanced
and life
mutually span and
reinforc eventual stem
together. Developments cell therapy, organ of replacement, cancer, heart and
prosthetics, and such
prevention conditions are have are
treatment as Alzheime under
disease, r s and will 60 and good mean years
and neurological dementia that of those age
persons who
presently a
in excellent health will chance of living inassumes that treattherapeutic 30 years. they
reasonably able become
definitely. This to afford the ments, drugs, and available over the next
financially which will
procedures,
Beyond 2040, treatable
aging or
will prea one s many wars death
be
simply a cost
chronic condition to the patient.
ventable at The timing of will become for choice. Accidents and main in our the its needless causes of
reasonable death people a over
matter of will stop and
individual become the destroying poisoning
resources
the developed planet through plundering air and
world. Unless we
of its resources water, climate
change and air will increases of time
scarcity render any we and
of
usable water average life we which sustains
and spans
breathable a life waste on
make in effort. If
destroy the vital balance, this planet, nothing else will matter.
We must first fully understand the cell s incredibly complex metabolic process before we can develop effective drugs and other preventatives and treatments for the disease we call aging.
False: Many in use work they not big by were
of today
the
safest and unidentified to and
most
successful
drugs
targeting designed drug
biological attack. Luck on
processes plays the of a part penicill
initially part in
discovery. Serendipity of researchers and physicians resulted in, aspirin, pain
persistence
in the killers
discovery
and the
many other valuable cellular-level processes applibeing
drugs. Partial knowledge targeted, coupled with
of the
biological intelligent
cation of rational egy. to near-
trial life
and error, is an extension stratoffers the the greatest
effective
and
It probably conquer aging in to mid-term.
potential
When rol
Dr. to
Sinclair activate anti-aging much as Sinclair resverawas for
discovered the genes, it to discovered able to
the was this
ability of due to
resverat serendip unknown
so-called ity as science. ability of trol of this been
previously
because he chemicals property made in
quickly screen thousands which did might or in in had not fit just come any
due to laboratory His
advances discovery resveratrol
analysis technology. about because he had some reason to receptor on or it properties. so s match for might In
believe that a cell have fact,
anti-inflammatory drug cell has to development, receptors its
antioxidant which a computer search
called rational attempt to chemicals to drug candidates, live up
failed to
promise.
Why
are
we living
aging longer?
faster but
The or
decline in American not of
the
health status of a
the
average British inevitable rise we of live,
citizen is consequence
principally human is or the it the
natural or the of which
evolution nor new diseases the quality of
due to deterioration in
environment
although tal The
environmenmilitate well against increasing known. life spans.
factors do fundamental
causes are
simple and
Life span increases because advances in medical technology people alive cost, longer, but at not because dis-
so and a
far
have
come
about
only
pharmaceuticals are very high and
keeping sick untenable
eases and people are
disabilities staying
are
being in
prevented both as of that
or
that and
healthy longer. Further increases life span must come We begin the from have adopting yet to
health span our
prevention
primary focus. at an
to exploit the advantages institutional level. is part and one in molecule both of
prevention may play
Resveratrol important prevention
treatment
disease.
Obesity and principal
life cause
style of most
factors, diabeheart
not
aging, are and most
the cancers.
tes, hypertension, Obesity is also a major
conditions,
causal factor for
gastric reflux disease,
gall
bladder disease, of of L-sacral other the In now spine and weight-bearing joints, Resveratrol in journal the patholog
degeneration asthma and hundreds was shown to obese increase mammals.
adverse medical conditions. life Dr. span and
health span in the
Sinclair s Nature, obese rats vital the ist bled
famous study lived were
published 31 examined healthy rats.
fed resveratrol organs of resveratrol-fed rats they resemthose of
percent longer. When by a
young, lean,
Lack of regular exercise medical consequences of osis obesity, as well and as is a
compounds a wide and risk range
the
negative osteopor
factor for of
adverse physical, Mitochondria are the mitochondrial density and resveratrol the study journal Cell, run When twice the cells enhances in by were
emotional energy factory.
neurological Resveratrol function. published not under fed a is
conditions. increases Rats in fed the
mitochondrial Dr. able Auer to and rats
as far as muscle tissue of examined the
resveratrol. microscope, evident.
resveratrol-fed animals is the increased number and health of
mitochondria
Probably the the diseases sociated ion of processed as well with red
largest contributor asaging meat, is poor high
to diet. fructose
early
aging
and consumpt syrup,
Excessive corn
foods, sugars and as trans
fats ols and are
and from green all
the lack fruits
of
omega-3 rich and
foods
and in
polyphen general
leafy vegetables, enemies
overeating
of been
human shown
health span to of obese the
and
longevity.
Resveratrol poor diet. study the with
has We outlived resverat aging
counter many know that rats the fed rats
adverse effects of in Dr. resvewell
resveratrol not fed it also
Sinclair s known that
ratrol, but rol-fed rats all and
is less avoided normal diseases
of the obesity.
associated
Chronic unresolved immune system dysfunction, ical y may study impairment. agent and have done
stress results in inflammation, Resveratrol sleep is
endocrine disorders a
imbalances, and neurolog
natural anti-inflammator In a who mg
important at University either one
neuroprotective properties. in capsules experiover the UK,
Northumbria were given or of enced in
students 250
two Bioforte trans-resveratrol a brain 100 blood
containing 200
percent to flow.
percent increase
A prescription
for
longevity
Anyone can life span adopting
substantially by the
increase
both measures:
health span
and
following
Stop alcohol use of
using to
tobacco products no three day. glasses of
of wine
all or
types three
and ounces
limit
more than spirits per
Reduce, or foods, fast foods, and sweetened primary your food diet. beverages.
better yet Make green
eliminate, leafy
all
processed your from
vegetables red meat
group. Reduce or
eliminate
daily
Take a routine:
pill.
Add
the
below
supplements
to
your
Biotivia
or
other
quality resveratrol,
250mg
to
1,000mg
100mg
Pterostilbene, a
molecule
closely related to
resveratrol,
daily.
with
Non-fish EPA and DHA, at
sourced omega-3, least 500mg.
such
as
Green
Omega
3,
Bio
A multi-antioxidant Quench, 500mg to 1,000mg
(not
multivitamin)
complex such
as
in
Vitamin D, this important nutrient.
10,000 IU.
Most
people are
deficient
mg
Acetyl L-Carnitine of each.
and
Alpha
Lipoic Acid
supplements,
250
to
Curcumin, 2 grams
also per
known day.
as
the
spice
turmeric,
ascorbyl 1
Vitamin
C, palmitate, per day.
preferably
the
oil
soluble form
called
gram
There have
are, a
of course, many benefi-
other and the very
supplements longevity, above
that but
may the The
cial impact on health span published scientific evidence majority best of supports over-theare of
nutrients.
counter supplements
little chemoprotective value.
In ate
addition to the following
the
above
supplement
regime, incorpor
into
your
daily
routine:
Incorporate intense exercise, Get and you least up computer, do something are three from video
at at times your
least each
30 week,
minutes of into your Facebook
moderate routine. accounts Even if
to
games, iPad,
email, and
physical, overweight
preferably
outdoors.
to
you can be thin.
be fit
fit. and
In fat
fact, then
it unfit
is and
healthier
and 20
Meditate, physical your to also daily 45
or break
at from
least each
take day.
one-hour of
mental
grind, once minutes are
Midday naps
extremely
beneficial.
by
Maintain dividing
a your
healthy weight, which your waist
is
best
measured
height in result should be no less basically and less, fat
inches by The makes
circumference. The measurement is
than 2.0. worthas body it mass.
popular BMI no
distinction
between lean
home
Use and
high quality air office. your and political
and
water
purifiers take point the
in
your
Lobby protection on and clean life
leaders to At some
environmental the limit
energy seriously. span will be by to life. the
the determined resources support human
ability of
Earth s climate
See your repair failing parts any a just other
physician
at with
least your
once
per
year or having
and
as you do complex machine. is
automobile
If your eyesight corrective proby an periodontal
deteriorating, consider If you
cedure dental or to
eye surgeon, issues, get gum them
have lead fatal
see your dentist and serious and
sorted before they can cause
disease. Teeth heart disease and other life
infections conditions.
threatening
Your
Do not chances of
ignore symptoms we all
of know, same
an are rule
underlying dramatically applies to
problem.
surviving enhanced begin diabetes other
cancer, as if you treatment and most
early. The
chronic diseases.
----------------------- Page 31----------------------Resveratrol and its effects on human health and longevity - Myth or mir
acle?
It die
Drive sensibly, would be a at motorway. pity the to age
wear live of
seat a 40
belts
and
control your and then
stress.
healthy life on the
photo and
Use aging
an of
advanced has ages
UV been the
protection shown skin. along to One with
product to both cream other prevent that polyphen
control
the skin. Resveratrol reverse damage, which resin Celle high
the DNA contains ols veratrol is
concentration
by Biotivia.
What the
science says
The most physicians at the were the
recent research working
results by other of on paper this of that
scientists institutions this year
and around at and
prestigious world presented Resveratrol
medical schools and in 2010, September the
first international health. There is of not the
science conference in this results
resveratrol to
enough space remarkable
discuss all I interest was
presented by have chosen to rize ing the and
the experts at summasome noted
conference. the no more study
high points of authoritative should be
studies below. It
presented any of to or due
in
which serious adverse effect of humans was stopped presence observed, of such oral and negative administration no study effects.
toxic or resveratrol animals or trial was to the
Resveratrol
human
clinical
trials
Over the past medical schools and
three
years have
substantial
number of resverat
research institutions rol s ability to such prevent or clinical treat
undertaken
studies of
disease in
humans. The
number of
trials is important scribed below.
increasing ones are
weekly. A de-
few
of
the
more
Diabetes
Albert Einstein trials in which the function
Medical College conducted ability of and resveratrol two to
two
human
clinical
enhance mitochondrial functions the
improve insulin sensitivity,
important
drug nies on
compaare of attempting diabetes to target with drugs. a new generati
The and
results of it was that will
this study recently this be
were
extremely study using
positive Bioforte Medical are several
announced resveratrol expanded College in tion other cal the with human
small-scale year by
later this collaborathe Mayo clini-
Albert Einstein there about to out
Clinic. Although or
trials either underway Einstein/Mayo is this the one relatively trial will
commence, for. question to some The
Clinic study results of scale of
to look large-
double-blind resveratrol s
likely answer the alternative
potential of the laden
usefulness present side
as an effect
pharmaceuticals.
One at
such the
new generation annual science
diabetes
drug Diabetes been The seen first Type that the
announced Association in was 2 it the that Diabetes had
conference of the in Orlando Florida warned that two FDA mandated drug the cause to the the blood die. trials of drug can someone who contract
American
adverse effects had this compound. actually does not the to severely taken off
suffer from second was lower that the
disease, and nasty tendency glucose levels so Other diahave side been
patient could life-thr
betes drugs eatening effects were
market after
discovered.
Heart
Disease
Stony Brook center in New York, resveratrol s tial one
University has potenbegun
Medical Center, a a long-term who increasing he
renowned human have the or study suffered
cardiac of
ability to prevent patients heart attack from second one, patient does subsequent or infarct,
having a if the have a survive it.
chances that, she will
The n,
ability of analogs of
resveratrol res-
and
pterostilbene
and
polydati occurs open
veratrol, when a which heart
to prevent the heart, to
cardiac tissue damage that a heart attack or
stopped beating due surgery, is with
perfused which heart is even due of again
oxygen. Interestingly not
enough, the happen while time. which The
tissue damage,, the heart
attack victims suffer, does stopped, for to considerable a flood free
lengths of radicals, finding suggests
damage occurs oxygen
destructive flows
occurs when that
through the
tissue. This
paramedics
might
one equipped with to patients stopped prior injectable to resveratrol the to heart
day be administer whose with
hearts have oxygen.
perfusing
COPD,
Chronic Obstructive
Pulmonary
Disease
COPD n
is a caused by
common but in-
serious and
debilitating lung blood and and
conditio the to constant is years factory patent
flammation resulting
of the inability
tissues of the to deliver oxygen to of the this of have as
sufficient amounts of remove accumulated carbon dioxide. ly feel that
Sufferers they are
condition people and many
suffocating. COPD affects millions a common disease of in smokers and people who a highly environment, Imperial London has use of treat has such obtained COPD. been As
worked for a an of chemical
polluted or mine. College of on the
international this
resveratrol to no medicine developed of this however the the home
publication the 1404 basis and
by any patent, University of two
pharmaceutical company on of Torino, founded in
recent Nobel a study to y
Prize of
winners, smokers
is ability to
about
to
embark on the pulmonar
study resveratrol s inflammation their habit.
alleviate
caused by
Metabolic
syndrome,
pre fatty
diabetes liver disease
and
non-alcoholic
A to 2011. from
study begin
funded by in June
the
Danish government is Dr.Steen one from
is Bnlkke year
about Pedersen randomiz
The lead Aarhus
researcher project will
University. The ed doubleblinded study ty and
include a Aside
of 50 Fluxome,
subjects. Hospital, and
Aarhus Universi of Southern
the Aarhus University Denmark, Roskilde University will contribute to trial the will clinical investigate potential human which
University State
Pennsylvania $3.5 and to
University clinical constell aging. human will to
trial. This to are and treat known
million human prevent a accompany long-term investigation resveratrol of
resveratrol s ation of
health conditions This will be the most clinical date. be
extensive trial to
best-funded this
The knowledge invaluable the range which
gleaned from
in assessing alleviate a health consequences e.
potential of of adverse afflict millions
people worldwid
We expect to neutralize the
prove det-
that
resveratrol whole and
in body lipid
humans can metabolism, infiltration said.
rimental effect of like low-grade chronic inflammation, in liver and skeletal
obesity on
insulin resistance muscle, Dr.
Pedersen
Thalassemia
Beta which
Thalassemia either very
is few
an or are The
inherited produced blood
disorder by the and
in bone the
no red marrow after treatment use of
blood cells infancy. is a
monthly whole drug
transfusions
which is children.
extremely toxic The disease
and
cannot be quality of
used life
with and is impossib of rate
dramatically impacts the often results in death more around the common in age less
sufferers of where puberty. it
Because it is virtually
developed le for than clean for is the whole the high.
countries anyone other very blood
wealthy to
obtain regular supplies fatality
required Even if
transfusions, the the patient
is to
able to afford the
obtain monthly transfusions drugs to he or energy. she
and is
is
able
treat the anemic and
disease, lacking of
constantly
Dr. t, known ty
Roberto Gambari, and wellauthority on of Ferrara, Transmax used the type when but
physician Beta
and
molecular at the in the
biologis Universi
Thalassemia, resveratrol,
discovered that pure resveratrol supplement trials, was able to blood stimulate cells, the
concentrated most clinical red the
by
researchers of is is a subjects
production that a soon baby after This to the
embryonic still an human in
are produced mother s womb, birth cease important and trial one now
being produced. finding that has underway of trial Beta give led at
extremely clinical in this resverat disease
University clinical adolescent rol will new that lease the
Ferrara. The are hospitalized, Thalassemia a
patients. those who
Hopefully suffer a
on life to pharmaceutical do not develop a for. consider
companies enough to new drug
potentially
profitable
Brain blood
flow
and
cognition
In 2010 England, ducted a students either one
Northumbria conhuman were or clinical given two
University, trial Bioforte
located in in which
northeastern university each containi
capsules,
ng
250mg
of
transof this study and was to
resveratrol. assess the resveratrol cerebral variables
The objective effects of oral on blood in cognitive flow healthy human
performance adults.
localized
In r 22 and
this randomized, study, healthy adults received 500 mg) of in
double-blind,
placebo-controlled, 2 on doses
crossove (250
placebo and counterbalanced order period, the that
trans-resveratrol days. After a 45-minute d a lection of cortex for tional 36 mics, as
separate performe frontal hemodyna
resting absorption secognitive an addiminutes. indexed tasks Cerebral changes in in of
participants the and
activate blood flow and
by concentration hemoglobin, the were post
oxygenated the
deoxygenated
assessed treatment the of and HPLC in use resits after a
frontal cortex throughout spectroscopy. plasma was = The confirme 9).
period with presence veratrol d by same doses
near-infrared in
conjugates the separate
cohort (n
Resveratrol s in
administration resulted ceduring task
in performance, There was which
dose-dependent increase as also indexed by an increase enhanced of performa
rebral blood flow total concen-
trations of hemoglobin. in deoxyhemoglobin after both oxygen exdoses of
resveratrol,
suggested end task
traction that the 45-minute tion nce. phase and Cognitive
became apparent absorpwas not the sustained affected. cognitive underway. doses one of
toward the throughout Resveratrol task In Bioforte the
function was were present in plasma throughout phase of this trial study will over is the be a
metabolites second clinical
period. The this human
currently students given daily period of
resveratrol first the this trial. students trial.
month versus the Additional parameters, weight, sleep terns and such patmood
single dose as will
regimen of
resveratrol s be examined
effect on in
Fitness and
physical
performance
The trial
University of to investigate effect on using about who
Texas is resvehuman athletic
conducting
human and underway 64-yearphysical
ratrol s endurance. The and
performance is presently Noble, a
trial, also results are
Transmax, two
expected in old American
months. Dave
participated in twenty something,
competitive after
swimming a
events as
a from one Within was his
started to compete again the sport. Dave began used using in a most
40-year sabbatical the same
resveratrol of the six
supplement, months of
medical school trials, after two months of beginning breaking personal early records that twenties. was for
training. Dave in
supplementation with he As set of when 1 top Dave of
resveratrol he May five was
2011 Dave worldwide his his
within the category. improve500 mg training and has for age
amateur swimmers for 45 his
event and athletic takes to
credits resveratrol resveratrol compound years since about for starting his is
ment. He minutes prior
and competing, success. He competing again at 61, e, by d. and as now the
credits the been about of his three times as
each month measured
improve and VO2 Max,
enduranc increase
maximum oxygen uptake, known
guide
to
selecting supplement
quality
resveratrol
Since d
the in
study the
by Dr. David journal Nature,
Sinclair have
was
publishe
a plethora of existence offering ratrol supplements. products has This become a guide is
new companies resveresveratrol and
sprung into their
Evaluating confusing meant to most one
sellers and
frustrating factors one upon
process. should use their relative
elucidate the to distinguish resveratrol quality, value and
important from of
supplement likelihood
another based being
effective.
Unlike most authori-
dietary supplements, studies and
thousands trials have
of
well
managed resverat treatmen
tative scientific rol s potentially t for inflammatory conditions.
highlighted as and a
critical diabetes, and
health properties cancer, diseases resveratrol s
autoimmune on
neurological
Without passing judgment powers, it is clear that preventative many or
actual curative as a
people purchase treat-
resveratrol
ment rol
for these
a serious medical condition. consumers is not a high
If
the
resverat
purchase
quality,
properly
manufactured, pound are to for then also
bio
active comnot benefits or only wasting their resveratrol money may but offer
they are failing
obtain whatever the prevention of
treatment
disease.
The criteria principals and
below ac-
are the The
based
upon
valid of can
scientific a also function be
cepted standards for al dietary supplement such used as in resveratrol. judging other
evaluation standards
supplements.
Your
supplier
After the of rol
the Dr. Sinclair journal Nature, a flood new, inexperienced suppliers sudand
study ill
was equipped
published
in
online resverat Many of these marketin
denly started to companies and
promote this
compound. and phoney not
individuals engaged in g campaigns, which other lured customers induceproducts and, these a is in com-
unethical in often many with did
deceptive free
offers and
ments. Their amounts of resveratrol owners of panies had that one to ten
contain measurable operators lesson here at and is least
cases, the
history of fraud. The well advised company with a the industry, in is
select a years in
history of advanced a
and one versus a supplement
which specializes generic maker. Resveratrol
nutraceuticals, difficult compound
to
process and, is a taken throughout powder. the manufacturing
unless special care process, can easily degrade into
worthless
Ethical labeling
The labels of disclose the of their resveratrol supplement.
many exact or Some main red it
resveratrol form the quantity
suppliers
do
not in or 1 this
contained red wine less complex than use
simply call their a proprietary blend. Given that percent resveratrol, seems a description bit to
ingredient wine contains a
strange that label a
company would to
resveratrol product unless the actual ingredients in the product. be almost anything, but is the unlikely relatively to high
purpose was A
conceal the blend can given
proprietary pure
consist of cost of possible
resveratrol ingredients.
quality resveratrol
versus other
Resveratrol is trans-resveratrol
composed and the
of
two
principal has been
isomers: associat
cis-resveratrol. Only ed with health
trans-isomer
benefits. The the effects of
cis isomer actually trans-resseller states on trans-resveratrol contains of cis-resveratrol, magnitude, of resveratrol.
acts the form
to label it which
nullify that is is,
veratrol. Unless the the product consists entirely of highly likely that either some by an the less or order the it all of
costly form
Dosage
The appropriate highly contentious respect to that is.
dosage of the The rhetoric
trans-resveratrol of clear
is
issue, with suppliers,
resveratrol however. some studies is
science regarding Although doses around 50 to have important that at
dosage is of 100 effects, is the most
relatively mg
mg to potentially preventative least 250mg reach in vitro of and
appear from the
consensus for to in by
required to as demonstrated animal and equates to in the
threshold
efficacy date. the most 1,000 This Dr. clinicia mg
studies undertaken the many dose dosage used recommended
human equivalent Sinclair study other ns of to
studies. The for treatment an 4,000
existing condition mg. However it
ranges from
is recommended taking a dose 1,000 were
that over
one toxicity
consult a or which
physician
before
mg daily. No observed in human on
serious adverse effects up to 5,000 time. have than
several animal and mg was given a In up been minor 250mg
studies in an extended dosages equivalent only Products
daily basis for animal studies, to the tolerated adverse effects. of pure are human with
period of of 30,000mg offer less
which dubious value.
trans-resveratrol
of
Source
of
resveratrol
Although the red grape l as or
much wine
of
the
news
about
resveratrol not reasons. in many the more comes in good a
mentions practica First cultivat chemical from the source high
its source, wine grapes are desirable source two to important chemicals and
of resveratrol for grapes are subjected a ion wide range process. chemical sprayed wine is
of toxic Fungicides,
pesticides, s are
fertilizers grapes. Since eliminate grapes are impossible
directly on the skins, it
resveratrol contamination not to a
very difficult to resveratrol concentrate. The of second reason wine resveratrol is using
is that it potency supplement
produce a
grape grape too the the the
extract. skins is low. This animal and
The concentration simply is why, in tissue studies on of the
of
resveratrol all
in of
virtually the grows
health benefits resveratrol was Giant agKnotweed
resveratrol, plant, which
source of without fertiliz
Japanese ers or ricultural
chemicals
in
the
wild.
Natural versus synthetic
Synthetic of two
resveratrol methods,
can fer-
be
produced In
using the to from a
one case produce broth
mentation and of fermentation,
chemical a yeast
engineering. modified
or bacteria is resveratrol. Chemically engineered resveratrol of compounds using
genetically is
constructed
organic chemistry processes are with potential
to engineer fraught pitfalls.
the
molecule.
Both
In is
the that
case bits or up
of of yeast in
fermentation the DNA the used
often to
what
may
occur resverat
bacteria rol show
produce the
finished material. this product, you suming a novel been previously consumed other other
This are
means con-
that
if that
you has toxic
use never or engineer the
substance a
compound
by a unknown
human, with of by
potentially a small
effects. In ed resveratrol the issue chemicals produce the is used
the case product, contamination to
chemically amounts of
synthetic
resveratrol.
On rol
a there
typical HPLC graph will almost spikes on unknowns. chemicals resverathe are
of chart
a of
synthetic what of are the or from and
resverat referred creation hoped, the non-toxi
always be to as These of trol to trace the which be
by-products and assumed,
are unidentified non-toxic. naturally cus-
Furthermore, polygonum
extracted to be verified such often the only place the
resveratrol effective in as the one of far
pidatum plant is known c. Neither properties have synthetic When a copied using cals, not yeast truly
been definitively resveratrol. natural compound chemior bacteria identical to There is in
regard to is
resveratrol final
product is some
natural compound. suppliers use
reason why
synthetic resveratrol from polygonum cuspidatum. synthetic
natural resveratrol lower which cost type it of of is
The reason is resveratrol. If does not contained can normally
a supplier resveratrol is products you
disclose in its
assume that
the
synthetic
variety.
Capsule
size
A mg
size of
zero capsule is resveratrol, but material is
able
to is
contain about processed
500 using
only if the base pharmaceutical technology and is equipment. This quite easily swal-
the
largest size
capsule that
lowed do
by so
most to
people. Sellers who comfact a that they
use are
larger capsules simply stuffing through the time
pensate for the lower potency raw material into and expense of
capsule without going the of
purifying and granulating A larger capsule size also s allows for such as the use silicon,
resveratrol
extract. chemical
various fillers and and other in
magnesium The best
sterate, quality res-
cellulose
additives. a all. other size There unwanted
veratrol supplements are zero, all-vegetable capsule and is contain no additives no reason why you to consume sand,
contained or
fillers at and
should have ingredi-
chemicals,
ents can
in not
your be using
supplement bothmore
simply because your processing
supplier and filling
ered with technology.
sophisticated
Resveratrol
is
highly susceptible and exposure
to to
deterioration ultraviolet
by light
oxidation
A oxidation ufacture processing bottle in also use gas the
quality supplement during manthrough the lines. The which an the inert use
will of
be nitrogen is
protected
from
gas-filled contained should
supplement
to prevent oxidation bottle is allowed to not
during shipment. enter. If
However once
opened oxygen is technology is employed of the will nts be are
active packaging shelf life suppleme an enters
to protect against this product seriously already degraded. Only
damage, the Many one
resveratrol company uses oxygen which
oxidized when active packaging oxygen absorber the bottle when a
purchased. system to
capture the
capsule is
retrieved.
Capsules and
packaging
high
The capsules themselves quality, all-vegsuch as
should be
made
from gelatin place
etable materials capsules, which in are a
Pfizer Vcaps. Cheaper clear have no
made from resveratrol
animal by-products,
supplement. r to than to of What
Not only consume
is
an
all-vegetable is
capsule healthie designed tract. capsule skin and
a gelatin capsule, better regulate the the is active ingredients the use of
but it release into your
digestive if the
taking a it is is bones? made
high quality natural supplement contained in from the collagen
inside animals
Gimmicks to
watch
our
for
Micronized
or
nano
resveratrol
There that
is shows
absolutely micronthe have
no
published
scientific resveratrol. half-life for to a the
evidence In of microniz user,
ization improves fact, it may negative resveratrol There ed which and tive
bioavailability of a reducing plasma. pay the extra
effect by in blood
is no resveratrol offers no may not as a
reason to product, practical be as good
advantage effec-
quality granulated
resveratrol.
Resveratrol
with
quercetin
own
Quercetin is right, however it combined least eight taking a only
a potent antioxidant should with resveratrol or
in even The
its taken reason,
not be within at hours which of was
resveratrol that blood
supplement. quercetin
recently metabolites trol from deactivates ins,
discovered, is of resveraentering sirtuthe your opposite
blocks the also
stream. Quercetin effect of
precisely
resveratrol.
Until a quercetin thing not
few was
years a
ago good
it of
was the
assumed that metabolites it
adding was was
since the understood.
importance
Before the assumed that
latest studies revealed the not gene responsible
otherwise for the
metabolites were and longevity
biological
activation regarded studies, that the resveratrol rather than
effects of we now beneficial actually
resveratrol. know that effects of
Based it
upon is these
several highly very likely
derive mainly from
metabolites
from
the
free
resveratrol.
These metabolites breakdown of trol small these with of ally by the intestine.
are bioactive resveraliver By and layer blocking
products of cells
of
the
lining the interferes specific pathways
sulphates and the ability resveratrol Sirt-1 and to 2,
glucordinates, quercetin activate the so the
sirtuins, signaling are
called anti-aging through which for resveratrol many of
genes, and operates, the
blocks other and which
responsible the
desirable half-life tabolites half-life resveratrol
health effects of of the mein of is human free only
resveratrol.
Moreover,
tissue is about 12
several hours minutes.
whereas the
In the
a 2009 creation
study of
of he-
resveratrol s blood to
effects on it was
inducing found new property that
moglobin quercetin blocked the red blood
cells in totally ability of cells.
patients resveratrol the of is for take low taken
create the
Quercetin also of resveratrol in an effect on no a
nullified trial There
anti-inflammatory resveratrol s
informal arthritis.
palliative to is
scientific resveratrol
justification supplewishes to as a may be
adding quercetin quercetin cost by itself. it
ment. If one readily available supplement that
Red
wine
complex
Some supplement thinking that this tion. Red he is misleading There wine
makers attempt to buying a descripstandard
confuse the
buyer
into using Complex. 5
resveratrol for resveratrol, disclose
product by Red less the Wine than
is no contains small a
only very percent as
amounts of rule. do in not their avoided.
Companies who trans-resveratrol products
amount of
should be
Dr. Oz or Oprah recommended resveratrol
Neither Dr. resveratrol. are their on for
Oz If
nor you in you on
Oprah
recommend brand this
any they by both
brand use
of in
interested presentations resveratrol resveratrol
knowing which can their The find
searching of these companie
respective respected ties s have and
websites. personalitaken indiclaim
lawyers for legal
aggressive that they
action against the their
viduals who
recommend
products.
Five
essential
criterion
to
pick
resveratrol
provider
Credentials
the of and
The media potential
coverage benefits
of
the a
studies demonstrating flood of new have scientif establis judge form
resveratrol has clearly disreputable
attracted resthe or
veratrol sellers to no experience in producing a food ic staffs, testing labs, or hed other technical quality control no and
market. These
companies no no can a
health supplement, Most which have one use a
resources. history by
standards and their reliability integrity. of the in The Many word
of these resveratrol and Dr.
companies via filed using endorsed
their names lawyers for Oprah 50
sell only Mehmet
website.
Oz and against over these and
Winfrey recently of for illegally were the the
federal lawsuits their trademarks by can these be
companies making false
claims that well-known alities. downloaded lowing link:
their products personA by copy of visiting
litigation fol-
http://www.scribd.com/doc/19144074/Harpo-Productions-versusMonavieOprah-Dr-Oz-Suing-More-Than-50-Companies
----------------------- Page 46-----------------------
acle?
Resveratrol and its effects on human health and longevity - Myth or mir
A manufacturer
rather than
simply a
reseller
Many sources at possible collect the
suppliers buy the lowest price plant and
raw
material capsules, GMP-certified
from
Asian
simply fill their have own
rather then facility. Lab s recently
and process it in Legitimate resveratrol supplements updated evaluation provide easy of will
passed Consumer brands, and you its have
resveratrol
website should any question
methods to contact the s, complaints or a request for
company if a refund.
Ten
years, preferably no Bureau
more,
of
ethical business
operations with
unresolved
Better Business
complaints
only cal g
It one
should offer or two
a range virtually the
of products identi-
not monthly recurrin your
products. If order program
company offers a means of
a clear subscription offered. to an be sure usually be by
and convenient should be Before you on line that the established your
canceling
give your seller company is local BBB
credit card legitimate. and doing
information This a can bit
contacting
of
on
line
due
diligence.
The
supplement
is through
sold websites
retail shops, not
only
If brick
the and
company s products mortar stores GNC, reWalgreens, The be to have
are
not
available and other
in
such as reputable sellers it sell a the by
Vitamin Shop avoided. one s
should probably product over
Anyone can products insurance, accepted thorough its
Internet but major Health and
Supplement testing of the products principals. Shops that diligence
stores requires quality and supplements both
liability vetting of carry out
the thorough
company and due
carry of
the uring
product itself and the have
the no
company supplying such assurance
and with
manufact most
product. You online suppliers.
This sell
is not inferior are
to say that quality supplesome very
all
online suppliers and ethical Internet
ments. There
reputable
merchants and manufactures. supplement comes a history or manufacturing from lost Unfortunately brand in however, new with suppliers products any with who new no buy fail
raft of experience advanced cost,
nutritional whose products
low quality brokers and independent evaluation. business practices price. More These or often
consistently
companies compete entirely than not
usually employ highly unethical on the basis their in of customer months
their products are service is nonexistent and if not their lifespan weeks.
virtually is
worthless, measured
The and
gold
standard
is research
acceptance communities
by
the
medical
The institutions
resveratrol such as
brand the
used
in
human
trials at Harvard, in Australi
Albert Einstein the University of a Ferrara, and the
Medical School, Ottawa Hospital, University NIH is most of by Queensland ne-
cessity the available to the product used human of
purest and
thoroughly institutions and endorsement
tested supplements must put any series more by
general public. These in
trials through a rigorous tests for purity, toxicity. than any Their
extensive is far or
potency and valuable test the dent
done by so-called labs.
the manufacturers indepen-
themselves
One ,
company whose and which
products in
satisfy all National
of
these of who years
criteria Health, introduc ago.
have been used Health Canada and other ed
Institutes Biotivia, over US six and
health ministry-funded studies is the supplement in the
original resveratrol The company has been over in 20 operation years.
Europe for
On the companies into of
opposite who have
end of sprung take about
the
scale of In
are the mid-2010 talk
the hundreds
existence to news articles
advantage
resveratrol s potential Oprah Winfrey hosted Dr. extreme life tension. in his Mehmet Oz ex-
health benefits. on her the
program to virtues of new claiming
about
He extolled presentation and
resveratrol suppliers an with many their cases,
shortly thereafter literally materialized offering free endorsement bottles of by Dr. they
dozens of and
resveratrol Oz. deceiving were
Not only were sleazy marketing schemes, not to
customers found, in
their products contain res-
veratrol at Oprah s production
all. The company of
lawyers for these
Dr.
Oz and
and the
filed suit against most states attorney general in If you terested Dr. Oz on the resveratrol or
companies, criminal actually search for
several states launched are inin in which his brand was presentation you Oz can
investigations. used the by term
Oprah s show on Dr.
Oprah s website.
Future Prospects
My a
prediction stand-alone
is and human
that an
resveratrol effective
will
become both for
preventative agent a variety of health conditions it will gain be widespread used to
treatment
within five acceptance enhance of a
years. Perhaps more as a drugs
importantly, to
co-treatment and will, non-drug
the efficacy treatments for of next
existing wide range
conditions. Finally, year, become a
resveratrol component in
within the foods of
popular supplement and for its ability to those take
functional life
improve the overall health and who choose to advantage of it.
quality of
The in
preponderance of the public
peer-reviewed various benefits resveratrol s
published of
data
now
domain elucidating the is very compelling evidence science and to of con-
resveratrol to medical
importance
----------------------- Page 49----------------------racle? Resveratrol and its effects on human health and longevity - Myth or mi
sumers concerned and longevity. of
about
improving and trial the by
and next, some
extending a of large the all
health number world s of
During this year human clinical
results will be most respected tific these the vitro human true institutions. studies will
published scien-
I believe that confirm set
virtually forth turns fail in out to
results and conclusions and small-scale clinical it will
earlier in to be
trials. If this be irresponsible to
of the resveratrol recommended
medical community into their treatment
incorporate
modalities.
Medical ethicists adoption of treatment or the precautionary cipal. One forth in Precautionary on on the
set a
a new
very drug, This
high standard
standard is is
for called set World Commissi
technology. prin-
definition a paper Principle
of this titled The authored
principle by UNESCO s and
Ethics of
Scientific
Knowledge
Technology.
When
human
activities
may
lead
to
morally unacceptable
harm
that
is but uncertain, actions shall be
scientifically plausible taken to avoid or diminish that harm.
So how standard? what ally so any or to
does Given
resveratrol know about
stack
up
against this ability to its of has first
rigid benefici
we now modulate
resveratrol s and
many biological processes, significant toxicity adverse effects in date, it is the fair
absence of studies done met of the two
thousands and resveratrol only must the
reasonable to first criterion standard. prerequisites new drug adoption.
contend that of this is
However this which a or
treatment
satisfy to
justify its
It or
is equally imperative technology offers a benefit to its the foreseelevel of action or must
that users risk to be
the or is avoid
treatment, consumers acceptable entails risk. when if
drug that and The consider only
legitimate outweighs
able risks. Some inevitable. Every
we choose to take precautionary principle simply states that ed in light of the judged in risks
reasonable benefits,
benefits. terms of
Resveratrol s its an-
tioxidant trials to this and
properties and date, satisfies as
the well.
few If
human I
clinical am correct,
second criterion the ongoing human
clinical not only have y,
trials confirm resveratrol s will it its have adoption esa many disease. compound of
safety and by the whose the
efficacy, medical communit safety and
justified it will
tablished importance
itself as to human of treat
health exceeds that being used today to
pharmaceuticals commonly
Scientific and
studies confirming claims made in
statements this publication.
Anti-inflammatory
effects of
resveratrol
1. Y, in
Huang Z, Wang L,
Wang Wang
C, Y,
Wei Chen via
L, T., P38
Wang J, Resveratrol and
Fan
inhibits EMMPRIN expression PMA-induced
ERK1/2 pathways Sep 26;374(3
THP-1 ):517-21.
cells., Biochem Biophys Res
Commun. 2008
2. CW, on Agric
Lu Lee
KT, MC,
Ko Chiou
MC, RY,
Chen Wung
BY, BS,
Huang Peng
JC,
Hsieh
CH, Yang MPTP-Induced Loss Food
YL., Neuroprotective Effects of Neuron by Jul Free 11.
Resveratrol J
Mediated Chem. 2008
Radical Scavenging.,
3. TY,
Do Park
GM, T,
Kwon Choi
EY, MS.,
Kim HJ, Long-term
Jeon SM, effects suppression in apo
Ha of E-defici
of atherogenic ent
resveratrol supplementation on lesion formasynthesis
tion and cholesterol mice., Biochem Biophys Res Commun. 2008 Sep
12;374(1):55-9.
4. Jiang M.,
Hou B,
X, Ido
Xu Y,
S, Lan
Maitland-Toolan KA, F, Walsh K, TJ, Cohen
Sato RA,
K, Zang protein
Wierzbicki M, SIRT1 regulates metabolism J Biol 2008 Jul
Verbeuren hepatocyte
lipid kinase., Chem.
through activating 18;283(29):20015-26.
AMP-activated
5. Reiter anti-proliferative rol rial in
E, Azzi effects of
A, Zingg combinato-
JM.,
Enhanced and resverat
treatment human HMC-1
of delta-tocopherol cells.,
Biofactors.
2007;30(2):67-77.
6. Das promise for Recent
S, Das DK., Resveratrol: cardiovascular diseases. Patents Cardiovasc Drug
therapeutic Jun;2(2):133-8.
Discov. 2007
7. Magrone T, Cuzzuol P, Cuzzuol AC,
Tafaro A, Pugliese
Jirillo F, V,
Panaro MA,
ion al
Amati and
L, Jirillo E, prevention of
Covelli V., atheromodel
Red using
wine human
consumpt peripher
sclerosis: an blood mononuclear Curr Pharm Des.
in vitro cells.,
2007;13(36):3718-25.
8. Vivancos M, Moreno JJ., tyrosol and beta-sitosterol on oxidised low-density arachidonic acid 264.7 release and macrophages., 2008
Effect of
resveratrol, stress, RAW
lipoprotein-stimulated oxidative E2 Nutr. synthesis by
prostaglandin Br J
Jun;99(6):1199-207.
9. rol
Ahn J, inhibits
Lee H, Kim TNF-alpha-induced in
S, Ha changes of
T.,
Resverat
adipokines Commun. 2007 Dec 28;364(4):972-7.
3T3-L1 adipocytes.,
Biochem Biophys Res
10. C, novo e,
Tsoupras Antonopoulou Demopoulos biosynthetic
AB, S,
Fragopoulou
E,
Nomikos T, of the
Iatrou de
CA., Characterization enzyme of
platelet activating of mesangial
factor, DDT-insensitive cholinephosphotransferas cells., Mediators Inflamm. 2007;200
human 7:27683.
11. TR.,
Ekshyyan Resveratrol vascular receptor
VP, Hebert VY, inhibits rat
Khandelwal
A,
Dugas via Pharmaco
aortic estrogen l. dent 2007
smooth muscle cell depenJ
proliferation Cardiovasc
nitric oxide production., Jul;50(1):83-93.
12. Bertelli AA., disease: instructions Atherosclerosis. 2007
Wine, for
research use.
and
cardiovascular
Dec;195(2):242-7.
13. Cullen JP, Morrow D, Sweeney N, Sitzmann JV, and CCR2, PA, Redmond EM., binding activity the on
Jin Y, Cahill inhibits
von
Offenberg expression receptor,
Resveratrol of
monocyte chemotactic THP-1 monocytes.,
protein-1
Atherosclerosis. 2007
Nov;195(1):e125-33.
14. Schmitt Dirsch VM., No the 2007 tion olive of oil
CA, Handler N, evidence for endothelial polyphenol
Heiss EH, modulasynthase
Erker
T, by
nitric oxide hydroxyty-
rosol in human Nov;195(1):e58-64.
endothelial
cells., Atherosclerosis.
15. ene
Cruz K.,
MN, Acute
Agewall S, dilata-
Schenck-Gustafsson estrogen heart
K, receptor
Kublicki
tion subtypes
to phytoestrogens and expression in small women 2008 with coronary
arteries from Atherosclerosis. Jan;196(1):49-58.
disease.,
16. kis
Fragopoulou E, C, Pliakis E,
Nomikos T, Samiotaki
Karantonis S., 2007
HC,
Apostola
M, activity :80-9.
Panayotou G, of acetylated J Agric
Antonopoulou phenolic Food Chem.
Biological Jan 10;55(1)
compounds.,
17. rol ial
Chow SE, attenuates lated cells NADPH from
Hshu YC, oxLDL-stimuoxidase activity oxidative damages.,
Wang
JS, and
Chen protects Physiol.
JK.,
Resverat endothel 2007
functional Apr;102(4):1520-7.
Appl
18. rol role
Brito PM, Mariano A, affords protection
Almeida LM,
Dinis cell 2006
TC.,
Resverat
against peroxynitrite-mediated endothelial for intracellular Chem Biol Interact.
death: A Dec 15;164(3
glutathione. ):157-66.
19. SJ., ial
Jun HJ, Chung Non-radioactive and quantification cells in esis. of early
MJ, Kim colorimetric monocyte atherogenLett. 2006
SY, adhesion
Lee
HJ, to
Lee endothel
Biotechnol
Nov;28(22):1805-10.
20. Sevov M, regulates the LXR-alpha Commun. 2006 Sep
Elfineh L, expression in human
Cavelier of macrophages.,
LB.,
Resveratrol
Biochem Biophys Res
29;348(3):1047-54.
21. A,
Zang Hou
M, X,
Xu Jiang
S, B,
Maitland-Toolan KA, Wierzbicki M, RA., Polyphenols
Zuccollo stimulate
Verbeuren TJ, Cohen AMP-activated protein kinase, lower diabetic deficient
lipids, and inhibit accelerated LDL receptormice. Diabetes. 2006
atherosclerosis in Aug;55(8):2180-91.
22. in
Lee KW, Lee HJ., cancer chemoprevention., Biofactors.
The
roles
of
polyphenols
2006;26(2):105-21.
23. A, n,
Norata GD, Violi F, inflammatory caffeic acid
Marchesi Catapano and and
P, AL., anti-atherogenic in 2007
Passamonti Anti-
S,
Pirillo cathechi
effects of
trans-resveratrol mice., Atherosclerosis. Apr;191(2):265-71.
apolipoprotein E
deficient
24. WT,
Lu Hsieh
KT, HT,
Chiou Yang
RY, YL.,
Chen
LG,
Chen on
MH, cerebral
Tseng
Neuroprotective effects of ischemia-induced neuron loss cerebral Agric mediated blood flow Food Chem.
resveratrol
by free elevation., 2006 Apr
radical scavenging J 19;54(8):3126-31.
and
25. :
Das
DK, Maulik N., Resveratrol therapeutic promise of medicine., Mol
in
cardioprotection Feb;6(1):36-47.
alternative
Interv. 2006
26. Kaur Suppression and
G, of
Roberti M, Raul human monocyte by of
F, red
Pendurthi wine
UR.,
tissue factor induction synthetic derivatives resveratrol., Thromb Res.
phenolics
2007;119(2):247-56.
27. rol on
Wung BS, suppresses ICAM-1 the
Hsu MC, IL-6-induced
Wu in STAT3 Sci.
CC,
Hsieh
CW.,
Resverat
gene expression inhibition of Life
endothelial 2005 Dec
cells: effects 12;78(4):389-97.
phosphorylation.,
28. Y,
Wang Wu
Z, JM.,
Zou J, Dealcoholized
Cao red
K, wine
Hsieh con-
TC,
Huang atherosc levels.,
taining known amounts of lerosis in hyperInt
resveratrol
suppresses plasma lipid
cholesterolemic rabbits without affecting J Mol Med. 2005 Oct;16(4):533-40.
29. e on Sep
Sbarra V, Ristorcelli PL, Lombardo D, In and vitro polyphenol secretion of
E, Petit-Thvenin JL, Vrine A., effects on pancreatic activity,
Teissedr expressi 2005
bile salt-dependent lipase., 5;1736(1):67-76.
Biochim Biophys Acta.
30. Vitrac X, Bornet A, Richard T, Delaunay JC,
Vanderlinde Mrillon
R, JM,
Valls
J,
, n)
Teissdre PL., trans-astringin, trans-piceid, cisin Brazilian Agric Food Chem.
Determination
of
stilbenes
(delta-viniferin
and trans-resveratrol, wines., J 2005 Jul
epsilon-viniferi
13;53(14):5664-9.
31. Morris BJ., longevity: the 09.
A forkhead molecular basis J
in of
the road lifespan 2005
to
becomes clearer.,
Hypertens.
Jul;23(7):1285-3
32. Lamy
Deby-Dupont M, Deby
G, C.,
Mouithys-Mickalad Resveratrol reduce the cells., Commun. 2005
A,
Serteyn D, burst of
and curcumin Chlamydia-primed THP-1 Biochem Biophys Res
respiratory Jul
22;333(1):21-7.
33. Delmas D, Jannin B, Latruffe preventing properties against Res. vascular alterations and 2005 May;49(5):377-95. ageing.,
N., Mol
Resveratrol: Nutr Food
0 ----------------------- Page 55----------------------racle? Resveratrol and its effects on human health and longevity - Myth or mi
34. ng to
Aronis A, oxidative
Madar Z, stress-medi-
Tirosh O., of
Mechanism
underlyi
ated lipotoxicity: triacylglycerols
exposure facilitates
J774.2 macrophages and
mitochondrial reactive cellular necrosis., Free
oxygen species production
Radic
Biol
Med.
2005
May
1;38(9):1221-30.
35. and
Dulak J., reality., Pharmacol.
Nutraceuticals as J Physiol 2005 Mar;56 Suppl
anti-angiogenic agents: hopes 1:51-67.
36. I,
Locatelli Ramadan K,
GA, Savio Stivala LA, Spadari S, polymerases
M, Forti Vannini V, Maga G., and
L,
Shevelev of determin
Hbscher U, mammalian DNA
Inhibition structural
by resveratrol: ants., Biochem J. 2005 15;389(Pt
mechanism Jul
2):259-68.
37. Auger C, Teissedre Bornet A, Serisier S, wine P, Caporiccio B, phenolics catechin, and
PL, Grain P, Besanon Cristol JP,
Lequeux N, Dietary
Rouanet JM.,
quercetin, lesterolemic hamFood sters Chem.
resveratrol
efficiently
protect hypercho Agric
against aortic fatty 2005 Mar
streak accumulation., J
23;53(6):2015-21.
38. Oak MH, ogenic properties phenols from Biochem. 2005
El of
Bedoui J, natural poly-
Schini-Kerth green tea.,
VB., J
Antiangi Nutr
red wine and Jan;16(1):1-8.
39. Caimi G, Carollo C, Lo failure: oxidative stress, endothelial dysfunction Nov;62(5):331-5. and
Presti R., Nephrol.
Chronic renal 2004
wine., Clin
40. Fukao H, Yamashita T, Kawai Y,
Ijiri Y, Fukunaga Suwa M,
Miura C, Yamamoto
M, Oiwa
Hashimoto K, J.,
M,
Effect of
trans-resveratrol and ysis. genicity and low-density lipoprotein 2004 Sep;15(6):441-6.
on
the
thromboapolipoprotein E-deficient mice., Blood Coagul Fibrinol
atherogenicity in receptor-deficient
41. rol
Kollr P, and other wine]
Hotolov constituents Ceska Slov
H., Farm.
[Biological 2003
effects of
resverat
of [Czech.]
Nov;52(6):272-81.
42. wine, 2003
Schriever resveratrol,
C, Pendland Chlamydia pneu-
SL,
Mahady GB., Atherosclerosis.
Red
moniae and the Dec;171(2):379-80.
French connection.,
43. logy the
Bhavnani BR., of conjugated equine estrogens prevention of
Estrogens and their neurodesuch
and
menopause: role
pharmaco in J
potential as
generative Steroid Biochem Mol
diseases Biol. 2003
Alzheimer s.,
Jun;85(2-5):473-82.
44. F,
De de
Lorgeril Leiris J.,
M, Salen Resveratrol of
P, and wine
Guiraud A, in
Boucher
non-ethanolic cardiology., Nutr
components Metab
experimental
Cardiovasc
Dis.
2003
Apr;13(2):100-3.
45. Di
Di Santo Tommaso R,
A, Mezzetti Donati MB, De
A, Napoleone Gaetano and
E,
G, down-regulate
Lorenzet R., tissue factor exhuman 2003
Resveratrol vascular
quercetin cells., J
pression by Thromb Haemost. May;1(5):1089-95.
stimulated
46. ols of
Zern TL, decrease
West KL, Fernandez plasma triglycaccumulation
ML., in
Grape the
polyphen aorta
erides and cholesterol ovariectomized guinea pigs., J Nutr. 2003
Jul;133(7):2268-72.
47. Sovak M., Analogs: A 2001
Grape Extract, Review., J
Resveratrol, Med Food.
and
Its
Summer;4(2):93-105.
48. of
Goldberg DM, three wine-related in Clin
Yan J, polyphe-
Soleas GJ., matrices
Absorption by healthy
nols subjects.,
three different Biochem. 2003
Feb;36(1):79-87.
49. Buzas
Slater SJ, Seiz CJ., Inhibition
JL, of
Cook AC, Stagliano protein kinase Biochim Biophys Acta. 2003
BA, Jan
C by 20;1637(1):59-69.
resveratrol.,
50. of n.,
Brito P, resveratrol globin Free 2002 and Radic
Almeida LM, Dinis with ferrylmyo-
TC.,
The
interaction oxidatio
peroxynitrite; protection Res.
against LDL
Jun;36(6):621-31.
51. Ignatowicz natural chemoprotective agent Pharmacol. 2001
E,
Baer-Dubowska
W.,
Resveratrol, Pol
a J
against degenerative
diseases.,
Nov-Dec;53(6):557-69.
52. Soleas GJ, Diamandis EP., wine
Grass A
L, Josephy PD, comparison of
Goldberg of four
DM, red
the anticarcinogenic properties polyphenols., Clin Biochem. 2002 Mar;35(2):119-24.
53. Y,
Wang Wu
Z, JM.,
Zou J, Effect of
Huang Y, resveratrol in
Cao on
K, Xu platelet Med
aggregation (Engl). 2002
in vivo and Mar;115(3):378-80.
vitro., Chin
54. Landrault Castagnino C, of rot JM, Gasc stilbene
N, Larronde Vercauteren J, F, Cros oligomers wines Agric Mar G, and and
F, Delaunay Merillon Teissedre astilbin in PL., in
JC, Levels
French varietal development., J Food Chem. 2002
grapes during noble
27;50(7):2046-52.
55.
Ratna WN,
Simonelli
JA.,
The
action of
dietary
phytochemicals quercetin, d echin, gene Sci. resveratrol expression., 2002 Feb
catand Life naringenin on estrogen-mediate
15;70(13):1577-89.
56. Pendurthi Mechanism of
UR, Meng F, resveratrol-mediof
Mackman N,
Rao
LV.,
ated suppression Thromb Haemost. 2002 Jan;87(1):155-62.
tissue factor gene
expression.,
57. n
Ruef of
J, Moser endothelin-1
M, Kbler W, expression by vascular
Bode
C.,
Inductio
oxidative stress in Cardiovasc Pathol. 2001 Nov-Dec;10(6):311-5.
smooth muscle cells.,
58. Y, vivo
Wang Wu phenol and 2002
Z, JM.,
Huang Y, Effects of
Zou red
J, wine
Cao and
K, wine
Xu polyin
resveratrol on in vitro., Int Jan;9(1):77-9.
platelet J Mol
aggregation Med.
59. AC,
Bhavnani Berco M.,
BR, Cecutti A, Comparison of
Gerulath the
A, red
Woolever wine in
antioxidant effects of components, vitamin E, and probucol on low-density postmenopausal women., Menopause. 2001
equine estrogens, lipoprotein
oxidation
Nov-Dec;8(6):408-19.
60. JG, ant
Wu Huang
JM, YZ.,
Wang ZR, Mechanism by red
Hsieh of
TC, Bruder JL, cardioa J phenolic Mol
Zou antioxid
protection present in Med. 2001
resveratrol, wine., Int
Jul;8(1):3-17.
61. A, s
Russo P, Cicala C.,
Tedesco I, Effects of
Russo M, de-alits Nutr
Russo
GL,
Venezia fraction
coholated red on platelet Metab Cardiovasc
wine and aggregation., Dis. 2001
phenolic
Feb;11(1):25-9.
62. JM.,
Bruder JL, Hsieh Induced cytoskeletal
T, Lerea changes
KM,
Olson
SC, cells
Wu by shear
in resveratrol nying stress.,
bovine pulmonary artery endothelial and the accompamodified BMC Cell responses to Biol. 2001;2:1.
arterial
63. tic
Heredia inhibition
A, of
Davis HIV-1 blood
C, in
Redfield activated
R., and
Synergis
resting peripheral macrophages, de
mononuclear
cells, monocyte-derived with J nucleosi Acquir
and selected drug-resistant isolates analogues combined a natural product, Syndr. 2000 Nov resveratrol.,
with Immune Defic
1;25(3):246-55.
64. Fong in
Chan D., and the inducible
MM, Mattiacci JA, Synergy between ethanol grape polyphenols, inhibition of nitric oxide
Hwang
HS, and
Shah
A,
quercetin, the synthase
resveratrol, Biochem
pathway.,
Pharmacol.
2000
Nov
15;60(10):1539-48.
65. Mizutani K, inhibits AGEs-induced and collagen smooth muscle cells from prone Commun. 2000 Jul spontaneously 21;274(1):61-7.
Ikeda K, proliferation synthesis strokehypertensive
Yamori Y., activity
Resveratrol in vascular
rats., Biochem Biophys Res
66. lou
Fragopoulou E, CA, Demopoulos of Food
Nomikos T, CA., biologically Chem. 2000
Antonopoulou
S,
Mitsopou red
Separation wine., J Agric Apr;48(4):1234-8.
active lipids from
67. Hsieh TC, Juan Resveratrol increases
G, Darzynkiewicz nitric oxide of
Z, p53
Wu and cell
JM., p21(WAF1 prolifer 1999
synthase, induces accumulation /CIP1), and suppresses ation Jun cultured bovine pulmonary by perturbing progression through S 1;59(11):2596-601.
artery endothelial and G2.,
Cancer Res.
68. ion :811-6.
Belguendouz L, Frmont L, of transresveratrol with plasma
Gozzelino 1998
MT., Mar
Interact 15;55(6)
lipoproteins., Biochem Pharmacol.
69. rol:
Soleas GJ, Diamandis molecule whose And
EP, time
Goldberg Biochem.
DM.,
Resverat 1997
has come? Mar;30(2):91-113.
gone?, Clin
70. EP, ion
Pace-Asciak Goldberg grape in Clin
CR, DM.,
Rounova O, Wines and modulators subjects., 1996 Mar
Hahn of
SE, platelet
Diamandis aggregat
juices as healthy human Chim Acta.
15;246(1-2):163-82.
71. RL., Sci.
Wilson T, Resveratrol
Knight TJ, promotes
Beitz ath-
DC,
Lewis
DS,
Engen Life
erosclerosis in 1996;59(1):PL15-21.
hypercholesterolemic
rabbits.,
72. G, human on .
Pace-Asciak Goldberg phenolics platelet
CR, DM.,
Hahn The
S, red
Diamandis wine and
EP,
Soleas block protecti
trans-resveratrol aggregation synthesis: heart Chim Acta.
quercetin for
and eicosanoid against coronary disease., Clin
implications 1995 Mar
31;235(2):207-19
Breast
Cancer and
Resveratrol
1. Schlachterman A, Valle Castillo L, Morell L, rol, nude AV, Cubano LA, quercetin, and catechin treatment mouse model., Transl Oncol. 2008
F, Wall Washington
KM, Combined
Azios
NG, resverat a
Dharmawardhane SF., reduces breast tumor Mar;1(1):19-27.
growth in
2. Lim 31
Nguyen TH, Mustafa FB, LH., ERK1/2 activation is quired for cells., Int 2008 resveratrol-induced J Oncol.
Pervaiz S, reapoptosis
Ng in
FS, MDA-MB-2
Jul;33(1):81-92.
3. Wang Y, Ye feedback pathway of sis resveratrol.
L, Leung estrogen
LK., A biosyntheis
positive by
in breast cancer cells ,Toxicology. 2008 Jun
contained
27;248(2-3):130-5.
4. Kline
Snyder RM, K., Vitamin E
Yu W, Jia analog alphaand
L,
Sanders BG, in
TEA, combination Nutr
methylseleninic acid, synerinhibit human
trans-resveratrol growth.,
gistically Cancer. 2008
breast cancer cell
May-Jun;60(3):401-11.
5. V,
Murias M, Zielinska-Przyjemska
Luczak MW, M, Jger W, activity
Niepsuj A, Szekeres of
Krajka-Kuzniak T, Jodynisis
Jagodzinski PP, Liebert J., Cytotoxic
3,3 ,4,4 ,5,5 -hexahydroxystilbene mediated by drial induction superoxide of p53 dismutase. and
against breast cancer cells downregulation of
mitochon
,Toxicol In
Vitro. 2008
Aug;22(5):1361-70.
6. M, And
De
Singh SK, Len
Moretta D, Almaguel F, DD., Precursor IGF-II and mature IGF-II (mIGF-II) expression pathways
De
Len
(proIGF-II) Bcl-X L
induce Bcl-2 in breast
through different signaling cancer cells. ,Growth Factors. 2008 Apr;26(2):92-103.
7. M,
Zahid M, Yang L,
Gaikwad NW, Rogan EG,
Ali MF, Cavalieri
Lu EL.,
F,
Saeed in
Prevention MCF-10F cells by trol., Free
of estrogen-DNA resveraRadic Biol Med.
adduct formation 2008 Jul
15;45(2):136-45.
8. Scarlatti Ghidoni R., Role by
F, of
Maffei R, non-canonical autophagy
Beau in Death
I, cell
Codogno P, death induced Aug;15(8
Beclin 1-independent resveratrol in
human ):1318-1329.
breast cancer cells., Cell
Differ. 2008
9. Wu Burghardt by -15.
F, R,
Khan Safe
S, S.,
Wu Q, Barhoumi Ligand structure-dereceptor Biol. 2008
R, alpha/Sp
pendent activation estrogens and gens., J
of estrogen xenoestro-
Steroid Biochem Mol
May;110(1-2):104
10. KS., Mol
Tang FY, Resveratrol tion Nutr and Food
Su YC, inhibits invasion Res. 2008
Chen NC, migraof human
Hsieh
HS,
Chen cells.,
breast-cancer
Jun;52(6):683-91.
11. De
Singh SK, Len M, of death
Moretta D, De Len
Almaguel F, D., Differential IGF-II on localization 2007
Wall
NR,
effect induced cell drial
proIGF-II and by regulatcellular breast
resveratrol and mitochon
ing survivin depolarization in cancer
cells., Growth Factors.
Dec;25(6):363-72.
12. B, human
Dip R, Gmuender
Lenz H,
S, Antignac JP, Naegeli H., Global gene induced by
Le
Bizec
expression profiles breast cancer cells., Endocr Relat Cancer. 2008
phytoestrogens in
Mar;15(1):161-73.
13. S, A,
Bader Y, Saiko P, D, Jger
Madlener Stark N, M, B,
S, Strasser Popescu R, Huber Erker T, Tentes I, G, cycle
S,
Maier Szakmary T.,
Gollinger W, Kopp
Handler N, Szekeres of
Fritzer-Szekeres M, Stilbene analogues other progression in an and MCF-7
Krupitza affect cell apoptosis array distinct
independently genetic and
each
of backgrounds., 2008
clones with Oncol Rep.
chemoresistant
Mar;19(3):801-10.
14. RA,
Ma Z, Lavasanifar
Molavi O, Haddadi A, A., Resveratrol
Lai
R,
Gossage
analog anti-tumor
trans
3,4,5,4 -tetramethoxystilbene different 20.
(DMU-212) from that
mediates of
effects via mechanism resveratrol., Cancer Chemother Pharmacol. 2008 Feb
15. KJ, r
Huang TC, Juan HF.,
Chang HY, Targeting
Hsu CH, therapy by ATP Proteome
Kuo synthase Res.
WH,
Chang inhibito
for breast carcinoma aurovertin B., J 2008 Apr;7(4):1433-44.
16. O,
Alkhalaf Ali A,
M, El-Mowafy Al-Attyiah R., in human through
A, Renno Resveratrol-
W,
Rachid is Res.
induced apoptosis mediated primarily 2008
breast cancer cells Arch Med
the caspase-3-dependent Feb;39(2):162-8.
pathway.,
17. Khan N, Afaq through dietary antioxidants: Signal. 2008
F,
Mukhtar H., promise.,
Cancer chemoprevention Antioxid Redox
progress and Mar;10(3):475-510.
18. Murias M, Thalhammer T, Jaeger cancer cell on.,
Miksits M, Szekeres
Aust T, of sul-
S,
Spatzenegger in
M, breast
W., Metabolism lines: impact of 1A1 2008
resveratrol on cell
fotransferase Cancer Lett. 18;261(2):172-82.
expression Mar
growth inhibiti
19. Zahid M, Inhibition of Chem
Gaikwad NW, depurinating
Rogan es-
EG, by
Cavalieri
EL.,
trogen-DNA adduct formation Res Toxicol. 2007 Dec;20(12):1947-53.
natural compounds.,
20. DF.,
Degner SC, Kemp Cyclooxygenase-2
MQ, pro-
Hockings
JK, aromatic
Romagnolo hydrocarbon linoleic
moter receptor mcf-7 acid., Nutr
activation by the in breast cancer cells: repressive Cancer.
effects of
conjugated
2007;59(2):248-57.
21. L, by
Pearce VP, Wright WE,
Sherrell Shay JW.,
J,
Lou
Z,
Kopelovich cells mediated
Immortalization of resveratrol., Oncogene. 2008
epithelial Apr
progenitor
10;27(17):2365-74.
22. rol
Wesierska-Gadek J, modulates roscovitinecycle
Kramer MP, human
Maurer M., MCF-7
Resverat
mediated cell cells., Food Chem Toxicol. 2008
arrest of
breast cancer
Apr;46(4):1327-33.,
23. ML.,
Neves MA, Combining
Dinis TC, computational
Colombo G, and
e on
Melo the
biochemical studies for anti-aromatase activity of polyphenols., ChemMedChem.
a rationale natural 2007
Dec;2(12):1750-62.
24. Sareen D, Darjatmoko Mitochondria, calcium, and calpain are apoptosis in Mol
SR,
Albert DM, of
Polans AS.,
key mediators breast cancer., 2007
resveratrol-induced
Pharmacol.
Dec;72(6):1466-75.
25. r
Koohi MK, assay to
Walther N, discriminate
Ivell tran-
R.,
novel
molecula Cell
scriptional Endocrinol. 2007
effects caused by Sep
xenoestrogens., Mol
30;276(1-2):45-54.
26. a tic
Vetvicka V, A, Vancikova J., Glucan and effects on
Volny Z,
T, Saraswat-Ohri Vetvickova
S,
Vashisht synergis Palacky
resveratrol Biomed Pap
complex--possible Med Fac Univ
immune system., Olomouc Czech. 2007 Jun;151(1):41-6.
27. Tang FY, Chiang EP, heregulin-beta1-mediated in . matrix human cancer metalloproteinase-9 breast cells. J Nutr
Sun
YC.,
Resveratrol and 2008 cell
inhibits invasion
expression Biochem.
May;19(5):287-94
28. in
Alkhalaf MDA-MB-231
M., Resveratrol-induced breast associated and Eur J with
growth inhibition mitogen-activated 2007 Aug;16(4
cancer cells is protein kinase signaling protein translation. ):334-41.
Cancer Prev.
29. Alkhalaf associated with T47D p53 human
M., Resveratrol-induced activation of
apoptosis
is in
and inhibition of breast cancer cells.,
protein translation
Pharmacology.
2007;80(2-3):134-43.
30. Marcsek ZL, Effect of formaldehyde MCF-7 veratrol on cells., Cell the Biol
Kocsis Z, and resviability Int. 2007
Szende B, of Vero,
Tompa HepG2
A., and
Oct;31(10):1214-9.
31. ML., or
Su JL, Forkhead
Yang CY, proteins
Zhao are
M, Kuo critical regulation Jul
ML, for and
Yen anti-tum
bone morphogenetic activity of trol., J Biol
protein-2 resveraChem. 2007
6;282(27):19385-98.
32. Benitez Castelln E, and Non-genomic oestrogen
DA, Pozo-Guisado Fernandez-Salguero action of receptors
E, PM.,
Clementi on androgen
M,
resveratrol in of J the
prostate cancer: modulation 3-kinase pathway., Br Cancer. 2007 May
phosphoinositide
21;96(10):1595-604.
33. Le Corre Bernard-Gallon DJ., human
L, Chalabi N, Differential
Delort L,
Bignon YJ, in
expression of breast cancer cell Nutr
genes induced by lines.,
resveratrol
Cancer. 2006;56(2):193-203.
34. in
La Vecchia C, Bosetti C., Mediterranean countries: open issues., Public Health Nutr. 2006
Diet
and
cancer risk
Dec;9(8A):1077-82.
35. Azios NG, Cammer M, Rac Dharmawardhane and Cdc42
Krishnamoorthy L, SF., Estrogen signal-
Harris M, and
Cubano LA, regulate
resveratrol of
ing to the actin breast cancer cells., Neoplasia. Feb;9(2):147-58.
cytoskeleton 2007
metastatic
36. Y,
Li Li
Y, F,
Liu Yao
J, L.,
Liu X, Xing Resveratrol-induced in
K, cell MCF7
Wang inhibihuman and
tion of breast cancer cells ated caspase-9., with Appl
growth and apoptosis are associmodulation Biochem 2006 of
phosphorylated Akt
Biotechnol.
Dec;135(3):181-92.
37. Ito , p53
Shibata MA, T, Mishima S, Y., Vaticanol reduces lymph node metastases mutation., Chemother
Akao Y, Morimoto C, and a lung
Shibata E, Nozawa Y, J, Otsuki novel resveratrol carrying tetramer
of mouse Cancer Pharmacol.
mammary carcinoma 2007
Oct;60(5):681-91.
38. Bader Y, mixtures of mitomycin Anticancer Res.
Getoff N., resveratrol C 2006 on
Effect of and cancer cells
resveratrol under
and
irradiation.,
Nov-Dec;26(6B):4403-8.
39. Zhao for
Landis-Piwowar KR, Y, Chan TH, QP., novel
Milacic V, Yan B, as and
Chen Dou a che-
D,
Yang
H, target
The proteasome anticancer drugs Drug
potential Dec;9(6):263-73.
mosensitizers.
Resist Updat. 2006
40. and rat.,
Whitsett resveratrol:
TG Jr, Lamartiniere mammary cancer of
CA.,
Genistein the
chemoprevention and mechanisms Expert Rev Anticancer Ther. 2006 Dec;6(12):1699-706.
action in
41. Narayanan BA., expression pattern: Curr predicting Cancer Drug Dec;6(8):711-27.
Chemoprotective agents alters global gene of 2006 action and targets.,
their mode Targets.
42. Wu wild-type ogens
F, Safe estrogen
S., Differential receptor alpha mutants by
activation and estrogens, Biol.
of antiestr 2007
C-terminal deletion and xenoestrogens in
breast cancer cells., J Jan;103(1):1-9.
Steroid Biochem Mol
43. Ebert B, Seidel A, breast cancer resistance of protein in Caco-2 cells benzo[a]pyrene-3-sulfate.
Lampen A., and
Phytochemicals induce transport
enhance the
Toxicol Sci.
2007
Apr;96(2):227-36.
44. WY., Cai.
Feng L, [Studies cer 2006 [Chinese]
Zhang on
LF, Yan T, active substance
Jin of
J, Tao anticanZhong Yao
effect in Polygonum Jul;29(7):689-91.
cuspidatum],
45. F, Borst
Breedveld P, van Eijndhoven Kuil P,
Pluim MA,
D, de
Cipriani Wolf CJ,
G,
Dahlhaus
A, Beijnen JH, Schellens JH., pH on transport
Scheffer GL, The effect of
Jansen G, protein (ABCG2)diglutamate, in in
low mediated folic vitro
breast cancer resistance of
methotrexate, acid,
7-hydroxymethotrexate, methotrexate resveratrol
mitoxantrone, topotecan, and drug transport models., Mol Pharmacol. 2007
Jan;71(1):240-9.
46. BY, Bao.
Ge Wang sion 2006 30.
H, CQ.,
Zhang JF, [Resveratrol
Guo BS, inhibits macrophages],
He B, expresYao Xue
Wang Xue
of EMMPRIN from Jul;41(7):625[Chinese]
47. Sala
Dolfini G, Erba
E, E,
Roncoroni Sacchi N,
L, Dogliotti Ghidoni R.,
E,
Resveratrol multicellular tumor spheroids Cancer Lett. 2007 8;249(2):143-7.
impairs the concomitant May
formation with ceramide
of
MDA-MB-231 accumulation.,
48. PJ, human
Tang Lin
HY, HY.,
Shih A, Cao Resveratrol-induced
HJ, Davis cyclo-
FB,
Davis in
oxygenase-2 facilitates breast cancer cells. Mol Cancer Ther. 2006
p53-dependent
apoptosis
Aug;5(8):2034-42.
49. Tang Davis J.
Lin HY,
HY, Shih
Lansing L, Merillon A, Vitrac X, Krisa HJ, Bergh alphaVbeta3 site J, for
JM, S,
Davis
FB, S, FASEB
Keating T, Cao PJ., Integrin
Quackenbush resveratrol.,
contains a receptor 2006 Aug;20(10):1742-4.
50. Whitsett Resveratrol, but J
T, not
Carpenter EGCG, in DMBA-induced
M, the
Lamartiniere
CA., rats.,
diet suppresses Carcinog. 2006 May 15;5:15.
mammary cancer in
51. WY.,
Feng L, Analysis
Jin of
J, the
Zhang LF, Yan resveratrol-binding
T,
Tao Acta
protein using Biochim Biophys Sin
phage-displayed random peptide library., 2006 May;38(5):342-8.
(Shanghai).
52. i L, from
Severgnini M, F, Mezzelani Ghidoni R, Peano De Bellis G, Strategies different
Bicciato S, A, Mattioli C, Bonnal R, Battaglia C., gene
Mangano E, M, Viti F,
Scarlatt Milanesi profiles
for comparing microarray
expression
nt.,
platforms: application Anal Biochem. 2006 1;353(1):43-56.
to Jun
case-control
experime
53. LK., in
Wang The
Y, red
Lee wine
KW, Chan polyphenol
FL, Chen resveon
S,
Leung
ratrol displays bilevel inhibition breast cancer cells., Toxicol Sci. 2006 Jul;92(1):71-7.
aromatase
54. K, and d
Kotha A, Khaled A,
Sekharam Zervos AS, R., and
M, Cilenti L, Carter B, Resveratrol induces the inhibits
Siddiquee Src activate
Turkson J, Jove Stat3 signaling apoptosis of Stat3 protein., Ther. 2006
malignant cells Mol Cancer
containing
Mar;5(3):621-9.
55. Larrosa Toms-Barbern FA, by es., JC., human
M, Espn
Gonzlez-Sarras ellagic acid-derived and
A,
Garca-Conesa produced
MT,
Urolithins, colonic
metabolites
microflora, J Agric 2006 Mar
exhibit estrogenic Food Chem. 8;54(5):1611-20.
antiestrogenic activiti
56. of
Choi HK, resveratrol
Yang on
JW, the
Kang ex-
KW.,
Bifunctional
effect
Lett.
pression of 2006 Oct
ErbB2
in
human
breast cancer cell., Cancer
28;242(2):198-206.
57. Lanzilli Cottarelli A, O, of Ravagnan G, Bonmassar
G, Fuggetta Serafino A, Turriziani M, E., Resveratrol growth and in Oncol. 2006
MP, Tricarico Falchetti R, Adamo R, Franzese activity
M,
down-regulates the breast cancer cells vitro., Int J
telomerase Mar;28(3):641-8.
58. Vyas S, growth factor II
Asmerom Y, mediates
De Len resve-
DD.,
Insulin-like D in
ratrol stimulatory effect on breast cancer cells., Growth Factors. 2006 Mar;24(1):79-87.
cathepsin
59. rol
Garvin S, Ollinger induces apoptosis and in 2006 human Jan
K, Dabrosin inhibits
C.,
Resverat in
angiogenesis vivo., Cancer Lett. 8;231(1):113-22.
breast cancer xenografts
60. S,
Minutolo Carboni I,
F, Sala Placanica S, a
G, G,
Bagnacani Prota G, Macchia M, ana-
A,
Bertini
Rapposelli Synthesis of on logue human cancer
Sacchi N, resveratrol
Ghidoni R., activity
with high breast cells., J
ceramide-mediated Med Chem. 2005
proapoptotic Nov
3;48(22):6783-6.
61. E., J
Nifli AP, Polyphenol tion Dairy with Res.
Kampa M, interacthe T47D 2005;72 Spec
Alexaki VI, human
Notas
G,
Castanas line.,
breast cancer cell
No:44-50.
62. Heber iated 2005
Harris DM, Besselink E, D., Phytoestrogens induce differential responses estrogen receptor in transfect-
Henning SM,
Go
VL, Beta-med
alpha- or Biol Med
ed breast cancer cells., Exp Sep;230(8):558-68.
(Maywood).
63. Miller ME, Holloway increases invasion in MDA-MB-231 expression and glandin E2 2005;22(2):149-56.
AC,
Foster WG., via Clin
Benzo-[a]-pyrene COX-II
breast cancer cells prosta(PGE2) output.,
increased Exp
Metastasis.
64. The n
Blumenstein I, chemoprotective agent trol in Res. stimulates vitro., Clin 2005 Aug
Keser B, resvera-
Wolter F, chloride
Stein
J., secretio
cyclic AMP-dependent Cancer 1;11(15):551-6.
65. Vyas regulates
S, Asmerom Y, De insulin-like growth in
Len
DD.,
Resveratrol
factor-II Oct;146(10):4224-33.
breast cancer cells., Endocrinology. 2005
66.
Guastalla
JP,
Bachelot
T,
Ray-Coquard
I.,
[Cyclooxygenase 2 Bull
and
breast cancer. concepts 1;91 Suppl to 2: clinical trials],
From biological Cancer. 2004 May S99-108. Review. [French]
67. Matsumura Comparative study human
A, of
Ghosh A, oestroeight 2005
Pope
GS,
Darbre PD., MCF7
genic properties of breast cancer cells. J Steroid Biochem Mol Biol.
phytoestrogens in Apr;94(5):431-43.
68. Waite KA, elevates PTEN Hum Mol
Sinden MR, levels., Genet. 2005
Eng Jun
C.,
Phytoestrogen
exposure
1;14(11):1457-63.
69. l es, a.
Azios NG, Dharmawardhane SF., exert disparate effects on and focal assembly in 2005 Feb;7(2):128-40. cell migration, adhesion MDA-MB-231 human
Resveratrol cell
and
estradio structur
surface actin
breast cancer cells., Neoplasi
70. a of ative
Monthakantirat O, Y, Miyase T, Warashina T, the rhizomes medicinal activity plant for cancer cell
De-Eknamkul Noguchi H., of the Belamcanda two lines., J
W, Phenolic Thai
Umehara K,
Yoshinag
constituents with 2005 prolifer Mar;68(3
chinensis Nat Prod.
breast ):361-4.
71. Le Corre Bernard-Gallon DJ., Mol breast Nutr 2005
L, Chalabi N, Resveratrol and
Delort L, molecular
Bignon YJ, mechanisms.,
cancer chemoprevention: Food Res. May;49(5):462-71.
72. Levi Ferraroni
F, M,
Pasche C, Lucchini F, La Vecchia C., Resveratrol J
Ghidoni R, 2005
and breast cancer risk., Eur Apr;14(2):139-42.
Cancer Prev.
73. E, rol and
Rodrigue Bracke M,
CM, Romeo
Porteu F, Navarro N, PH, Gespach The
Bruyneel resverat
C, Garel MC., induces tensin,
cancer chemoprotective agent protein with 5;24(20):3274-84.
a cell-matrix adhesion antitumor activities., Oncogene. 2005 May
signaling
74. Pozo-Guisado E, Benayas MJ, Centeno
Merino JM, A,
Mulero-Navarro S, Fernandez-Salguero involves and J
LorenzoPM.,
F, Alvarez-Barrientos Resveratrol-induced apopa B., 2005 tosis in MCF-7 caspase-independent mechanism Int J May Oct human
breast cancer cells Bcl-2 Int
with downregulation of Cancer. 2005 Erratum in: M M]. Fernandez
NF-kappa Cancer. to
20;115(1):74-84. 10;116(6):1004. Pedro Pedro
Salguero, Fernandez-Salguero,
[corrected
75. J.,
Wietzke Regulation
JA, of
Ward the
EC, human
Schneider vitamin
J,
Welsh
is
D3 receptor promoter in mediated through Sp1 sites., Mol Cell Endocrinol. 2005 Jan
breast cancer cells 31;230(1-2):59-68.
76. ve
Manson MM, agents in prevention.,
Farmer PB, cancer
Gescher A,
Steward WP., 2005;166:257-75.
Innovati
Recent Results Cancer Res.
77. JK, in J
Kim H, Barnes S,
Hall P, Grubbs C., grape
Smith seed rats
M,
Kirk
M,
Prasain
Chemoprevention by carcinogen-
extract and is diet
genistein dependent.,
induced mammary cancer in Nutr. 2004 Dec;134(12 Suppl):3445S-3452S.
78. Aggarwal BB, Seeram NP, Shishodia of
Bhardwaj A, S, Takada Y.,
Aggarwal and
RS, therapy
Role of resveratrol cancer: preclinical and studies. Anticancer Res.
in prevention clinical 2004
Sep-Oct;24(5A):2783-840.
79. n
Bianco NR, Chaplin LJ, of quinone re-
Montano MM.,
Differential
inductio
ductase by n-induced DNA
phytoestrogens and
protection
against oestroge
damage. Biochem J.
2005
Jan
1;385(Pt
1):279-87.
80. PJ, and
Zhang S, Lin HY., ratrol-induced apoptosis cancer
Cao HJ, Oestrogen
Davis FB, inhibits
Tang HY, resveof
Davis p53
post-translational in breast J
modification Jul
cells. Br
Cancer. 2004
5;91(1):178-85.
81. and Berry the
Simopoulos cancer., 2004 JP,
AP., Eur
The J
traditional Cancer Prev. Laux MT, Rodriguez
diet
of
Greece M,
Jun;13(3):219-30. Flanders JA,
Aregullin
E., Identification of a induction of apoptosis human J breast cancer cells Altern Med. 2004
p53-dependent by the
pathway in natural product,
of resveratrol.,
Complement
Apr;10(2):235-9.
82. Le Corre Bernard-Gallon D., of Chim
L, Fustier P, Effects of the with
Chalabi N, of
Bignon YJ, a panel
resveratrol on genes interacting BRCA1 Acta.
expression the human
oncosuppressor in 2004
breast cell
lines., Clin
Jun;344(1-2):115-21.
83. Sala Ghidoni R.,
G, Minutolo F, Resveratrol structure
Macchia M, and in
Sacchi N, prostate
ceramide-associated cancer cells., Drugs Exp Clin Res.
growth inhibition
2003;29(5-6):263-9.
84. Gehm Amundsen
BD, BM,
Levenson Cushman M, Estrogenic
AS, Liu Jordan VC, effects of
H,
Lee
EJ, in
Jameson JL.,
resveratrol
breast cancer cells role ing of
expresswild-type AF-2., J 2004 estrogen Steroid receptors:
mutant and AF-1 and Biol.
Biochem Mol
Mar;88(3):223-34.
85. SB, ols.,
Cooray HC, Barrand MA.,
Janvilisri Interaction
T, of
van
Veen
HW, plant
Hladky polyphen
the breast cancer resistance Biochem Biophys Res Commun. 2004 Apr
protein with
23;317(1):269-75.
86. SR, in
Jo Park
EH, JS,
Hong Kim
HD, SH,
Ahn Lee
NC, YS,
Jung Kang
JW, KS.,
Yang involved
Modulations of the the chemoprotective
Bcl-2/Bax
family were
effects of Fisch) in MCF-7 cancer :1715-9.
licorice root human breast Agric Food
(Glycyrrhiza Chem. 2004
uralensis Mar 24;52(6)
cell., J
87. a
Cheung CY, real-time
Chen J, polymerase the
Chang chain
TK.,
Evaluation
of
reaction method for expression in MCF-7 human Toxicol Methods.
quantification of cells., J
CYP1B1 gene Pharmacol
breast carcinoma 2004
Mar-Apr;49(2):97-104.
88. PM.,
Pozo-Guisado Resveratrol
E,
Lorenzo-Benayas MJ, phosphoinositide recep-
Fernndez-Salguero 3-kinase pathway in cell
modulates the through an estrogen
tor alpha-dependent mechanism: proliferation., Int J Cancer. 2004 Mar 20;109(2):167-73.
relevance
89. Fulda S, Debatin KM., factor-related apopto-
Sensitization
for by
tumor the
necrosis chemopro
sis-inducing ligand-induced apoptosis tective agent resveratrol. Cancer Res. 2004 Jan
1;64(1):337-46.
90. SH, human
Kim Park
YA, KY,
Choi Choi
BT, YH.,
Lee YT, Resveratrol and 2004
Park
DI,
Rhee of
inhibits cell proliferation breast carcinoma MCF-7 cells., Oncol Rep.
induces apoptosis Feb;11(2):441-6.
91. A.,
Hose CD, Induction
Hollingshead M, of CYP1A1 in the
Sausville agent
EA,
Monks
tumor cells by hylphenyl]-5-fluoro-benzothiazole: patient sensitivity., Ther. 2003 a Mol
antitumor
2-[4-amino-3-met marker for
potential Cancer
surrogate
Dec;2(12):1265-72.
92. P, ic
Scarlatti Sacchi N,
F, Sala Ghidoni R.,
G, Somenzi G, Resveratrol and apoptosis FASEB
Signorelli in J. metastat 2003
induces growth inhibition breast cancer cells via ceramide
de novo Dec;17(15):2339-41.
signaling.,
93. Fustier P, abatier C, Communal
Le Y,
Corre L, Bignon YJ,
Chalabi N,
Vissac-S
BRCA2 2003
Bernard-Gallon DJ., mRNA expression Jul
Resveratrol
increases lines., Br
BRCA1 J
and Cancer.
in breast tumour cell 7;89(1):168-72.
94. by ms
Aziz MH, resveratrol: and in (review)., Jul;23(1):17-28.
Kumar in vivo Int
R, vitro
Ahmad
N.,
Cancer chemoprevention underlying mechanis
studies and the J Oncol. 2003
95. s dent
El-Mowafy AM, adenylyl-cyclase
Alkhalaf in human
M.,
Resveratrol
activate
breast cancer cells: a cytostatic mechanism. Carcinogenesis. 2003
novel, estrogen May;24(5):869-73.
receptor-indepen
96. RK., Asian
Roy M, Induction in Pac Tumor J
Chakraborty S, of Apoptosis Cells by Cancer Prev.
Siddiqi M,
Bhattacharya Compounds.,
Natural Phenolic
2002;3(1):61-67.
97. of
Wietzke
JA, Vitamin D3
Welsh J., receptor
Phytoestrogen proD3
regulation human
moter and 1,25-dihydroxyvitamin breast cancer cells., J Steroid Biochem Mol Biol. 2003
actions in
Feb;84(2-3):149-57.
98. Eder Agric
Klinge CM, Risinger R, Jungbauer A., activity in Food Chem. 26;51(7):1850-7. white 2003 and Mar
KE, Watts Estrogenic red wine
MB,
Beck
V, J
extracts.,
99. J,
Levenson Simons LA,
AS, Ward
Gehm JE
BD, 3rd,
Pearce ST, acts
Horiguchi as with an ER
Jameson JL, Jordan VC., estrogen receptor (ER) in alpha., Int breast cancer cells J Cancer. 2003
Resveratrol agonist
stably transfected May
1;104(5):587-96.
100. Schmitt Hormonal and . of
E, Lehmann L, Metzler M, genotoxic activity Toxicol Lett. 2002 Dec
Stopper H., 15;136(2):133-42
resveratrol.,
101. SF,
Brownson Mabry TJ.,
DM, Azios Flavonoid
NG, cancer.,
Fuqua
BK, J
Dharmawardhane Nutr. 2002
effects relevant to Nov;132(11 Suppl):3482S-3489S.
102. ation
Ding and
XZ, Adrian TE., induces apoptosis pancreatic
Resveratrol
inhibits
prolifer 2002
in human Nov;25(4):e71-6.
cancer cells., Pancreas.
103. S,
Pozo-Guisado E, Santiago-Josefat
Alvarez-Barrientos PM., The MCF-7 of
A,
Mulero-Navarro
B, activity
Fernandez-Salguero of resveratrol
antiproliferative but the not cell in cycle.,
results in MDA-MB-231 human
apoptosis in breast cancer alteration Nov
cells: cell-specific Biochem Pharmacol. 2002
1;64(9):1375-86.
104. Banerjee Suppression of
S, Bueso-Ramos 7,12-dimethylbenz
C,
Aggarwal rats and
BB., by matrix
(a)anthracene-induced resveratrol: role
mammary carcinogenesis in
of nuclear factor-kappaB, cyclooxygenase 2, metalloprotease 9. Cancer Res. 2002 Sep 1;62(17):4945-54.
105. KM,
Levenson Kaiser SA,
AS, Ward
Kliakhandler JE 3rd,
IL,
Svoboda KM,
Pease
Jordan oestrogen of Aug
VC., Molecular classification of receptor modulabasis of expressing gene
selective profiles
tors on the breast cancer cells oestrogen receptor 12;87(4):449-56.
expression J
alpha., Br
Cancer. 2002
106. Dubuisson modulates human and
JG, Dyess mammary
DL,
Gaubatz JW.,
Resveratrol
epithelial cell kinase activation heterocyclic 2002 Aug
O-acetyltransferase, of amine carcinogen
sulfotransferase, N-hydroxy-PhIP.,
the Cancer Lett.
8;182(1):27-32.
107.
Levenson
AS,
Svoboda KM,
Pease
KM,
Kaiser SA,
Chen with
B,
Simons LA, PA, of
Jovanovic Jordan VC., Gene the estroalpha-selective estrogen breast wild-type estrogen expression receptor receptor profiles
BD, Dyck activation
gen modulator .,
receptor complex in
cancer cells Cancer Res. 1;62(15):4419-26.
expressing 2002 Aug
108. HD, of
Kim Rhee
HJ, CH,
Chang Park
EJ, JH,
Bae Choi
SJ, SW.,
Shim
SM, from
Park seeds
Cytotoxic and Paeonia lactiflora., Pharm Res. 2002
antimutagenic Arch Jun;25(3):293-9.
stilbenes
109. Eng Tekmal RR, Sci.
ET, Chen
Williams D, Mandava U, S., Anti-aromatase wine., Ann N
Kirma Y
N, Acad
chemicals in red 2002 Jun;963:239-46.
110. Bruggisser Schaffner W, Interference antioxidants with tetrazolium
R, von Daeniken Tullberg-Reinert H., of the plant MTT extracts, 2002
K,
Jundt
G,
phytoestrogens and May;68(5):445-8.
assay. Planta Med.
111. rol Res
Bove on
K, Lincoln DW, growth of 4T1 in Mar vitro
Tsan MF., breast and in
Effect of
resverat
cancer cells Commun. 2002 8;291(4):1001-5.
vivo., Biochem Biophys
----------------------- Page 73----------------------Resveratrol and its effects on human health and longevity - Myth or mi
racle?
112. on Redox
Serrero G, the expression modulators Signal. 2001 Dec;3(6):969-79., in
Lu of human
R., Effect of resveratrol autocrine growth breast cancer cells., Antioxid
113. so 2001
Simopoulos special about Greece? Nov;131(11
AP., the
The diet
Mediterranean of
diets: What J
is Nutr.
The scientific Suppl):3065S-73S.
evidence.,
114. Moon
Bhat RC,
KP, Lantvit D, Christov Pezzuto JM., Estrogenic antiestrogenic properties models., Res. 2001 Oct of
K,
Mehta
RG, in
and mammary tumor Cancer
resveratrol
15;61(20):7456-63.
115. Lee nscriptional
JE, Safe mechanism
S., in
Involvement of the inhibiby
post-tra in
tion of CYP1A1 expression breast cancer cells., Biochem Pharmacol. 2001 Oct
resveratrol
15;62(8):1113-24.
116. na cell Sep
Sgambato A, Wolf Resveratrol, proliferation
A, FI, a and
Ardito R, Cittadini natural phenolic preDNA damage.,
Faraglia A.,
B, compound, Mutat Res.
Boninseg inhibits 2001
vents oxidative 20;496(1-2):171-80.
117. M,
Soleas GJ, Diamandis
Goldberg EP., Do
DM, wine
Grass L, polyphe-
Levesque
nols cancer cell 2001
modulate lines?, Clin
p53 gene Biochem.
expression
in
human
Jul;34(5):415-20.
118. the
Pervaiz bedside?,
S., Leuk
Resveratrol--from Lymphoma. 2001
the
bottle to
Feb;40(5-6):491-8.
119. H, and cell
Nakagawa Shikata N,
H, Hioki
Kiyozuka Y, K, Tsubura A., human
Uemura Y,
Senzaki growth
Resveratrol inhibits may mitigate the effect of stimulator., Oncol. 2001
breast cancer cell a Clin
linoleic acid, J Cancer Res Apr;127(4):258-64.
potent breast cancer
120. Cuendet M, genase and lipoxygenase
Pezzuto JM., in Drug
The
role
of
cyclooxy
cancer chemoprevention., 2000;17(1-4):109-57.
Metabol Drug
Interact.
121. Huber J., [Phytoestrogens and classical hormone therapy?] Ther Umsch. 2000
SERMS, alternatives Oct;57(10):651-4.
to [German]
122. G,
Damianaki Hatzoglou
A, A,
Bakogeorgou Panagiotou
E, S,
Kampa
M,
Notas
E., J
Gemetzi C, Kouroumalis E, Potent inhibitory action of red Cell wine polyphenols Biochem. 2000 on Jun
Martin PM, human
Castanas
breast cancer cells.,
6;78(3):429-41.
123. G, and
Basly JP, Chulia AJ.,
Marre-Fournier F, Estrogenic/anscavenging Life Sci.
Le
Bail
JC, of
Habrioux (E)-
tiestrogenic and (Z)-resveratrol., 2000 Jan
properties
21;66(9):769-77.
124. T, ption
Subbaramaiah Telang N, AJ., in
K, Michaluart Dannenberg
P,
Chung
WJ,
Tanabe transcri
Resveratrol inhibits human mammary cells., Ann N
cyclooxygenase-2 Y Acad Sci.
epithelial :214-23.
1999;889
125. ants 1999
Weisburger JH., as exemplified
Mechanisms in vegtea.,
of Food
action of Chem
antioxid
etables, tomatoes and Sep-Oct;37(9-10):943-8.
Toxicol.
126. ner
Ulsperger G, Hejna
E, M,
Hamilton Hoffmann Resveratrol
G, O,
Raderer M,
Baumgart
Mallinger R., AHTO-7 human osteoblasts carcinoma Oncol. to cell 1999
pretreatment in J response
desensitizes to
growth stimulation supernatants., Int Nov;15(5):955-9.
127. Gottlieb pinpointing an Cancer Inst.
N., Soybean in anti-cancer effect., 1999 Oct 6;91(19):1610-2.
a J
Haystack? Natl
128.
Hsieh TC,
Burfeind
P,
Laud
K,
Backer JM,
Traganos on ic JM., by
F,
Darzynkiewicz
Z,
Wu control of gene expressi metastat
Cell cycle resveratrol
effects and in human cell J
breast carcinoma potentials., Int 1999
lines with Oncol.
different
Aug;15(2):245-52.
129. Lu derived from of
R, Serrero G., grape, exhibits
Resveratrol, inhibits
natural product the growth
antiestrogenic activity and human breast cancer cells. J Cell Physiol. 1999
Jun;179(3):297-304.
130. N,
Subbaramaiah Tanabe T,
K, Inoue
Chung H,
WJ, Jang AJ., in
Michaluart M, Resveratrol
P,
Telang
Pezzuto JM, cyclooxygenase-2 tion and mammary epithelial Biol Chem.
Dannenberg transcripactivity cells., J 1998 Aug
inhibits human
phorbol ester-treated
21;273(34):21875-82.
131. Clment Chemoprotective agent CD95 Aug veratrol, signaling-de-
MV, resa
Hirpara JL,
Chawdhury
SH,
Pervaiz S.,
natural product derived from in human tumor
grapes, triggers
pendent apoptosis 1;92(3):996-1002.
cells., Blood. 1998
132. red Eur
Kopp wine. nation J
P., A
Resveratrol, possible
a phytoestrogen explaof the
found
in
for the Endocrinol.
conundrum 1998
French paradox ?,
Jun;138(6):619-20.
133. Fang insecticide:
N, Casida JE., correlation for
Anticancer rot-
action of of
cub
enoid constituents oxidoreductase Natl and Acad Mar
between inhibition decarboxylase A. 1998
NADH:ubiquinone Proc
induced ornithine Sci U S 31;95(7):3380-4.
activities.,
134. e
Mgbonyebi effect of
OP, Russo synthetic
J, Russo resvera-
IH.,
Antiproliferativ J
trol Oncol. 1998
on human breast epithelial Apr;12(4):865-9.
cells., Int
135. Gehm Resveratrol, for
BD, a
McAndrews polyphenolic
JM,
Chien wine, S
PY, is A.
Jameson JL., an 1997 agonist Dec
compound found in the estrogen Acad
grapes and receptor., Sci U
Proc Natl 9;94(25):14138-43.
Chemoprotective
effects of
resveratrol
1. of a
Langcake,P. resveratrol era and response Physiol. Plant
and by other to Pathol.,
Pryce,R.J. (1976) The Vitis vinifmembers of infection 9, the or 77 86.
production as
Vitaceae injury.
2. Nonomura,S., Kanagawa,H. constituents of polygonaceous plants. I.
and
Makimoto,A. the
(1963) Chemical components
Studies on
of
Ko-jo-kon
(Polygonum SIEB et ZUCC). Yakugaku Zasshi, 83,
cuspidatum 983 988.
3. Siemann,E.H. and phytoalexin resveratrol in wine. Am.
Creasy,L.L. J. Enol.
(1992) Concentration Vitic., 43, 49 52.
of
4. on
Creasy,L.L. potential berries. J.
and of Am.
Coffee,M. grape Soc. Hort.
(1988) Phytoalexin Sci., 113,
producti
230 234.
5. and of ,
Foroozesh,M., Primrose,G., Guengerich,F.P. (1997) Aryl cytochrome acetylenes P450-
Guo,Z., Bell,L.C., as enzymes.
Alworth,W.L.
mechanism-based inhibitors Chem. Res. Toxicol.
dependent monooxygenase 10, 91 102.
6. Chanvitayapongs,S., (1997) Amelioration of in
Draczynska-Lusiak,B. antioxidants 8,
and and
Sun,A.Y. resveratrol
oxidative stress by PC12 cells. Neuroreport, 1499 1502.
7. Belguendouz,L., Resveratrol inhibits ion-dependent and
Fremont,L. metal independent
and
Linard,A. of
(1997) porcine
peroxidation
low-density teins.
lipoproBiochem. Pharmacol., 53, 1347 1355.
8. Fauconneau,B., Waffo-Teguo,P., Huguet,F., Decendit,A. and Merillon,J. and cell M. (1997) Comparative antioxidant properties of phenolic cultures using Life Sci., 61, study of
Barrier,L.,
radical scavenger vinifera
compounds in vitro 2103 2110.
from Vitis tests.
9. on
of
Frankel,E.N., Waterhouse,A.L. and human LDL by resveratrol
Kinsella,J.E. (letter).
(1993) Inhibiti Lancet, 341,
oxidation 1103 1104.
10. and
Pace-Asciak,C.R., Hahn,S., Goldberg,D.M. (1995) red block wine human phenolics plate-
Diamandis,E.P., Soleas,G. trans-resveratrol synthesis: Acta, 235, and implicat 207 219.
The quercetin ions let for
aggregation protection disease.
and eicosanoid against Clin. Chim.
coronary heart
11. of Acta,
Kimura,Y., stilbenes
Okuda,H. and on arachidonate leukocytes.
Arichi,S. Biochim.
(1985) Effects Biophys.
metabolism in 834, 275 278.
12. W., c
Bertelli,A.A., Giovannini,L., Giannessi,D., Fregoni,M. and Bertelli,A. (1995) Antiplatelet and natural resveratrol in red wine. Int. J.
Migliori,M., of 1 3.
Bernini, syntheti
activity
Tissue React., 17,
13.
Chung,M.I.,
Teng,C.M.,
Cheng,K.L.,
Ko,F.N. and
Lin,C.N.
(1992) An 58,
antiplatelet of Veratrum formosanum. Planta Med.,
principle 274 276.
14. Belguendouz,L., Fremont,L. Interaction of transres55, veratrol with 811 816. plasma lipoproteins.
and Biochem.
Gozzelino,M.T. (1998) Pharmacol.,
15. Jang,M., Cai,L., Udeani,G.O., Beecher,C.W., Fong,H.H.,
Slowing,K.V.,
Thomas,C.F., and a
Farnsworth,N.R., Kinghorn,A.D., Mehta,R.G., Pezzuto,J.M. (1997) Cancer chemoprotective activity natural product derived from grapes. Science, 275, of 218 220.
Moon,R.C. resveratrol,
16. of Other
Johnson,J.L. resveratrol the Lipid 131 143.
and on
Maddipati,K.R. (1998) Paradoxical H synthases.
effects
two prostaglandin Mediat., 56,
Prostaglandins
17. D.,
Rotondo,S., Rajtar,G., de Gaetano,G.,
Manarini,S.,
Celardo,A.,
Rotillo, trans-re leukocyt
Evangelista,V. sveratrol, a e
and Cerletti,C. natural polyon J. human
(1998) Effect of polymorphonuclear
phenolic compound, function. Br.
Pharmacol.,
123,
1691 1699.
18. Chen,C.K. activity of l.,
and Pace-Asciak,C.R. resveratrol and isolated rat
(1996) Vasorelaxing aorta. Gen. Pharmaco
quercetin in 27, 363 366.
19. Celotti,E., (1996) Resveratrol some Recioto and
Ferrarini,R., content of
Zironi,R. from 47 52. dried
and
Conte,L.S. grapes:
wines obtained Amarone. J. A, 730,
Valpolicella
Chromatogr.
20. Gehm,B.D., (1997) Resveratrol, is
McAndrews,J.M., Chien,P.Y. a found in estroNatl Acad.
and
Jameson,J.L. wine, 94,
polyphenolic compound an agonist for the receptor. Proc.
grapes and Sci. USA,
gen 14138 14143.
21. Mizutani,K., (1998) Resveratrol the MC3T3-E1
Ikeda,K., stimulates
Kawai,Y.
and
Yamori,Y. osteoblastic
proliferation and cells. Biochem. Commun.,
differentiation of 253, 859 863.
Biophys. Res.
22. rol
Ragazzi,E., activity
Froldi,G. and on guinea pig normal and 79 82.
Fassina,G.
(1988) Resverat animals.
isolated trachea from Pharmacol. Res. Commun., 20
albumin-sensitized
(suppl. 5),
23. ant
Han,Y.N., activity
Ryn,S.Y. and of resveratrol with Arch. its
Han,B.H. monoamine
(1990) Antioxid oxidase-A
closely correlates inhibitory activity.
Pharmacol.
Res.,
13,
132.
24. Murakami,S., Arai,I., Kido,T. and Kozawa,M. H+,
Muramatsu,M.,
Otomo,S., on
Baba,K., gastric
(1992) Effect of stilbene K(+)-ATPase. Biochem. Pharmacol., 44, 1947 1951.
derivatives
25. Jayatilake,G.S., Geahlen,R.L., Ashendel,C.L., inhibitors from Polygonum
Jayasuriya,H., Lee,E.S., Chang,C.J. Nat.
Koonchanok,N.M., (1993) Kinase 1805 1810.
McLaughlin,J.L. and cuspidatum. J.
Prod., 56,
26. Ben Induction
Av,P., Crofford,L.J., Wilder,R.L. of vascular growth factor expression prostaglandin interleukin-1: a angiogenesis. 83 87.
and in
Hla,T. (1995) synovial mechanism
endothelial fibroblasts by for E and inflammatory FEBS
potential
Lett., 372,
27. the
Goodwin,J.S. and immune response prostaglandins. J.
Ceuppens,J. by Clin.
(1983) Regulation 3,
of
Immunol.,
295 315.
28.
Sheng,H.,
Shao,J.,
Morrow,J.D.,
Beauchamp,R.D. and
DuBois,R.N. by
(1998) of E2 apoptosis in human and 58, Bcl-2 expression
Modulation prostaglandin colon
cancer cells. Cancer Res.,
362 366.
29. Shin,N.H., (1998) Inhibitory .
Ryu,S.Y., effects of
Lee,H., Min,K.R. sheep
and
Kim,Y.
hydroxystilbenes on Planta Med., 64, 283 284.
cyclooxygenase from
seminal vesicles
30. rol
Jang,M. and Pezzuto,J.M. on 12-O-tetradec-
(1998) Effects of events and
resverat gene
anoylphorbol-13-acetate-induced oxidative expression in mouse skin. Cancer Lett., 134, 81 89.
31. Subbaramaiah,K., Tanabe,T., Inoue,H., Jang,M., Pezzuto,J.M. inhibits cyclooxyeated genase-2 transcription human mammary epithelial
Chung,W.J., and and
Michaluart,P., Telang,N.,
Dannenberg,A.J. (1998) Resveratrol activity Biol. in Chem., 273, phorbol ester-tr 21875 21882.
cells. J.
32. rol,
Martinez,J. and Moreno,J.J. natural polyphecompound, production. on 59,
(2000) Effect of
resverat
nolic prostaglandin
reactive 865 870.
oxygen species and
Biochem. Pharmacol.,
33. of
Stewart,J.R., Christman,K.L. and resveratrol autophosphorylation
O Brian,C.A. of
(2000) Effects
on the protein kinases.
phorbol ester-responsive but not protein
Inhibition of protein kinase d kinase c isozyme autophosphorylation. Biochem. Pharmacol., 60,
1355 1359.
34. Jang,M. activity of trol. Drugs
and Pezzuto,J.M. resveraExp. Clin. Res.,
(1999) Cancer chemoprotective 25, 65 77.
35. of er ,
Prochaska,H.J. and NAD(P)H:
Santamaria,A.B. (1988) Direct measurement cells assay cultured in Anal. microtit Biochem.
quinone reductase from wells: a screening for 169, anticarcinogenic 328 336.
enzyme inducers.
36. Nielsen,M., Ruch,R.J. reverses tumor-promoter-induced inhibition communication. Biochem. Biophys. Res. Commun.,
and of 275,
Vang,O. (2000) Resveratrol gap-junctional intercellular 804 809.
37. in
Trosko,J.E. and carcinogenesis. Front. Biosci.,
Ruch,R.J. 3,
(1998) Cell cell
communication
D208 D236.
38. Jadeski,L.C., Hum,K.O., (2000) Nitric oxide promotes stimulating
Chakraborty,C. and
Lala,P.K. by
murine mammary tumour growth and
metastasis
Int.
tumour J.
cell migration, Cancer, 86, 30 39.
invasiveness
and
angiogenesis.
39. , situ
Yagihashi,N., Kasajima,H., Morita,T., Murakami,T. expression and of
Sugai,S.,
Matsumoto,K.,
Ebina,Y. in
Yagihashi,S. nitric in human
(2000) Increased colorectal
oxide Arch., 436,
synthase 109 114.
cancer. Virchows
40. Thomsen,L.L., Lawton,F.G., Moreno,V. and in
Knowles,R.G., synthase
Beesley,J.E.,
Riveros-
Moncada,S. (1994) Nitric oxide human gynecological cancer. Cancer Res., 54,
activity
1352 1354.
41. ion NFB
Tsai,S.H., Lin-Shiau,S.Y. and of nitric oxide synthase and in trol.
Lin,J.K.
(1999) Suppress activation 673 680. of
the down-regulation of the macrophages by resveraBr. J. Pharmacol., 126,
42. Huang,S., DeGuzman,A., (2000) Nuclear factor-B is activity correlates of human melacells in with nude
Bucana,C.D.
and
Fidler,I.J. and metastas 6,
growth, angiogenesis, mice. Clin.
noma 2573 2581.
Cancer Res.,
43. rol
Manna,S.K., suppress-
Mukhopadhyay,A. and activation
Aggarwal,B.B. of
(2000) Resverat
es factors NF-B,
TNF-induced activator
nuclear transcription role of
protein-1, and apoptosis: reactive oxygen intermediates and lipid peroxidation. J.
potential 164,
Immunol.,
6509 6519.
44. wine
Wadsworth,T.L. and polyphenolics querand in
Koop,D.R. on
(1999) Effects of pro-inflammatory 57, 941 949.
the cytokine
cetin expression
resveratrol RAW 264.7 Biochem.
macrophages.
Pharmacol.,
45. Kawada,N., (1998) Effect of
Seki,S., antioxidants,
Inoue,M. resve-
and
Kuroki,T. on 27, the 1265 1274.
ratrol, quercetin, and functions of cultured stellate cells and
N-acetylcysteine, rat hepatic
Kupffer cells. Hepatology,
46. . on Med.
Matsuda,H., Kageura,T., and Yoshikawa,M.
Morikawa,T.,
Toguchida,I., from
Harima,S rhubarb Bioorg.
(2000) Effects of stilbene nitric oxide production Chem. 10,
constituents
in lipopolysaccharide-activated Lett., 323 327.
macrophages.
47. . of
Shamon,L.A., Chen,C., Mehta,R.G., and Pezzuto,J.M. (1994) A correlative antimutagens that approach demonfor
Steele,V., the
Moon,R.C
identification Res., 14,
strate 1775 1778.
chemoprotective activity.
Anticancer
48. of
Mehta,R.G. effective
and Moon,R.C. chemoprotec-
(1991) Characterization in vitro using an
tive agents in mammary gland initiation-promotion protocol. Anticancer Res., 11,
593 596.
49. J., the
Lee,S.K., Mehta,R.G., Kinghorn,A.D. antioxidant
Mbwambo,Z.H.,
Chung,H.,
Luyengi,L.,
Gamez,E. of
and Pezzuto,J.M. potential Comb.
(1998) Evaluation Chem. High
of Screen.,
natural products. 1, 35 46.
Throughput.
50. rol on
Ciolino,H.P., Daschner,P.J. inhibits transcription of receptor. of the
and
Yeh,G.C. by
(1998) Resverat preventing activati
CYP1A1 in vitro aryl hydrocarbon Cancer Res., 58,
5707 5712.
51. aryl on
Ciolino,H.P. and hydrocarbon-induced tochrome P-450 1A1 by resveratrol. Mol. Pharmacol.,
Yeh,G.C. cyenzyme activity 56,
(1999) Inhibition and
of
CYP1A1 expressi
760 767.
52. A.,
Casper,R.F., Milgrom,E. Savouret,J.F.
Quesne,M., and
Rogers,I.M., has
Shirota,T., antagonist
Jolivet, activity
(1999) Resveratrol
on
the
aryl
hydrocarimplications Pharmacol., for prevention of
bon receptor: dioxin toxicity. Mol. 56, 784 790.
53. , bone
Singh,S.U., Girard,J.B., Tenenbaum,H.C. formation
Casper,R.F., Savouret,J.F.
Fritz,P.C., and of aryl
Sukhu,B.,
Ganss,B.
(2000) Inhibition in vitro described J.
dioxin effects on hydrocarbon receptor
by antagonist,
a newly resveratrol. 167,
Endocrinol.,
183 195.[Abstract]
54. rol Res.
Chun,Y.J., is a cytochrome Commun.,
Kim,M.Y. selective P450 262, 1A1 20 24.
and human
Guengerich,F.P. (1999) Resverat Biochem. Biophys.
inhibitor.
55. S.,
Hecht,S.S., Rao,A.V.
Kenney,P.M., and
Wang,M., of
Trushin,N., butylated and
Agarwal, hydroxya
Upadhyaya,P. nisole, myo-inositol, as tumoricurcumin, inhibitors plus
(1999) Evaluation
esculetin, resveratrol of benzo(a)pyrene
lycopene
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung A/J mice. Cancer Lett., 137, 123 130.
genesis in
56. Sharma,S., (1994) Screening
Stutzman,J.D., Kelloff,G.J. of po-
and
Steele,V.E. markers of
tential chemoprotective agents using carcinogenesis. Cancer Res., 54, 5848 5855.
biochemical
57. u,A.,
Damianaki,A., Bakogeorgou,E., Kampa,M., Panagiotou,S., Gemetzi,C.,
Notas,G.,
Hatzoglo and
Kouroumalis,E., Martin,P.M.
Castanas,E. on Potent human cells.
(2000) inhibitory action of breast cancer J. Cell Biochem., red 78, wine polyphenols
429 441.
58. Huang,C., Ma,W.Y., Resveratrol suppresses cell p53-dependent transformation and pathway. 237 242.
Goranson,A.
and
Dong,Z. (1999) through a
induces apoptosis
Carcinogenesis, 20,
59. Waffo,T.P., Fauconneau,B., Deffieux,G., ren,J. and Merillon,J. M. activity cell
Huguet,F.,
Vercaute
(1998) Isolation, identification, and of three stilbene newly J. extracted from Nat. Prod., 61, Vitis
antioxidant vinifera
glucosides cultures. 655 657.
60. Zini,R., Morin,C., Tillement,J.P. (1999) Effects of Drugs resveratrol Exp. Clin. on Res., the 25,
Bertelli,A., rat brain 87 97.
Bertelli,A.A. respiratory
and chain.
61. C.
Zou,J.G., Huang,Y.Z., and Wu,J.M. (1999) inhibits oxidative
Chen,Q.,
Wei,E.H., and
Hsieh,T. azo
Resveratrol compound-initiated
copper ion-induced
Mol.
modification Biol. Int., 1089 1096.
of 47,
human
low
density lipoprotein.
Biochem.
62. a
Fukuhara,K. new type agent.
and of
Miyata,N. DNA-cleaving Chem.
(1998) Resveratrol 3187 3192.
as
Bioorg. Med.
Lett., 8,
63. Ahmad,A., Farhan,A.S., (2000) DNA breakage by phage ratrol and inactivation. Lett., 154, Cu(II): reaction Cancer 29 37.
Singh,S. resve-
and mechanism
Hadi,S.M. and bacterio
64. Miura,T., Muraoka,S., Fujimoto,Y. (2000) Antioxidative derivatives (In Citation).
Ikeda,N.,
Watanabe,M. stilbene
and
and prooxidative Process Pharmacol.
action of 86,
Toxicol.,
203 208.
65. n, the
Cadenas,S. vitamin E,
and and
Barja,G. PBN oxidative Med.,
(1999) Resveratrol, DNA 26,
melatoni
protect against renal kidney carcinogen KBrO3. Free
damage induced by 1531 1537.
Radic. Biol.
66. Fontecave,M., Lepoivre,M., Guittet,O. (1998) Resveratrol, eotide reductase. 421, 277 279. a FEBS
Elleingand,E., Gerez,C. inhibitor of
and ribonucl
remarkable Lett.,
67. Sun,N.J., Woo,S.H., (1998) DNA polymerase and corylifolia. topoisomerase J. Nat.
Cassady,J.M.
and from
Snapka,R.M. Psoralea
II inhibitors Prod., 61,
362 366.
68. , rol,
Schneider,Y., Vincent,F., Bergmann,C., Seiler,N. and a
Duranton,B.,
Badolo,L., effect of
Gosse,F. resverat
Raul,F. (2000) Anti-proliferative natural component wine, on human
of grapes and Cancer Lett., 158, 85 91.
colonic cancer cells.
69. red
Elattar,T.M. wine and
and its
Virji,A.S. components of
(1999) The on human oral
effect of squamous
growth carcinoma Res.,
and proliferation cells. Anticancer 19, 5407 5414.
70. Surh,Y.J., Hurh,Y.J., Lee,S.J. (1999) Resveratrol, in antioxidant present in human promyelocytic
Kang,J.Y., an red wine,
Lee,E., Kong,G. and induces apoptosis 1 10.
leukemia (HL-60) cells. Cancer Lett., 140,
71. In rol.
Babich,H., Reisbaum,A.G. vitro response of
and
Zuckerbraun,H.L. cells to
(2000) resverat
human gingival epithelial S-G Toxicol. Lett., 114, 143 153.
72. acid
Moreno,J.J. release,
(2000) Resveratrol prosta-
modulates
arachidonic
glandin synthesis, and Pharmacol. Exp. Ther., 294, 333 338.
3T6
fibroblast
growth. J.
73. (1998) from tumor
Clement,M.V., Hirpara,J.L., Chemoprotective agent grapes,
Chawdhury,S.H. and a
Pervaiz,S.
resveratrol,
natural product derived in human
triggers CD95 signaling-dependent cells. Blood, 92, 996 1002.
apoptosis
74. Holmes-McNary,M. properties of of trans-resveratrol activation of Cancer Res., 60,
and are the
Baldwin,A.S.,Jr (2000) Chemoprotective associated with IB kinase. inhibition
3477 3483.
75. ,L., rol Res.
Ragione,F.D., Cucciolla,V., Soldati,G., Manna,C., arrests the cycle at Commun.,
Borriello,A.,
Pietra,V.D.,
Racioppi
Galletti,P. and cell division S/G2 250, phase 53 58.
Zappia,V. Biochem.
(1998) Resverat Biophys.
transition.
76. Suh,N., Luyengi,L., Pezzuto,J.M. (1995) Discovery cell
Fong,H.H.,
Kinghorn,A.D.
and HL-60
of natural product chemoprotective agents utilizing differentiation as a model. Anticancer Res., 15,
233 239.
77. Hsieh,T.C., (1999) Resveratrol and ial Res.,
Juan,G., increases
Darzynkiewicz,Z. induces accumulation bovine pulmonary through S and
and of
Wu,J.M. p53
nitric oxide synthase, p21(WAF1/CIP1), and suppresses cultured cell proliferation by perturbing progression 59, 2596 2601.
artery endothel G2. Cancer
78. and in 109,
Tsan,M.F., Sacco,J. Resveratrol THP-1 human monocytic 405 412.
White,J.E., (2000) induces Fas leukaemia
Maheshwari,J.G.,
Bremner,T.A.
signalling-independent apoptosis cells. Br. J. Haematol.,
79. and s 254,
Carbo,N., Argiles,J.M.
Costelli,P., (1999)
Baccino,F.M.,
Lopez-Soriano,F.J. wine, Res. decrease Commun.,
Resveratrol, a tumour growth in
natural product present in a Biophys.
rat tumour model. Biochem. 739 743.
80. Tessitore,L., Davit,A., (2000) Resveratrol depresses by the growth of affecting bax pression.
Sarotto,I.
and
Caderni,G. crypt foci
colorectal aberrant and p21CIP ex1619 1622.
Carcinogenesis, 21,
81. Gautam,S.C., Xu,Y.X., Chapman,R.A. (2000) a Resveratrol prospective selectively agent for
Dumaguin,M., inhibits ex vivo Bone
Janakiraman,N. and leukemia cells: 25,
bone 639 645.
marrow purging.
Marrow Transplant.,
82. ,F.,
Hsieh,T.C., Burfeind,P., Darzynkiewicz,Z. and
Laud,K., effects and cell
Backer,J.M., control of lines with
Traganos gene differen
Wu,J.M. (1999) Cell cycle expression by resveratrol t in human metastatic J.
breast carcinoma potentials. Int. 245 252.
Oncol., 15,
83. MacCarrone,M., Lorenzon,T., (1999) Resveratrol prevents lipoxygenase activity.
Guerrieri,P. cells
and by 265,
Agro,A.F. inhibiting 27 34.
apoptosis in K562 and cyclooxygenase Eur. J.
Biochem.,
84. MacCarrone,M., Nieuwenhuizen,W.E., Melino,G., Veldink,G.A., Vliegenthart,J.F. Membrane modifican tions of in human programmed death Eur. by J.
Dullens,H.F., and
Catani,M.V., (1996)
Finazzo,A.A. cells
erythroleukemia K562 transforming Biochem.,
during inductio or
cell cisplatin. 297 302.
growth factor 1 241,
85. Lu,R. and product derived from
Serrero,G. grape,
(1999) Resveratrol, and inhibits
natural the
exhibits antiestrogenic activity growth of human breast
cancer
cells. J.
Cell
Physiol.,
179,
297 304.
86. ,G. of
Basly,J.P., Marre-Fournier,F., and Chulia,A.J. (2000) Estrogenic/antiestrogenic (E)and (Z)-resveratrol. Life Sci., 66, and 769 777.
Le
Bail,J.C.,
Habrioux
scavenging
properties
87. Mgbonyebi,O.P., Russo,J. Antiproliferative effect of synInt. thetic J. resveratrol Oncol., 12, on human 865 869.
and
Russo,I.H.
(1998) cells.
breast epithelial
88. P.A., the
Ashby,J., Beresford,N. Sumpter,J.P. red wine
Tinwell,H., and
Pennie,W., weak of
Brooks,A.N.,
Lefevre,
(1999) Partial and constituconsideration cells and
oestrogenicity of its superagonist effects.
ent activity J. its Appl.
resveratrol: in MCF-7 suggested Toxicol.,
cardiovascular protective 19, 39 45.
89. and Text]
Slater,I., red wine tion. Hum. Turner,R.T.,
Odum,J. and consump-
Ashby,J. 18,
(1999) Resveratrol 625 626.[Free Full
Exp. Toxicol., Evans,G.L., Maran,A. estrogen
Zhang,M., resveratrol an in
and Sibonga,J.D. agonist Endocrinology, 140,
(1999) Is 50 54.
growing rats?
90. Mizutani,K., (2000) Resveratrol
Ikeda,K., attenuates
Kawai,Y. and Nutr.
and bone Sci.
Yamori,Y. loss in
ovariectomy-induced stroke-prone spontaneously (Tokyo), hypertensive 46, 78 83.
hypertension rats. J.
Vitaminol.
91. Hsieh,T.C. growth, cell cycle in and human Exp.
and Wu,J.M. (1999) Differential arrest, of apoptosis by cancer cell lines. 249, 109 115.
effects on resveratrol
induction prostate Cell Res.,
92. Mitchell,S.H., Zhu,W. and inhibits the expression in and LNCaP Res., function prostate 59,
Young,C.Y.
(1999) Resveratrol receptor
of the androgen cancer cells. Cancer 5892 5895.
93. agent on
Hsieh,T.C. resveratrol in
and
Wu,J.M. (2000) Grape-derived prostate-specific receptor 20,
chemoprotective expressi
decreases LNCaP cells
antigen (PSA)
by mechanism. 225 228.
an androgen Anticancer Res.,
(AR)-independent
94. , izes to
Ulsperger,E., Hamilton,G., Hoffmann,O. and Mallinger,R. AHTO-7 human osteoblasts carcinoma Int. J. to cell
Raderer,M.,
Baumgartner,G., Hejna,M. pretreatment in desensit
(1999) Resveratrol growth stimulation supernatants. 955 959.
response
Oncol., 15,
95. T.R. Soc.
McMurtey,K.D. (1996) Resveratrol (ed.) Wine: Nutritional and Therapeutic
in
wine.
In Am.
Watkins, Chem.
Benefits.
96. Bertelli,A.A., Giovannini,L., Stradi,R., t,J.P. and Bertelli,A. (1998) phytoalexin Clin. orally Res., Evaluation of in resveratrol administered 24, 51 55. in
Urien,S., of Drugs
Tillemen natural Exp.
kinetic parameters wine to rats.
97. Bertelli,A.A., Giovannini,L., Stradi,R., Tillement,J.P. (1996) Plasma, urine and eratrol (3,4 ,5-trihydroxysof tilbene) after red wine J. tissue levels of or Int. 67 71.
Bertelli,A. trans- and
and cis-resv
short-term to rats.
prolonged
administration
Tissue React., 18,
98. Bertelli,A., (1998) Plasma and Drugs resveratrol Exp. Clin. 24,
Bertelli,A.A., Gozzini,A. tissue concentrations and Res.,
and
Giovannini,L.
pharmacological activity.
133 138.
99. Kuhnle,G., Spencer,J.P., Debnam,E.S., Srai,S. K., absorbed Rice-Evans,C. in the and small
Chowrimootoo,G.,
Schroeter,H., is
Hahn,U. (2000) Resveratrol glucuronide. Biochem.
intestine Biophys. Res. 212 217.
as resveratrol Commun., 272,
100. Andlauer,W., (2000) Assessment
Kolb,J., Siebert,K. of resveratrol the perfused
and small
Furst,P. intestine
bioavailability in
of
the 26,
rat. 47 55.
Drugs
Exp.
Clin.
Res.,
101. Teel,R.W. phytochemicals of P450-linked
and Huynh,H. cytochrome enzyme activity.
(1998) Modulation Cancer Lett., 133,
by 135 141.
Decreased platelet
aggregation
and
resveratrol
1. H, by 3.
Yang YM, Wang HQ., adenosine reducing C
Wang XX, Resveratrol
Chen JZ, attenuates platelet Chin
Wang
SJ,
Hu
diphosphate-induced protein kinase activity., Am J
activation Med. 2008;36(3):603-1
2. H,
Yang YM, Wang HQ.,
Chen JZ, Resveratrol A2 receptor reducing
Wang XX, attenuates
Wang
SJ,
Hu
thromboxane activation by 2008
agonist-induced platelet Eur J Pharmacol.
phospholipase C activity., Mar 31;583(1):148-55.
3. JZ., ion
Yang YM, [Suppressive resveratrol and its nism] Yao
Wang XX, effect in
Wang vitro
SJ, of
Wang platelet
HQ,
Chen aggregat
on ADP induced human active mechaXue Xue Bao. 2008
Apr;43(4):356-60.
[Chinese]
4. Olas B, Stochmal A, anti-platelet ol-rich extracts bark berries of of Yucca
Wachowicz Oleszek W., and from:
B, Tomczak A, Comparative properties seeds of
Erler of grape
J, polyphen and
antioxidant
Aronia melanocarpa, schidigera in 2008
vitro., Platelets.
Feb;19(1):70-7.
5. Koutsas C, Liakopoulou-Kyriakides M., Conjugation of derivatives., Protein Pept 2007;14(10):1014-20.
Sarigiannis resveratrol Lett.
Y, with
Stavropoulos RGD and
G, KGD
6. as Soc
an
de
la Lastra CA, antioxidant and and
Villegas pro-oxidant clinical
I.,
Resveratrol
agent: mechanisms Trans. 2007 Nov;35(Pt
implications., Biochem
5):1156-60.
7. T., e Epub
Saiko P, Resveratrol
Szakmary and its
A, Jaeger W, analogs: disease and Res. 2008
Szekeres neurodegenerativ
defense against cancer, coronary maladies or just 2007 a Aug fad?, 17. Mutat
Jan-Feb;658(1-2):68-94.
8. KH, on:
Shen MY, Chou DS, mechanisms pivotal roles
Hsiao Sheu of of
G, JR.,
Liu CL, Inhibitory in J
Fong platelet
TH,
Lin activati 2007
resveratrol p38 MAPK GMP. Br
and NO/cyclic Nov;139(3):475-85.
Haematol.
9.
Olas B,
Saluk-Juszczak J,
Wachowicz
B.,
D-glucar
1,4-lactone
and
resveratrol platelets., Cell Biol
as Toxicol.
antioxidants in blood 2008 Apr;24(2):189-99.
10. Chen vascular from activity., 2007 2007 Apr
YJ, Wang endothelial
JS, cell
Chow
SE., in
Resveratrol antithrombogenic Chin J
protects
ox-LDL-induced reduction Chin J Physiol.
Feb 28;50(1):22-8. Erratum in: 30;50(2):98.
Physiol.
11. Wu CC, concentrations of Med. the 2007
Wu CI, resveratrol
Wang WY, potentiate
Wu
YC.,
Low Planta
antiplatelet effect of May;73(5):439-43.
prostaglandins.,
12. from 93.
Opie LH, concepts
Lecour S., The to protective Eur Heart
red sigJ.
wine 2007
hypothesis: Jul;28(14):1683-
nalling molecules.,
13. RJ,
de van
Lange de
DW, Wiel
Verhoef S, Gorter G, A, Akkerman extract inhibits for the
Kraaijenhagen platelet
JW., activation 1: Alcohol Clin
Polyphenolic grape through PECAMan Exp explanation Res. 2007
French paradox.,
Aug;31(8):1308-14.
14. Ahmed
Saeed SA, Connor JD, S, Mesaik MA,
Imran, Quadri J, of
Tasneem S,
Choudhary MI., 3-kinase: effects on l
Inhibitors platelet
phosphatidylinositide aggregation., Pharmaco
reactive oxygen species and Rep. 2007 Mar-Apr;59(2):238-43.
15. ch human
Athar M, Back L, Bickers DR, Resveratrol: a cancer prevention., Toxicol Appl
JH, Kim
Tang AL.,
X,
Kim
KH,
Kopelovi
review of 2007
preclinical Nov
studies for
Pharmacol.
1;224(3):274-83.
16. c 2006
Providncia R., drinks: scientific basis of the Nov;25(11):1043-58.
Cardiovascular protection French Paradox., Rev
from Port
alcoholi Cardiol.
17. kis
Fragopoulou E, C, Pliakis E,
Nomikos T, Samiotaki
Karantonis S., 2007
HC,
Apostola
M, activity :80-9.
Panayotou G, of acetylated J Agric
Antonopoulou phenolic Food Chem.
Biological Jan 10;55(1)
compounds.,
18. Z,
Csiszar Rivera A,
A, Smith Ungvari Z.,
K, Labinskyy Resveratrol activation inhibition.,
N, of Am
Orosz coronary J
attenuates TNF-alpha-induced arterial endothelial cells: Physiol Heart role Circ of NF-kappaB Physiol. 2006
Oct;291(4):H1694-9.
19. G., with
Stef G, Resveratrol
Csiszar A, inhibits
Lerea K, aggregafrom 2006
Ungvari Z,
Veress
tion of platelets aspirin resistance., J Cardiovasc Pharmacol.
high-risk Aug;48(2):1-5.
cardiac patients
20. Olas Resveratrol,
B, a
Nowak P, Ponczek M, natural phenolic reduce carbonylation Gen proteins
Wachowicz
B.,
compound may peroxynitrite in blood ):215-22.
induced by 2006 Jun;25(2
platelets.,
Physiol Biophys.
21. i
Zbikowska HM, T., Response to resveratrol.,
Olas of
B, blood
Wachowicz platelets 1999
B,
Krajewsk
Platelets.
Jul;10(4):247-52.
22. WY.,
Feng L, Analysis
Jin of
J, the
Zhang LF, Yan resveratrol-binding
T,
Tao Acta
protein using Biochim Biophys Sin
phage-displayed random peptide library., 2006 May;38(5):342-8.
(Shanghai).
23. M,
Vilar S, Fraiz N,
Quezada E, Alcaide C,
Santana L, Cano E, and
Uriarte E, vasorelaxant hybrids.,
Ynez and Bioorg
Orallo platelet Med
F., Design, synthesis, antiaggregatory of 2006
activities Chem Lett. 15;16(2):257-61.
coumarin-resveratrol Jan
24. h in Lett.
Wirleitner H, Fuchs suppresses human peripheral 2005 Sep 15;100(2):159-63.
B, D.,
Schroecksnadel K, Resveratrol
Winkler C, biochemical
Schennac pathways
interferon-gamma-induced blood mononuclear cells
in
vitro., Immunol
25. rol
Mousa SS, Mousa on angiogenesis
SS, and
Mousa tumor
SA.,
Effect of the
resverat chick
platelet/fibrin-accelerated chorioallantoic membrane model., Nutr
growth in
Cancer. 2005;52(1):59-65.
26. Olas Resveratrol
B, Wachowicz B, inhibits polyphosmetabolism 2005 in
Holmsen H, activated
Fukami MH., platelets.,
phoinositide Biochim Biophys Acta. Aug
15;1714(2):125-33.
27. Olas antioxidant blood ):251-60.
B, with platelet
Wachowicz effects on
B.,
Resveratrol, Platelets.
a 2005
phenolic Aug;16(5
functions.,
28. Delmas D, Jannin B, Latruffe preventing properties against
N.,
Resveratrol:
Res.
vascular alterations and 2005 May;49(5):377-95.
ageing.,
Mol
Nutr
Food
29. ms
Ulrich S, of the
Wolter F, Stein chemoprotective resveratrol Nutr Food and Res.
JM., its
Molecular analogs in
mechanis carcinog
effects of enesis., Mol 2005
May;49(5):452-61.
30. rol
Huang YL, derivatives Vitis
Tsai from
WJ, the
Shen roots J
CC, Nat
Chen Prod.
CC., 2005
Resverat Feb;68(2
of ):217-20.
thunbergii.,
31. W., from
Olas B, Inhibition hesion Yucca
Wachowicz of blood
B, Stochmal platelet ad-
A,
Oleszek
and secretion by different schidigera Roezl. bark., 2005 Feb;21(2):199-206.
phenolics
Nutrition.
32. ms al
Wolter F, of the effects of cancer: key amines?, J
Ulrich S, Stein chemoprotective resveratrol role of Nutr. 2004 and poly-
J., its
Molecular analogs in
mechanis colorect
Dec;134(12):3219-22.
33. of ship
Szewczuk COX-1 by
LM, red
Penning TM., a
Mechanism-based inactivation structure-activity relation
wine m-hydroquinones: study., J Nat Prod. 2004 Nov;67(11):1777-82.
34. study ,
Dong of
HH, Ren protective
HL., prop-
New in
progression
in
the disease.
erties of Bratisl Lek
resveratrol Listy.
anticardiovascular
2004;105(5-6):225-9.
35. Bradamante scular protective
S, Barenghi L, effects of resveDrug Rev. 2004
Villa
A.,
Cardiova
ratrol. Cardiovasc
Fall;22(3):169-88.
36. Hao protection Med
HD, by Food.
He LR., resveratrol., 2004
Mechanisms J
of
cardiovascular
Fall;7(3):290-8.
37. Kaneider NC, Patsch JR, Wiedermann and and
Mosheimer B, CJ., Inhibition signaling adin
Reinisch by
N, resveratrol cells
of thrombin-induced quercetin: effects on enosine nucleotide platelet-neutrophil interactions.,
metabolism
endothelial
Thromb Res.
2004;114(3):185-94.
38. Fukao H, Yamashita T, Kawai Y, trans-resveratrol and ysis. genicity and low-density lipoprotein 2004 Sep;15(6):441-6.
Ijiri Y, Fukunaga Suwa on M, the
Miura C, Yamamoto thrombo-
M, Oiwa
Hashimoto K, J.,
M,
Effect of
atherogenicity in receptor-deficient
apolipoprotein E-deficient mice., Blood Coagul Fibrinol
39. rol
Kollr P, and other wine]
Hotolov constituents Ceska Slov
H., Farm.
[Biological 2003
effects of
resverat
of [Czech.]
Nov;52(6):272-81.
40. wine, 2003
Schriever resveratrol,
C, Pendland Chlamydia pneu-
SL,
Mahady GB., Atherosclerosis.
Red
moniae and the Dec;171(2):379-80.
French connection.,
41. Chen LN, Zang cardiovascular protective resveratrol], Jul;34(3):272-4.
WJ, Tang effects of Ke
YH., Xue
[Progress Jin Zhan.
in 2003
Sheng Li [Chinese]
42. Drug
Granados-Soto V., News Perspect. Jun;16(5):299-307.
Pleiotropic 2003
effects of
resveratrol.,
43. Guiso
Togna GI, M., Olive
Togna oil platelet
AR, Franconi isochromans reactivity.,
M, J
Marra Nutr.
C, 2003
inhibit human Aug;133(8):2532-6.
44. W., from
Olas B, Inhibition in Yucca
Wachowicz B, of oxidative
Stochmal stress
A,
Oleszek
blood platelets by different schidigera Roezl. bark., 2003 Jul-Aug;19(7-8):633-40.
phenolics
Nutrition.
45. t 2003
Kaldas MI, Walle and metabolism human intestinal Mar;55(3):307-12.
UK, by
Walle
T.,
Resveratrol Pharm
transpor
Caco-2 cells., J
Pharmacol.
46.
Olas
B,
Wachowicz
B,
Saluk-Juszczak J,
Zielinsk
i on 5.
T.,
Effect of
resveratrol,
a on 2002 platelet Aug activati 15;107(3-4):141[Role of free
natural polyphenolic compound, induced by endotoxin or thrombin., Thromb Res. Suttnar J, Msov L, Sorelov V, blood platelet Lek Cesk. 2002
Scheiner T, radicals in [Czech] tion], Cas
Dyr JE., activaSep
22;141 Suppl:47-9.
47. W.,
Olas B, Anti-platelet
Wachowicz effects of
B, Stochmal differfrom Yucca
A,
Oleszek
ent phenolic Roezl. bark., Platelets. May;13(3):167-73.
compounds 2002
schidigera
48. Sinha K, Chaudhary G, Gupta effect of resveratrol against oxidamodel tive of 2002 stress in stroke in Jun middle cerebral rats., Life Sci.
YK.,
Protective
artery occlusion
28;71(6):655-65.
49. Ignatowicz natural chemoJ protective Pharmacol.
E, agent
Baer-Dubowska
W.,
Resveratrol, diseases.,
a Pol
2001Nov-Dec;53(6):557-69.
50. Y,
Wang Wu
Z, JM.,
Zou J, Effect of
Huang Y, resveratrol in
Cao on
K, Xu platelet Med
aggregation (Engl). 2002
in vivo and Mar;115(3):378-80.
vitro., Chin
51. El-Mowafy AM., guanylyl cyclase in signaling coronary mechanism
Resveratrol arterial in
activates
membrane-bound novel
smooth muscle: a protection.,
support of Commun. 2002 Mar
coronary
Biochem Biophys Res
15;291(5):1218-24.
52. al
Bhat KPL, effects of Antioxid Redox
Kosmeder resveratrol. Signal. 2001
JW
2nd,
Pezzuto JM.,
Biologic
Dec;3(6):1041-64.
53. Y, vivo
Wang Wu phenol and 2002
Z, JM.,
Huang Y, Effects of
Zou red
J, wine
Cao and
K, wine
Xu polyin
resveratrol on in vitro., Int Jan;9(1):77-9.
platelet J Mol
aggregation Med.
54. SK.,
Huang SS, Resveratrol
Tsai MC, reduction
Chih of rats Sci.
CL, Hung infarct subjected 2001 Jul
LM, to
Tsai focal
size cerebral
in Long-Evans ischemia., Life
20;69(9):1057-65.
55. the
Pervaiz bedside?,
S., Leuk
Resveratrol--from Lymphoma. 2001
the
bottle to
Feb;40(5-6):491-8.
56. and
Stojanovic mechanism action of
S, of
Sprinz H, Brede the antioxidant and
O., its
Efficiency analogues
trans-resveratrol
in
the tion.,
radical liposome Arch Biochem Biophys.
oxida2001 Jul 1;391(1):79-89.
57. JG, ant
Wu Huang
JM, YZ.,
Wang ZR, Mechanism by red
Hsieh of
TC, Bruder JL, cardioa J phenolic Mol
Zou antioxid
protection present in Med. 2001
resveratrol, wine., Int
Jul;8(1):3-17.
58. A, s
Russo P, Cicala C.,
Russo
GL,
Venezia fraction
phenolic
Feb;11(1):25-9.
59. Olas szczak J, by
B, Kaca
Wachowicz W., The the and platelet throm-
B, Szewczuk effect of ressecretory
J,
Saluk-Ju
veratrol on endotoxin bin.,
process induced
Microbios.
2001;105(410):7-13.
60. de
Ibern-Gmez M, la Torre-Boronat and J 2000
Roig-Prez MC.,
S,
Lamuela-Ravents natural and blended
RM,
Resveratrol peanut butters., Food Chem.
piceid levels in Agric Dec;48(12):6352-4.
61. into
Jonsson the rapid
KO, Hedin effects of and
HL, 17
Fowler CJ., steroids
Investigation upon beta-amy
beta-estradiol loid(25-35)-induced C . activation in human Methods Find
neuroactive
of phosphoinositide-specific platelets., Exp Clin Pharmacol. 2000
phospholipase Oct;22(8):615-20
62. de of on
Romero-Prez AI, La TorreBoronat MC., resveratrol
Lamuela-Ravents
RM, quantitative
Andrs-Lacueva C, extraction powdery mildew Jan;49(1):210-5.
Method for the and piceid berry Agric
isomers in grape the stilbene content., J
skins. Effect of Food Chem. 2001
63. parts
Aburjai of Rheum
TA., Anti-platelet palaestinum.,
stilbenes
from
aerial
Phytochemistry. 2000
Nov;55(5):407-10.
64. rol on
Kirk RI, decreases events in platelet Blood Cells
Deitch JA, Wu early signaling
JM,
Lerea has
KM.,
Resverat
washed platelets but in whole blood., Mol Dis. 2000
little effect
Apr;26(2):144-50.
65. i on
Olas T,
B, Zbikowska Buczynski A,
HM,
Wachowicz effect of
B,
Krajewsk
Magnuszewska A., Inhibitory free radical generation in blood platelets., Acta
resveratrol
Biochim Pol.
1999;46(4):961-6.
66. r
Zhu CB,
Y, Huang Kissinger
T, PT.,
Cregor M, Liquid chro-
Long
H,
Kissinge
for g Mar
matography with the determination an
multichannel
electrochemical detection rat blood Appl. utilizin 2000
of trans-resveratrol in automated blood sampling B
device., J Chromatogr 31;740(1):129-33.
Biomed Sci
67. rol Clin
Naderali EK, Doyle induces vasorelaxation of
PJ, mes-
Williams from
G.,
Resverat
enteric and uterine arteries Sci (Lond). 2000 May;98(5):537-43.
female guinea-pigs.,
68. Sanders Occurrence of edible ):1243-6.
TH, McMichael resveratrol in J Agric
RW Food
Jr, Chem.
Hendrix KW., 2000 Apr;48(4
peanuts.,
69. lou
Fragopoulou E, CA, Demopoulos of Food
Nomikos T, CA., biologically Chem. 2000
Antonopoulou
S,
Mitsopou red
Separation wine., J Agric Apr;48(4):1234-8.
active lipids from
70. C.,
Paul B, Occurrence
Masih of
I, Deopujari resveratrol and
J, an
Charpentier ayurvedic
pterostilbene medicine from
in age-old darakchasava, India., J Dec 15;68(1-3):71-6.
Ethnopharmacol. 1999
71. de in
Romero-Prez AI, La Torre-
Ibern-Gmez major Agric
M,
Lamuela-Ravents derivative
RM,
Boronat MC., Piceid, the grape juices., J Food Chem. 1999
resveratrol
Apr;47(4):1533-6.
72. Dobrydneva Trans-Resveratrol Br
Y, Williams inhibits
RL,
Blackmore human
PF.,
calcium influx in J Pharmacol. Sep;128(1):149-57.
thrombin-stimulated 1999
platelets.,
73. RM,
Das DK, Bertelli
Sato AA,
M, Ray Bertelli red wine:
PS, A., role
Maulik G, of
Engelman
Cardioprotection of antioxidants., Drugs Exp Clin Res.
polyphenolic
1999;25(2-3):115-20.
74. T.,
Blardi P, Stimulation
De of oral man.,
Lalla A, endogenous
Volpi L, adenosine
Di
Perri and
release by resveratrol in Clin Res.
administration of Drugs Exp
quercetin
1999;25(2-3):105-10.
75. M.,
Bavaresco Stilbene
L, Fregoni C, compounds: from to wine., Drugs
Cant the Exp
E, Clin
Trevisan Res. 1999;25(
grapevine 2-3):57-63.
76. on Clin
Bertelli wine and their Res.
AA., its
Recent progress components and
in
research Drugs Exp
favorable effects on 1999;25(2-3):51-2.
health.,
77. Ferrero Fulgenzi A, s Proc. Phytoalexin granulocyte and 1998
ME, Corsi
Bertelli AA, MM, Bertelli
Pellegatta A.,
F, modulate
resveratrol
(3-4 -5-trihydroxystilbene) adhesion.,
monocyte endothelial Dec;30(8):4191-3.
Transplant
78. ni Exp
Bertelli A, L., Plasma and ratrol Clin
Bertelli AA, tissue resve-
Gozzini A,
Giovanni Drugs
concentrations and Res.
pharmacological activity.,
1998;24(3):133-8.
79. Cichewicz resveratrol to cereus., J
RH, Kouzi piceid by Nat Prod.
SA., Biotransformation Bacillus 1998 Oct;61(10):1313-4.
of
80. red Eur
Kopp wine. nation J
P., A
Resveratrol, possible
a phytoestrogen explaof the
found
in
for the Endocrinol.
conundrum 1998
French paradox ?,
Jun;138(6):619-20.
81. and
Constant J., Alcohol, the French paradox., Coron Artery Dis. 1997 Oct;8(10):645-9.
ischemic
heart
disease,
82. Blache D, Loreau N., Gas
Rustan I, Durand P, chromatographic
Lesgards
G,
cells Nov
analysis of after in
resveratrol in vitro incubaB
plasma, lipoproteins Biomed Sci Appl.
and 1997
tions., J Chromatogr 21;702(1-2):103-10.
83. Orsini F, Pelizzoni F, Rogers CB., Isolation, synthesis, antiplatelet aggregation 3-O-beta-D-glucopyranoside and 1):1082-7. related compounds., activity J
Verotta L, and of Nat Prod.
Aburjai T, resveratrol 1997 Nov;60(1
84. G.,
Orsini F, Synthesis
Pelizzoni F, of biologically
Bellini B, active
Miglierini resveratrol
polyphenolic glycosides series)., Carbohydr Res. 1997 Jun
(combretastatin and
20;301(3-4):95-109.
85. rol:
Soleas GJ, Diamandis molecule whose And
EP, time
Goldberg Biochem.
DM.,
Resverat 1997
has come? Mar;30(2):91-113.
gone?, Clin
86. as Lab
Soleas GJ, Diamandis EP, Goldberg biological fluid: history, prodisease prevention.,
DM., J
Wine Clin
duction, and role in Anal. 1997;11(5):287-313.
87. Rotondo Gaetano G., Red function.,
S, wine,
Rotilio D, aspirin and
Cerletti platelet 1996
C, Nov;76(5):818-9.
de
Thromb Haemost.
88. s ents
Goldberg DM, E, Soleas G, to of assay the biological Chem.
Tsang Ng
E, E.,
Karumanchiri Method phenolic
A,
Diamandi constitu
concentrations of interest in 1996 May
wines., Anal
15;68(10):1688-94.
89. EP, ion
Pace-Asciak Goldberg grape in Clin
CR, DM.,
Rounova O, Wines and modulators subjects. 1996 Mar
Hahn of
SE, platelet
Diamandis aggregat
juices as healthy human Chim Acta.
15;246(1-2):163-82.
90. A,
Bertelli Tillement
AA, JP.,
Giovannini Plasma, urine trans- and
L, and
Stradi R,
Bertelli
tissue stilbene) wine
levels of after
cis-resveratrol (3,4 ,5-trihydroxy red
short-term or to rats., Int 1996;18(2-3):67-71.
prolonged administration of J Tissue React.
91. M,
Bertelli Fregoni M,
AA, Giovannini Bavaresco A., Exp
L,
Bernini W, activity
Migliori of
L, Bertelli cis-resveratrol., Drugs 1996;22(2):61-3.
Antiplatelet Clin Res.
92. RL., Sci.
Wilson T, Resveratrol
Knight TJ, promotes
Beitz ath-
DC,
Lewis
DS,
Engen Life
erosclerosis in 1996;59(1):PL15-21.
hypercholesterolemic
rabbits.,
93.
Goldberg
DM.,
More
on
antioxidant
activity
of
resveratrol Chem. 1996
in
red
wine., Clin
Jan;42(1):113-4.
94. G, human on .
Pace-Asciak Goldberg phenolics platelet
CR, DM.,
Hahn The
S, red
Diamandis wine and
EP,
Soleas block protecti
trans-resveratrol aggregation synthesis: heart Chim Acta.
quercetin for
and eicosanoid against coronary disease., Clin
implications 1995 Mar
31;235(2):207-19
95. Bertelli Migliori M, and
AA, Giovannini L, Bernini W, Fregoni M, activity red
Giannessi of
D,
Bertelli A., Antiplatelet natural resveratrol in wine., Int J
synthetic
Tissue React. 1995;17(1):1-3.
96. CN.,
Chung MI, Teng An antiplatelet Veratrum formosanum.,
CM, Cheng principle Planta Med.
KL, of 1992
Ko
FN,
Lin
Jun;58(3):274-6.
Anti
aging
1. Fu and
P,
Oliva J, French BA, French SW., Sirt1 The
Li is role
J, Bardag-Gorce involved in of
F,
energy metabolism: resveratrol., Exp
chronic ethanol feeding
Mol
Pathol. 2008
Aug
28.
2. of
Orallo F., eternal youth?, Curr 2008;15(19):1887-98.
Trans-resveratrol: Med Chem.
magical elixir
3. MA,
Rayalam Baile CA.,
S, Yang Resveratrol inhibits Res.
JY, Ambati S, induces adipogenesis
Della-Fera in 3T3-L1
apoptosis and adipocytes., Phytother 2008 Aug 7.
4. on
Markus MA, and treatment
Morris BJ., Resveratrol of common of aging., Clin
in
preventi
clinical conditions ):331-9.
Interv Aging. 2008;3(2
5. E, Y., on Aug
Cao C, Bagdasarian Song SIRT1 UVBof tured 4.
Lu A,
S, Kivlin R, Tamakloe T, Kouttab N, against cell culCell
Wallin B, Wang WJ, Xu death Mol A, via Med.
Card Wan modulati 2008
X, Chu WM, confers protection and p53 skin
H(2)O(2)-induced and JNK in keratinocytes., J
6. R.,
Lpez-Lluch Mitochondrial
G, Irusta PM, biogenesis and Gerontol.
Navas 2008
P,
de
Cabo
healthy aging. Exp
Sep;43(9):813-9.
7. Barger Weindruch R., tion mimics gene sion heart., Exp
JL, Kayo Short-term
T, Pugh consump-
TD,
Prolla TA, mixture mouse
of a expres-
resveratrol-containing nutraceutical caloric restriction in
of long-term Gerontol. 2008
Sep;43(9):859-66.
8. t: Dose
Mattson mechanisms therapeutic Response. Aug
MP, of
Son TG, action and of
Camandola neurohormetic
S.,
Viewpoin
potential 2007
phytochemicals.,
6;5(3):174-86.
9. G, AT, and and
Calabrese Calafato Giuffrida Rizzarelli
V, S,
Cornelius Bellia F,
C, Bates
Mancuso C, TE, T,
Pennisi
Stella AM, Schapira E., Cellular A Novel
Dinkova Kostova Chemoprevention Disorders
Stress Response: Nutritional Neuroprotection in Longevity., Neurochem Res.
Target for
Aging, Neurodegenerative 2008 Jul 16.
10. Price HA, Le DA,
Pearson KJ, NL, Labinskyy WR, Zhang Kamara D, Y, Dunn
Baur N, Minor SR,
JA, Lewis Swindell RK, Perez Sharma K,
KN, E,
Peshkin L, Jamieson Ikeno Y, Sinclair
Pleshko N, Couteur D, Navas de P, Cabo
Woollett Elliott PJ,
LA, Csiszar A, Becker KG, NS, and
Ingram DK, Wolf R., Resveratrol deterioration
Ungvari Z,
delays aspects of
age-related dietary
mimics transcriptional
2008
restriction without extending Aug;8(2):157-68.
life
span., Cell
Metab.
11. J, KW, rol ONE.
Barger JL, Hacker TA,
Kayo Wang
T, Y,
Vann JM, Raederstorff C,
Arias
EB,
Wang Saupe
D, Morrow JD, Leeuwenburgh Cartee GD, Weindruch
Allison DB, of in
R, Prolla TA., A low dose partially mimics caloric restriction 2008 and Jun retards aging 4;3(6):e2264. parameters
dietary resverat mice., PLoS
12. of
Chen CY, nuts., Asia Nutr.
Blumberg Pac J
JB., Clin
Phytochemical
composition
2008;17 Suppl
1:329-32.
13. LM., via 2008
Deng JY, Activation
Hsieh of
PS, Huang estrogen
JP, Lu receptor
LS, is
Hung
crucial for resveratrol-stimulating muscular both insulindependent and Jul;57(7):1814-23. -independent pathways.,
glucose uptake Diabetes.
14. Csiszar Kaminski PM, Cabo ion ic C, R,
A, Wolin
Labinskyy MS, Zhang
N,
Podlutsky Hu and F,
A, de
Mukhopadhyay Ballabh P,
P, Pacher P, Ungvari Z., resveratrol stress and Circ
Vasoprotective effects of of cigarette smoke-induced alterations., J oxidative Physiol Heart
SIRT1: attenuat
proinflammatory phenotyp 2008 Jun;294(
Am 6):H2721-35.
Physiol.
15. ,
Guarente L., Cold Spring Harb 2007;72:483-8.
Sirtuins Symp Quant
in Biol.
aging
and
disease.
16. CR, ,
Rossi L, Rotilio G., Polyphenols Neurochem Apr 16.
Mazzitelli Benefits for Res. Brain 2008
S, from Aging
Arciello Dietary and
M, Alzheimer s
Capo Disease.
17. Harikumar multitargeted agent . ciated
KB, for
Aggarwal age-assoCell
BB.,
Resveratrol:
chronic diseases.,
Cycle. 2008
Apr;7(8):1020-35
18. H, d 1710.
Huang J, Sun Y,
Gan Zhang
Q, Z,
Han Tong
L, T.,
Li SIRT1
J, Zhang overexpreswith Mar activate 5;3(3):e
sion antagonizes cellular ERK/S6k1 signaling in human diploid fibroblasts., PLoS
senescence ONE. 2008
19. Baxter RA., Anti-aging review and report of a new Dermatol. antioxidant skin 2008 Mar;7(1):2-7.
properties potent care
of
resveratrol: J Cosmet
formulation.,
20. J, CNS
Palls M, Camins A.,
Verdaguer Modulation
E, of
Tajes
M,
Gutierrez-Cuesta Recent Patents
sirtuins: new Drug Discov. 2008 Jan;3(1):61-9.
targets for
antiageing.,
21. J.,
Hsu Sirt1 aging
CP, Odewale I, protects the and stress. Biol
Alcendor heart from Chem. 2008
RR,
Sadoshima
Mar;389(3):221-31.
22. Engel N, unexpected side J
Mahlknecht effects of
U.,
Aging
and
anti-aging: Int
everyday medication Mol Med. 2008 Feb;21(2):223-32.
through sirtuin1
modulation.,
23. HJ,
Bickenbach Posner MC,
KA, Kron
Veerapong SJ, Resveratrol TNF-
J, is
Shao an Ther.
MY,
Mauceri
Weichselbaum RR., inducer of CArG-driven alpha ):133-9. gene
effective 2008 Mar;15(3
therapy.,
Cancer Gene
24. ay ,
Swindell WR., data identifies responses to Mech Ageing Dev. Mar;129(3):138-53.
Comparative common
analysis among
of mouse
microarr tissues.
caloric restriction 2008
25. PJ,
Burton DG, Lowe J,
Sheerin AN, Rhys-Williams
Ostler EL, W, RG.,
Smith
K,
Giles
Kipling DG, Faragher permits the reproducible detection muscle cells., Ann 2007 of N
Cyclin D1 human Sci. vascular
overexpression smooth
senescent Y Acad
Nov;1119:20-31.
26. Baumann Dermatol Ther.
LS., 2007
Less-known
botanical
cosmeceuticals.,
Sep-Oct;20(5):330-42.
27. L,
Gambuti Moio L., on of Sci.
A, Strollo D, Erbaggio Effect of winemaking praccolor indexes and selected Aglianico wine., J 2007 Nov;72(9):S623-8.
A,
Lecce
tices phenolics Food
bioactive
28. as Soc
de an
la Lastra CA, antioxidant and and
Villegas pro-oxidant clinical
I.,
Resveratrol
agent: mechanisms Trans. 2007 Nov;35(Pt
implications., Biochem
5):1156-60.
29. Putics A, Vgh Resveratrol induces the
EM, Csermely heat-shock human cells
P, from
Soti
C.,
response and protects stress., Antioxid Redox Signal. 2008 Jan;10(1):65-75.
severe heat
30. a
Rasouri S, Lagouge M, neuroprotective axis?], Med Sci (Paris). 2007
Auwerx J.,
[SIRT1/PGC-1: [French]
Oct;23(10):840-4.
31. Mattson MP., health., Ageing Res Jan;7(1):43-8. Epub
Dietary factors, Rev. 2008 2007 Sep 1.
hormesis
and
32. D,
Bass TM, Partridge
Weinkove D, L., Effects of in Mech
Houthoofd resveratrol
K,
Gems and
on lifespan Caenorhabditis elegans., Ageing Dev. 2007
Drosophila
melanogaster
Oct;128(10):546-52.
33. Wang
Hudson TS, TT, Young
Hartle DK, HA, Arany
Hursting of
SD, prostate
Nunez
NP, cancer
P, growth by
Green JE., muscadine
Inhibition grape skin
extract and Cancer Res. 2007
resveratrol Sep
through distinct
mechanisms.,
1;67(17):8396-405.
34. Dawes
Stefani M, IW, Morris BJ., resveratrol N Y
Markus MA, Lin The effect on Acad a Sci. cell 2007
RC, model
Pinese M, of human
of aging., Ann
Oct;1114:407-18.
35. P, Cell
Cucciolla Zappia V,
V, Della
Borriello Ragione from basic
A,
Oliva
A, the
Galletti clinic.,
F., Resveratrol: Cycle. 2007 Oct 15;6(20):2495-510.
science to
36. Barrera-Garca VD, Aguirre C, Voilley A,
Gougeon RD, Chassagne
Di
Majo
D,
De
D., polyphenols . wood.,
Different sorption in contact with oak J Agric Food Chem.
behaviors 2007 Aug
for
wine
22;55(17):7021-7
37. yeast
Kaeberlein Sir2 in Cell. 2007
M, Kennedy BK., vivo?, Aging Aug;6(4):415-6.
Does
resveratrol
activate
38. t
Heiss EH, Schilder YD, with resveratrol induces stress- and p53-positive
Dirsch VM.,
Chronic treatmen
redox senescence in
ataxia telangiectasia-mutated (ATM)-dependent cancer cells., J
39. A,
Biol Ch Sananbenesi
Kim F,
D, Nguyen MD, Rodgers JA, DA, protects amyotrophic Sui Tsai
Dobbin MM, G,
Fischer
JT, Puigserver n EMBO LH., in
Delalle I, Baur P, Sinclair SIRT1 deacetylase models for disease and Jul
Armour SM,
against neurodegeneratio lateral sclerosis.,
Alzheimer s J. 2007
11;26(13):3169-79.
40. rol
Frjd S, is a
Cozzone D, class IA
Vidal H, Pirola L., phosphoinositBiochem J. 2007
Resverat Sep
ide 3-kinase 15;406(3):511-8.
inhibitor.,
41. on
Sedding D, Sirt1 expression?, 25;100(10):1396-8.
Haendeler Circ Res.
J., 2007
Do May
we
age
42. for
Gruber J, Tang trade-off
SY, Halliwell between survival resveratrol
B., and
Evidence of Caenorha
fitness caused by
treatment
bditis elegans., Acad Sci.
Ann 2007
Apr;1100:530-42.
43. es 2007
Dasgupta B, Milbrandt AMP kinase activity in neurons., Proc Natl Apr 24;104(17):7217-22. Acad
J., Sci
Resveratrol U S
stimulat A.
44. A,
Ungvari Xiangmin
Z, Z, Increased NF-
Orosz Smith
Z, K,
Labinskyy Csiszar H2O2 rat 2007
N,
Rivera promotes Am
A., endothelial J
mitochondrial in aged Physiol.
production arteries.,
kappaB activation Physiol Heart Circ Jul;293(1):H37-47.
45. of J
Kallithraka young red on Agric 2007
S, wines
Mamalos A, based of minor
Makris DP., polyphenolic
Differentiation constituents.,
chemometrics Food Chem. May
2;55(9):3233-9.
46. Bastianetto tective effects of ucts: peptides role 0):1720-5.
S, Brouillette natural prod-
J,
Quirion R., kinases, Res. 2007
Neuropro amyloid Oct;32(1
interaction and a for
with intracellular possible
transthyretin., Neurochem
47. N, G Acad
Jefremov Karelson
V, E.,
Zilmer M, Antioxidative
Zilmer K,
Bogdanovic of Y
effects of plant protein signaling tion Sci. of 2007
polyphenols: from to preven-
protection Ann N
age-related pathologies., Jan;1095:449-57.
48. .,
Tang Mol
BL, Chua Aspects Med.
CE., 2008
SIRT1
and
neuronal
diseases
Jun;29(3):187-200.
49. in
Russo GL., Ins and cancer chemoprevention., Biochem Pharmacol. 2007
outs Aug
of
dietary phytochemicals
15;74(4):533-44.
50. Blagosklonny senescence-promoting genes to Mar;12(5-6):218-24.
MV.,
An
anti-aging pill. Drug
drug
today: from
anti-aging
Discov Today. 2007
51. Cell.
Austad SN., Vertebrate 2007 Apr;6(2):135-8.
aging
research
2006., Aging
52. Stipp D., 5;155(2):68-70, 72,
Live 74
forever?, passim.
Fortune.
2007
Feb
53. Holme AL, decisions., J 2007
Pervaiz S., Bioenerg
Resveratrol Biomembr.
in
cell
fate
Feb;39(1):59-63.
54. 2007
Labie D, Ferr P., Feb;23(2):122. [French]
[Cheers !],
Med
Sci
(Paris).
55. N,
Ungvari Xiangmin
Z, Z,
Orosz Olson
Z, S,
Rivera A, Podlutsky
Labinskyy A,
Csiszar A., Resveratrol stress resistance., Am Physiol Heart Circ Physiol.
increases J 2007
vascular
oxidativ
May;292(5):H2417-24.
56. Chen target for Trends
D, Guarente calorie restriction Mol Med. 2007
L., SIR2: mimetics., Feb;13(2):64-71.
potential
57. Sinclair aging?, Newsweek. 11;148(24):80,
D, 2006 82,
Komaroff Dec 84.
AL.,
Can
we
slow
58. a
Koo tale
SH, of
Montminy M., two sirt1s?,
In Cell.
vino 2006
veritas: Dec
15;127(6):1091-3.
59. JK,
Yang H, Kisielewski
Baur A,
JA, Chen Howitz KT,
A, Miller C, Zipkin synthesis
Adams of
RE, compounds in: Anne cative Aging
Sinclair DA., that extend yeast lifespan., Cell. 2007 Aging
Design and repliCell. 2007 [added];
Feb;6(1):35-43. Erratum Kisielewski, [added].
Aug;6(4):593. [added]; Konrad T
Adams, Jeffrey K Howitz, [added];
Zipkin, Robert E
60. Kaeberlein versus gluttony., Nov
M, Rabinovitch Nature. 2006
PS.,
Medicine:
grapes
16;444(7117):280-1.
61. Lerin S, RG, de
Baur C,
JA, Kalra
Pearson KJ, Price A, Prabhu VV, G, O, Lewis Gwinn
NL, Jamieson Allard K, D, Fishbein Pistell PJ, KW,
HA, Poosala Spencer
JS, Lopez-Lluch Becker KG, Boss Wang M, Lakatta EG, Shaw Cabo RJ, R,
Ramaswamy S, Le Couteur D, Navas P, Sinclair
Puigserver P, DA., Resveratrol of mice
Ingram DK, on a
improves health and survival high-calorie diet., Nature. 2006 Nov 16;444(7117):337-42.
62. The ,
Terzibasi short-lived
E, fish
Valenzano DR, Nothobranchius new 2007 model
Cellerino aging
A., studies.
furzeri as a Exp Gerontol. Jan-Feb;42(1-2):81-9.
system for
63. Kode
Yang A,
SR, Wright J, Bauter M, Rahman I., Sirtuin regucigarette RelA/ NF-kappaB lungs in smoke-induced in vivo:
Seweryniak
K,
lates release via in Lung p65 rat for Cell
proinflammatory mediator in vitro J and Physiol
macrophages implications and 2007
chronic inflammation Mol Physiol.
aging., Am
Feb;292(2):L567-76.
64. Mattson MP, Low-dose toxins that induce adaptive Trends Neurosci. 2006 Nov;29(11):632-9.
Cheng
A., neuronal
Neurohormetic
phytochemicals:
stress responses.,
65. Yao resveratrol s
Y, Tian mechanism Zhong
T, of Yao
Nan KJ., immunity Cai. 2006
[Research in
on
anti-aging], [Chinese]
May;29(5):464-7.
66. Z,
Csiszar Rivera A,
N, of Am
Orosz coronary J
Oct;291(4):H1694-9.
67. I, rol
Horn TL, Crowell JA,
Cwik Booth
MJ, TD,
Morrissey
RL,
Kapetanovic of 2007 resverat Jan;45(1
McCormick DL., in p53(+/-)
Oncogenicity (p53 Chem
evaluation Toxicol.
knockout) ):55-63.
mice., Food
68. Ramassamy compounds in their
C., the
Emerging treatment
role
of a
polyphenolic review of
of neurodegenerative intracellular targets., Pharmacol. 2006 Sep
diseases: Eur J 1;545(1):51-64.
69. the
Afaq F, prevention
Mukhtar H., Botanical of photocarcino-
antioxidants
in
genesis and ):678-84.
photoaging.,
Exp
Dermatol.
2006
Sep;15(9
70. logy 2006
Collins JJ, of delayed aging
Evason K, Kornfeld and extended Exp
K.,
Pharmaco
lifespan of Caenorhabditis elegans., Oct;41(10):1032-9.
Gerontol.
71. have
Spinney L., it., Nature. 2006 15;441(7095):807-9.
Gerontology: Jun
eat
your
cake
and
72. Anekonda TS., Alzheimer s disease?, Res Rev. 2006
Resveratrol--a boon Brain Sep;52(2):316-26.
for
treating
73. of
Baur JA, resveratrol: dence., Nat
Sinclair the in Rev Drug
DA., vivo
Therapeutic evi-
potential
Discov. 2006
Jun;5(6):493-506.
74. the old
Valenzano pharmacology a new molecule.,
DR, of
Cellerino aging:
A., to
Resveratrol validate
and an
vertebrate model Cell Cycle. 2006
May;5(10):1027-32.
75. Lane
Ingram DK, MA, Roth
Zhu GS,
M, Mamczarz deCabo R., mimetics: an
J, emerging
Zou
S, research
Calorie restriction field., Aging Cell. 2006 Apr;5(2):97-108.
76. Labinskyy N, Pacher P, Oroszi G,
Csiszar A, Wu J,
Veress G, Ungvari Z.,
Stef
G,
Vascular dysfunction in resveratrol, an anti-inflammatory phytoestrogen., Curr
aging: potential Med Chem.
effects of
2006;13(9):989-96.
77. Sinclair DA, secrets of longevity 2006
Guarente genes., Sci 54-7.
L., Am.
Unlocking
the
Mar;294(3):48-51,
78. A, onset
Valenzano Domenici
DR, L,
Terzibasi Cellerino
E, A.,
Genade T, and
Cattaneo
Resveratrol prolongs lifespan of age-related markers in vertebrate., Curr
retards the 2006 Feb
a short-lived 7;16(3):296-300.
Biol.
79. of
Osawa T., anti-aging
[Recent development therapy Nippon Ronen
and
future direction Nov;42(6
by ):587-95.
supplements]
Igakkai Zasshi. 2005
[Japanese]
80. 2005
Tatar M., SIR2 Nov;2(5):281-2.
calls
upon
the
ER.,
Cell
Metab.
81. Supornsilchai V, Wuttke W, Sder O., rat Phytoestrogen adrenocor-
Svechnikov
K,
Seidlova-Wuttke D, steroidogenesis by
resveratrol
suppresses
tical oxylase.,
cells Horm
by Res.
inhibiting
cytochrome
P450
c21-hydr
2005;64(6):280-6.
82. L., ing
Viswanathan role
M, for
Kim SK, Berdichevsky SIR-2.1 regulastress response span., Dev Cell. genes
A, in
Guarente determin
tion C. 2005
of ER elegans life Nov;9(5):605-15.
83. by Epub
Anekonda sirtuins disease., 2005 Oct
TS, in J 7.
Reddy PH., Alzheimer s Neurochem.
Neuronal 2006
protection Jan;96(2):305-13.
in of
to
becomes clearer.
Hypertens.
Jul;23(7):1285-3
85. Sinclair restriction and lation., Mech
DA., Toward a longevity reguAgeing Dev. 2005
unified theory of Sep;126(9):987-1002.
caloric
86. as Mol
de an aging Nutr
la Lastra CA, anti-inflammatory agent: mechanisms Food Res. 2005
Villegas and antiand clinical
I.,
Resveratrol implications.,
May;49(5):405-30.
87. Delmas D, Jannin B, Latruffe preventing properties against Res. vascular alterations and 2005 May;49(5):377-95. ageing.,
N., Mol
Resveratrol: Nutr Food
88. Provinciali Bartozzi B, Effect spontaneous May
M, Di
Re F, Stasio G, on
Donnini A, Smorlesi the
Orlando F, A., of
of resveratrol mammary tumors in
development J
HER-2/neu transgenic 20;115(1):36-45.
mice., Int
Cancer. 2005
89. J, S,
Kaeberlein Westman EA,
M, McDonagh Caldwell
T,
Heltweg B, PS,
Hixon Fields by
SD, Napper A, Curtis R, Bedalov A, Kennedy BK., activation Chem. 2005
DiStefano of Apr sirtuins
Substrate-specific resveratrol. J Biol 29;280(17):17038-45.
90. Burzynski activation?, Med 2005;64(1):201-8.
SR., Aging: gene Hypotheses.
silencing
or
gene
91. Jarolim Goldfarb DS, assay cerevisiae., 2004 for FEMS
S, Millen J, Breitenbach M., replicative Yeast Res. lifespan
Heeren G, A novel in
Laun
P,
Saccharomyces
Nov;5(2):169-77.
92. Bauer JH, accelerated assay la
Goupil S, for the
Garber GB, identi-
Helfand SL., in Aug
An Drosophi 31;101(3
fication of lifespan-extending melanogaster., Proc Natl Acad Sci U S
interventions A. 2004
5):12980-5.
93. model
Flurkey systems in Pract
K, Currer JM., ageing research., Res Clin
Pitfalls
of Metab. 2004
animal Sep;18(3
Best ):407-21.
Endocrinol
94. SL, in
Wood Tatar
JG, M,
Rogina B, Sinclair
Lavu D.,
S, Howitz K, Sirtuin and delay
Helfand ageing
activators metazoans., 2004 Aug
mimic caloric restriction Nature. 5;430(7000):686-9.
95. Aging
Leslie M., Knowledge 14;2004(28):nf67.
Resveratrol Environ.
to 2004
the Jul
rescue.,
Sci
96. Picard F, Senawong T, L., ma.,
Kurtev M, Machado De M, fat
Chung
N,
Topark-Ngarm MW,
A,
Oliveira R, Leid Sirt1 promotes zation in Nature. 2004 white Jun
McBurney mobiliby
Guarente PPAR-gam
adipocytes
repressing
17;429(6993):771-6.
97. to
Horseman RE., lamp shades., Feb;32(2):198, 197.
Say J
yes Calif
to Dent
sirtuin; Assoc. 2004
no
98. Couzin J., Scientific family feud., Science. 2004 Feb 27;303(5662):1276-9.
community.
Aging
research s
99. O Neill Jan;2(1):E12.
B.,
In
Methuselah s
Mould., PLoS
Biol.
2004
100. Pocar P, expression of
Augustin CYP1A1 in
R, Fischer B., bovine in
Constitutive and
cumulus oocyte-complexes biological implications., Endocrinology. 2004
vitro: mechanisms
Apr;145(4):1594-601.
101. Corder R, health? It s Nature. 2003
Crozier A, too early Nov
Kroon to
PA., say.,
Drinking
your
13;426(6963):119.
102. 2003
Finkel T., Ageing: a Sep 11;425(6954):132-3.
toast
to
long
life., Nature.
103. Hall Compounds ing
SS., Longevity research. activate life-extendgenes., Science. 2003 Aug
In
vino
vitalis?
29;301(5637):1165.
104. logy the
Bhavnani BR., of conjugated equine estrogens prevention of
Estrogens and their neurodesuch
and
menopause: role
pharmaco in J
potential as
generative Steroid Biochem Mol
diseases Biol. 2003
Alzheimer s.,
Jun;85(2-5):473-82.
105. Lavu
Howitz KT, S, Wood
Bitterman KJ, JG, Zipkin
Cohen
HY,
Lamming DW,
B, ae
RE, Chung Sinclair activators lifespan., Sep
P, DA.,
Kisielewski A, Small molecule
Zhang
LL,
Scherer cerevisi
of sirtuins Nature. 2003
extend Saccharomyces
11;425(6954):191-6.
106. wine
Flamini chemistry. nols., Mass
R., Part Spectrom
Mass I:
spectrometry polypheRev. 2003
in
grape
and
Jul-Aug;22(4):218-50.
107. Di
Boscolo Gioacchino P, on
P, M,
del Di
Signore A, Giampaolo
Sabbioni L, Reale
E, M,
Conti resveratrol Sci. tion 2003
Paganelli lymphocyte
R, Giaccio M., proliferarelease., Ann
Effects of Clin Lab
and cytokine Spring;33(2):226-31.
108. Schwedhelm E, Maas Clinical pharmacokinetics e tioxidants stress., and Clin
R, of
Troost R, ansystemic
Bger
RH., oxidativ
their impact on Pharmacokinet.
2003;42(5):437-59.
109. Lpez-Burillo S, Tan Manchester LC, Reiter RJ., C Melatonin, xanthurenic and alpha-lipoic
DX, acid,
Mayo
JC,
Sainz EGCG,
RM, vitamin
resveratrol,
by tic
acid differentially reduce oxidative Fenton reagents: a actions., May;34(4):269-77. study J of their Pineal Res.
DNA
damage induced and synergis
individual 2003
110. YP, al J
Sparrow Jockusch
JR, S,
Vollmer-Snarr Itagaki Y, damage DNA
HR, Zhou Nakanishi in
J,
Jang
K., A2E-epoxides cells. Vitamin E and Biol other Chem.
retinal pigment epitheli formation.,
antioxidants 2003 May
inhibit A2E-epoxide
16;278(20):18207-13.
111. MC., aging J
Pozo-Bayn Study of
MA, low
Hernndez
MT,
Martn-Alvarez PJ, during the varieties.,
Polo
molecular weight phenolic of sparkling wines manufactured Agric Food Mar with Chem. red 2003 and
compounds white grape
26;51(7):2089-95.
112. to in
Liu C, cigarette
Russell RM, smoke and of
Wang a
XD., phar-
Exposing
ferrets
macological dose vitro retinoic
beta-carotene lungs J via Nutr.
supplementation enhance induction of
acid cytochrome 2003
catabolism in P450 enzymes., Jan;133(1):173-9.
113. Bastianetto S, possible protective brain
Quirion R., agents of
Natural extracts
as
aging., Neurobiol
Aging. 2002
Sep-Oct;23(5):891-97.
114. and
Sun AY, Simonyi A, beyond: neuroprotective
Sun
GY.,
The
French Paradox
Feb
effects of polyphenols., 15;32(4):314-8.
Free
Radic
Biol
Med.
2002
115. rol
Igura K, Ohta and quercetin esis in
T, Kuroda Y, inhibit angiogen2001
Kaji Sep
K.,
Resverat
vitro. Cancer Lett.
28;171(1):11-6.
116. ment cell 5.
Frankel of the
D, Schipper HM., astroglial substra-
Cysteamine
pretreat PC12
tum (mitochondrial iron vulnerability to oxidative injury.,
sequestration) enhances Exp Neurol. 1999
Dec;160(2):376-8
117. Cheng
Sun Y.,
AY, Chen YM, Ethanol-induced death Res. by 1997 lipid
James-Kracke peroxidation
M, in
Wixom PC12
P, cells.,
cell Neurochem
Oct;22(10):1187-92.
118. ive.,
Pezzuto J Agric Aug
JM., Food
Grapes and Chem. 2008
human
health: a
perspect
27;56(16):6777-84.
Immune
boosting
effect of
resveratrol
1. PJ., Rev.
Udenigwe Potential
CC, of
Ramprasath resveratrol
VR, in
Aluko
RE,
Jones Nutr
anticancer and anti-inflammatory 2008 Aug;66(8):445-54.
therapy.,
2. Barger Weindruch R., tion mimics gene sion heart., Exp
JL, Kayo Short-term
T, Pugh consump-
TD,
Prolla TA, mixture mouse
of a expres-
resveratrol-containing nutraceutical caloric restriction in
of long-term Gerontol. 2008
Sep;43(9):859-66.
3. CW., Int
Yang Y, Resveratrol
Paik JH, induces the
Cho D, suppression
Cho
JA, T
Kim cells.,
of tumor-derived Immunopharmacol. Apr;8(4):542-7.
CD4+CD25+ 2008
regulatory
4. ntary
Clarke JO, and alternative
Mullin GE., approaches Nutr
A Clin
review of Pract. 2008
compleme Feb;23(1
to ):49-62.
immunomodulation.,
5. WM, in
Lo
Pan
MH, CY,
Gao Wang
JH, M, activity and SCID
Lai CS, Dushenkov of mice., Mol
Wang S,
YJ, Ho
Chen
CT., COLO
Antitumor 205 cells in
3,5,4 -trimethoxystilbene Carcinog. 2008
xenografts Mar;47(3):184-96.
6. Ward key is
E,
Banerjee Munn
T, DH,
Duhadaway Mellor AL,
JB,
Gaspari P, Muller AJ.,
SutantoA
Malachowski in vivo nism of inhibition
WP, Prendergast GC, antitumor mecha-
action of natural product-based of indoleOncogene. 2008
brassinins May 1;27(20)
amine :2851-7.
2,3-dioxygenase.,
7. LG,
Block G, McManus JF,
Jensen CD, Hudes ML.,
Norkus EP,
Dalvi
TB,
Wong
Usage long-term 2007
patterns, multiple
health, and dietary
nutritional
status of J.
supplement users: a Oct 24;6:30.
cross-sectional study., Nutr
8. YL,
Hsieh SC, Tsai YH,
Lu Lin
CC, CS,
Horng Lai
YT, HC.,
Soo The
PC,
Chang endotoxi
bacterial n-induced acute 2-9. injury in
metabolite lung rats., Microbes
2,3-butanediol ameliorates Infect. 2007
Oct;9(12-13):140
9. of
Das S, resveratrol., Drug
Das DK., Anti-inflammatory Inflamm Allergy 2007 Sep;6(3):168-73.
responses
Targets.
10. a tic
Vetvicka V, A, Vancikova
Volny Z,
T, Saraswat-Ohri Vetvickova
S,
Vashisht synergis
J., Glucan and resveratrol effects on immune Med Fac
complex--possible Univ
system., Biomed Pap Repub. 2007 Jun;151(1):41-6.
Palacky Olomouc Czech
11. YK.,
Li T, Resveratrol
Fan GX, Wang induces apoptosis,
W, Li influences
T,
Yuan mouse
IL-6 lymphocytic 2007
and exerts immunomodulatory leukemia and in
effect on vivo., Int
both in vitro Sep;7(9):1221-31.
Immunopharmacol.
12. MA.,
Salinas Adenosine
I, Rodrguez arrests apoptosis not of
A, in the Dev
Meseguer phagocytes Comp Immunol.
J, from
Esteban
in lymphocytes but primary leucocyte cultures teleost fish, 2007;31(12):1233-41.
Sparus aurata L.,
13. ated
Penberthy tolerance
WT., for
Pharmacological targeting disease., Curr Drug
of
IDO-medi
treating autoimmune Apr;8(3):245-66.
Metab. 2007
14. JN.,
Sharma S, Resveratrol
Chopra K, Kulkarni and curcumin
SK,
Agrewala and CD80
suppress immune response co-stimulatory 3. pathway., Clin Exp
through CD28/CTLA-4 Immunol. 2007
Jan;147(1):155-6
15. rs.,
Nam Mini 2006
NH., Rev
Naturally Med Chem.
occurring
NF-kappaB
inhibito
Aug;6(8):945-51.
16. of and
Rachon D, genistein
Rimoldi G, Wuttke W., and resveratrol on interferon-gamma
In
vitro
effects
the production of interleukin-10 (IL-10)
(IFNgamma) Phytomedicine. 2006
by stimulated Jun;13(6):419-24.
murine splenocytes.,
17. M, and
Brta I, Turek B,
Smerk P, Brtov
Polvkov perspectives
Z, in
Sestkov nutrition
H,
Lango
J., Current trends and cancer prevention., Neoplasma.
2006;53(1):19-25.
18. X, with Cell
Tao HY, Iribarren JM., the
Wu P,
CF, Zhao
Zhou YQ,
Y, Le
Gong YY,
WH, Wang
Zhang
The grape function
component of cheon
resveratrol phagocytic
interferes leukocytes.,
moattractant receptors Mol Immunol. 2004 Feb;1(1):50-6.
19. h
Schroecksnadel K, H, Weiss G,
Winkler C, Fuchs D., compound human Chem
Wirleitner resveratrol
B,
Schennac
Anti-inflammatory homocysteine formation cells in in Lab stimulated vitro., Clin Med.
suppresses mononuclear
peripheral
blood
2005;43(10):1084-8.
20. h in Lett.
Wirleitner H, Fuchs suppresses human peripheral 2005 Sep 15;100(2):159-63.
B, D.,
Schroecksnadel K, Resveratrol
Winkler C, biochemical
Schennac pathways
interferon-gamma-induced blood mononuclear cells
in
vitro., Immunol
21. T., Xi
Li T, [Preliminary of Bao Xue
Sheng study
L, on and Zi 2005
Fan GX, anti-tumor its Mian
Yuan YK, function
Li
resveratrol Yu Fen Za Zhi.
immunological Yi
mechanism], [Chinese]
Sep;21(5):575-9.
22. Marier JF, Castillo JR, lpha,
Chen K, Prince P, Vachon P.,Production of tumor
Scott ex necrosis
G,
del factor-a
vivo lipopolysaccharide-induced interleukinand in
1beta, sveratrol dependent Apr;69(2):151-4.
interleukin-6 is suppressed a concentrationmanner., Can J Vet
by Res.
trans-re 2005
23. rol Mol
as aging Nutr
de an
la Lastra CA, anti-inflammatory and
Villegas and anticlinical
I.,
Resverat
agent: mechanisms Food Res. 2005
implications.,
May;49(5):405-30.
24. in
Kimura Y., New vivo evaluation and from
anticancer of the
agents: in antitu-
vitro
and
mor isolated
antimetastatic actions of medicinal Vivo. 2005
various compounds
plants., In
Jan-Feb;19(1):37-60.
M, Di
Re F, Stasio G, on
Orlando F, A., of
development J
mice., Int
Cancer. 2005
26. B, in Sci.
Wang Davis
LX, C,
Heredia A, Redfield
Song R.,
H, Zhang Resveratrol of
Z,
Yu
glucuronides as the humans: characterization, synthesis, and anti-HIV 2004 Oct;93(10):2448-57.
metabolites
resveratrol J Pharm
activity.,
27. rol in
Khanduja inhibits amine-induced mice., J Sci
KL, Bhardwaj N-nitrosodiethylornithine Nutr (Tokyo).
A,
Kaushik G., and
Resverat
decarboxylase 2004
cyclooxygenase
Vitaminol
Feb;50(1):61-5.
28. of of Yi
Yu L, resveratrol tion human T Xue [Chinese]
Wu alone
SL, and
Zhang its A
M, Pan combinaon the
CE.,
[Effect
with cyclosporin peripheral blood lymphocytes], Za Zhi. Xi 2003
immune function Zi Mian
Bao Yu Fen Nov;19(6):549-51.
29. CM,
Kim Park
GY, YM.,
Cho H, Resveratrol
Ahn SC, inhibits maturation 2004
Oh YH, phenoof
Lee
typic and functional marrow-derived dendritic cells., Int Immunopharmacol.
murine bone
Feb;4(2):245-53.
30. H,
Gao X, Chapman RA,
Deeb D, Gautam SC.,
Media
J,
Divine G,
Jiang
in
Immunomodulatory activity vitro and in vivo effects.,
of im-
resveratrol:
discrepant 2003 Dec
munological 15;66(12):2427-35.
Biochem Pharmacol.
31. Losa oxidation
GA., in
Resveratrol human blood cells., Eur
modulates J Clin
apoptosis Invest. 2003
and Sep;33(9
mononuclear ):818-23.
32. Di
Boscolo Gioacchino P, on
P, M,
del Di
Signore A, Giampaolo
Sabbioni L, Reale
E, M,
Conti resveratrol Sci. tion 2003
Paganelli lymphocyte
R, Giaccio M., proliferarelease., Ann
Effects of Clin Lab
and cytokine Spring;33(2):226-31.
33. A,
Dallal O, Muraskas
Ravindranath JK, Namak
TM, SY,
Choudhry
MA,
Kohn
Alattar MH, Sayeed MM., following sepsis in neonatal rats., Biol Neonate.
T-cell proliferative
responses
2003;83(3):201-7.
34. WM,
Feng Zou
YH, JP.,
Zhou Low
WL, dose
Wu of
QL, Li resveof
XY,
Zhao
ratrol Pharmacol
enhanced Sin. 2002
immune response
mice., Acta
Oct;23(10):893-7.
35. of
Bhat KP, resveratrol., Acad Sci.
Pezzuto JM., Ann N 2002
Cancer chemoprotective activity Y
May;957:210-29.
36. Ignatowicz natural chemoJ protective Pharmacol.
E, agent
Baer-Dubowska
W.,
Resveratrol, diseases.,
a Pol
2001Nov-Dec;53(6):557-69.
37. Falchetti Tricarico M, 2001 ratrol Nov
R, Fuggetta Ravagnan G.,
MP, Lanzilli G, Effects of resvefunction., Life Sci.
on human immune cell 21;70(1):81-96.
38. Gao Gautam SC.,
X, Xu YX, Immunomodulatory
Janakiraman suppression and
N, of cytokine
Chapman RA, lymphocyte producti
activity of resveratrol: proliferation, development on., of cell-mediated Biochem Pharmacol. 2001 Nov
cytotoxicity,
1;62(9):1299-308.
39. er
Schneider Y, R, Seiler N,
Duranton Raul F., tumorigenesis animal model Nutr
B, Goss Resveratrol and of
F,
Schleiff host-def
inhibits intestinal ense-related gene expression in an adenomatous polyposis.,
modulates human
familial
Cancer. 2001;39(1):102-7.
40. A,
Bertelli Corsi M,
AA, Ponti
Ferrara F, Diana W, Ferrero ME,
G,
Fulgenzi in co-factor
Bertelli A., grapes and wine, phagocytosis
Resveratrol, enhances in human
a natural stilbene intrapromonocytes: a
in
antiinflammatory
and Int J Tissue
anticancer chemoprotective activity., React. 1999;21(4):93-104.
41. Wadsworth TL, polyphenolics quercetin on resveratrol in RAW on 264.7
Koop and
DR.,
Effects of cytokine Apr
the
wine expressi
pro-inflammatory macro1999
phages., Biochem Pharmacol.
15;57(8):941-9.
42. of l.
Tan red
Y, wine,
Lim LH., inhibits and
trans-Resveratrol, human eodegranulation., Br
an J
extract Pharmaco
sinophil activation 2008 Sep 8.
43. Dave Kennish L, yte
M, Patel
Attur J,
M, Palmer G, Abramson SB., resveratrol effects polarization protects and
Al-Mussawir
HE,
The antioxidant apoptosis via mitochondrial Rheum. 2008
against chondroc ATP production.,
on Arthritis
Sep;58(9):2786-97.
44. kara gold May
Khanna D, AB, Sung A, mine Opin 1.
Sethi B,
G, Ahn Aggarwal
KS,
Pandey MK, as Epub
Kunnumak a 2007
Aggarwal BB., for arthritis Pharmacol. 2007
Natural products treatment., Curr Jun;7(3):344-51.
45. 2005
Inoue H., Apr;63(4):578-83.
[Endogenous
ligands for
PPARs], Nippon Rinsho.
[Japanese]
46. on Prod.
Adams M, Pacher T, Greger H, of leukotriene biosynthesis by 2005 stilbenoids from Jan;68(1):83-5.
Bauer
R., J
Inhibiti Nat
Stemona species.,
47. M, mouse
Baolin L, Nagai H., the mast
Inami Y, Resveratrol
Tanaka H, inhibits from
Inagaki N, bone
Iinuma
release of cells in
mediators 2004
marrow-derived
vitro., Planta Med.
Apr;70(4):305-9.
48. N, ol, sion, Med.
Shigematsu Yoshimatsu
S, H,
Ishida S, Sakata T,
Hara M, Korthuis wine
Takahashi polyphen
RJ., Resveratrol, a red prevents superoxide-dependent inflammatory plateletactivating 2003 Apr responses
constituent
induced by Free
ischemia/reperfu Radic Biol
factor, or oxidants., 1;34(7):810-7.
49. Huang KS, tetramers of tions the of roots the
Lin M, resveratrol
Cheng from
GF.,
Anti-inflammatory and the conforma
of Vitis amurensis seven-membered some oligostilbenes.,
ring in Sep;58(2):357-62.
Phytochemistry. 2001
50. RR, nt ipase
Schwartz Dean DD, (OH)(2)D(3) effects on kinase A(2) C and
Z, Boyan mediates protein
Sylvia VL, Del BD., 24R,25its membrane
Toro
F,
Hardin
receptor-depende via phosphol
and alkaline cyclooxygennot Cell cyclooxygenase-2 Physiol.
phosphatase in
ase-1 but chondrocytes., J 2000
growth plate
Mar;182(3):390-401.
51. Agr and
MacCarrone M, AF., Resveratrol
Lorenzon prevents by Eur
T, Guerrieri apoptoinhibiting J
P,
sis in K562 cells cyclooxygenase activity., Biochem. 1999 Oct
lipoxygenase
1;265(1):27-34.
52. AF.,
Knight J, Eicosanoid
Taylor GW, biosynthesis
Wright P, in
Clare
AS, the
Rowley sea
an advanced deuterostomate invertebrate, squirt (Ciona intestinalis)., Biochim Biophys Acta. 1999 Jan
4;1436(3):467-78.
53. Hall analysis by Am peroxy lipid tion Soc
LM, of
Murphy RC., 5-hydro-
Electrospray
mass acids
spectrometric generated
and 5-hydroxyeicosatetraenoic peroxidaof Mass red blood Spectrom. cell 1998 ghost
phospholipids., J
May;9(5):527-32.
54. A,
Rotondo Rotillo D, V, Cerletti
S, de
Rajtar G, Gaetano G, C.,
Manarini Evangelista
S,
Celardo
Effect of
trans-resveratrol,
a Br
natural polyphenolic on J
compound, leukocyte function.,
human polymorphonuclear Pharmacol. 1998
Apr;123(8):1691-9.
55. as Lab
Soleas GJ, Diamandis EP, Goldberg biological fluid: history, prodisease prevention.,
DM., J
Wine Clin
duction, and role in Anal. 1997;11(5):287-313.
56. s in
Kimura Y, isolated plants human
Okuda from
H, Kubo medicinal
M.,
Effects of and
stilbene
on arachidonate polymorphoJ
metabolism
degranulation Feb;45(2):131-9.
nuclear leukocytes.,
57. Pendurthi UR, agonist-induced monocyte Res. adhesion to 2002 May cultured
Rao
LV., human
Resveratrol endothelial
suppresses cells., Thromb
15;106(4-5):243-8.
58. TY,
Do Park
GM, T,
Kwon Choi
EY, MS.,
Kim HJ, Long-term
Ha of E-defici
of atherogenic ent
tion and cholesterol mice., Biochem Biophys Res
Commun. 2008
Sep
12;374(1):55-9.
59. J,
Zhou Ding
M, FY,
He Xu
JL, GL.,
Yu SQ, [Effect of
Zhu RF, resveratrol rats
Lu on and
its
chronic obstructive mechanism], Yao Xue Bao. 2008
pulmonary Xue
disease in
Feb;43(2):128-32.
[Chinese]
60. Csiszar Kaminski PM, Cabo ion ic C, R,
A, Wolin
Labinskyy MS, Zhang
N,
Podlutsky Hu and F,
A, de
Mukhopadhyay Ballabh P,
P, Pacher P, Ungvari Z., resveratrol stress and Circ
Vasoprotective effects of of cigarette smoke-induced alterations., J oxidative Physiol Heart
SIRT1: attenuat
proinflammatory phenotyp 2008 Jun;294(
Am 6):H2721-35.
Physiol.
61. Harikumar multitargeted agent . ciated
KB, for
Aggarwal age-assoCell
BB.,
Resveratrol:
chronic diseases.,
Cycle. 2008
Apr;7(8):1020-35
62. Namazi H., account for the 2008
A novel action of
molecular resverainjury.,
mechanism Ann Vasc
to Surg.
trol against reperfusion May-Jun;22(3):492.
63. D, l ,
Bukowska Neumann M,
A, Schild L, Gardemann A, FW, Huth dysfuncsignaling (Maywood).
Keilhoff C, in
G, Goette A,
Hirte Lendecke
Neumann KH, Rhl U., Mitochondrial tion Exp 2008 and Biol redox Med
atrial tachyarrhythmia.
May;233(5):558-74.
64. YT.,
Yu HP, Resveratrol
Hsu JC, attenuates
Hwang TL, hepatic via
Yen estrogen
CH,
Lau receptor
injury -related Shock.
after trauma-hemorrhage pathway., 2008 Sep;30(3):324-8.
65. Z,
Csiszar Rivera A,
N, of Am
Orosz coronary J
Oct;291(4):H1694-9.
66. nol C
Wung BS, upregulates heme and
Hsu MC, endothelial
Wu
CC, via 2006
Hsieh novel
CW.,
Piceatan
oxygenase-1 tyrosine
expression kinase Res.
protein kinase
pathways.,
Pharmacol
Feb;53(2):113-22.
67. HO,
Kaplan S, Topkara VK,
Morgan JA, Oz MC.,
Bisleri G,
Cheema FH,
Akman on Ann
Effects of resveratrol in adhesion molecule expression nitric Thorac Surg. oxide 2005 synthesis in Nov;80(5):1773-8.
storage solution and vein grafts.,
68. K,
Uchida Y, Meng Y,
Yamazaki Hiramatsu
H, N,
Watanabe Kasai
S, Kitamura by mesangial
Hayakawa M., cells.,
A, Enhancement Clin
Yamauchi K, of NF-kappaB
Yao J, activity
resveratrol in Exp Immunol. Oct;142(1):76-83.
cytokine-exposed 2005
69. rol on
Wung BS, suppresses ICAM-1 the
Hsu MC, IL-6-induced
Wu in STAT3 Sci.
CC,
Hsieh
CW.,
Resverat
gene expression inhibition of Life
endothelial 2005 Dec
cells: effects 12;78(4):389-97.
phosphorylation.,
70. E, kappa
Leiro J, Orallo F.,
Arranz JA, Effect of genes Int
Fraiz involved
N,
Sanmartn in
ML,
Quezada
cis-resveratrol on B signaling., Immunopharmacol. 2005
nuclear factor
Feb;5(2):393-406.
71. QY., itis
Meng Y, Effect of
Zhang M, resveratrol
Xu on
J, Liu XM, microcirculation severe acute
Ma pancreat
disorder and lung in rats., World Gastroenterol. 2005
injury following J Jan 21;11(3):433-5.
72. HK.,
Ahn KS, Inhibitory
Kim JH, activity
Oh of the THP1
SR, Ryu stilbenes expression cells.,
SY, from of
Lee cell
medicinal plants on adhesion molecules on Planta Med. 2000
Oct;66(7):641-4.
73. Ferrero Pellegatta F, A., F, De Activity
ME, Corsi
Bertelli AE, MM, Bonfrate R, of
Fulgenzi A, M, Ferrara L, on Bertelli
Caterina in vitro
Giovannini resveratrol
ium.,
granulocyte Am J
and Clin
monocyte Nutr. 1998
adhesion
to
endothel
Dec;68(6):1208-14.
Inhibit
LDL
oxidation
1. study ,
Dong HH, Ren of protective erties of Bratisl Lek
HL., prop-
New in
progression
in
the disease.
resveratrol Listy.
anticardiovascular
2004;105(5-6):225-9.
2. Bradamante scular protective
S, Barenghi L, effects of resveDrug Rev. 2004
Villa
A.,
Cardiova
ratrol. Cardiovasc
Fall;22(3):169-88.
3. rol
Kollr and other wine]
P, Hotolov constituents Ceska Slov Farm.
H., 2003
[Biological
effects of
resve
of [Czech.]
Nov;52(6):272-81.
4. of n.,
Brito P, resveratrol globin Free 2002 and Radic
Almeida LM, Dinis with ferrylmyo-
TC.,
The
interaction oxidatio
peroxynitrite; protection Res.
against LDL
Jun;36(6):621-31.
5. TC,
Wu
Zou
JG, JM.,
Huang YZ, Resveratrol
Chen Q, inhiband azo
Wei
EH,
Hsieh
its oxidative Biol cation Int.
copper ion-induced modifiof 1999 human low
compound-initiated Biochem Mol
density lipoprotein.,
Jun;47(6):1089-96.
6. Belguendouz inhibits metal ity
L, Fremont L, ion-depen-
Linard A., of
Resveratrol porcine low-dens
dent and independent lipoproteins., Biochem Pharmacol. 1997
peroxidation May
9;53(9):1347-55.
Cancer
and
Resveratrol
1. Vidavalur Significance of Exp in Clin
R, wine
Otani and
H, Singal PK, resveratrol
Maulik N.,
cardiovascular disease: Cardol. 2006
French paradox revisited.,
Fall;11(3):217-25.
2. Wang TT, Hudson TS, Davies NM, Takahashi Y, SD., YS, Seifried H, Differential Effects of on In
Wang Kim
TC,
Remsberg Perkins SN, LNCaP Human Jun
CM, Hursting Prostate 26.
Vinyard BT,
Resveratrol Cancer Cells In Vitro and
Androgen-responsive
Vivo., Carcinogenesis. 2008
3. Kline
Snyder RM, K., Vitamin E
Yu W, Jia analog alphaand
L,
Sanders BG, in
TEA, combination Nutr
methylseleninic acid, synerinhibit human
trans-resveratrol growth.,
gistically Cancer. 2008
breast cancer cell
May-Jun;60(3):401-11.
4. M, rol Pac
Seeni A, Sugiura S, Suppression in The for J
Takahashi Sato SY,
S, Takeshita Shirai T.,
K,
Tang Resverat
of Prostate Transgenic Rat Prostate
Cancer Growth by
Adenocarcinoma of Cancer Prev. 2008
(TRAP) Model., Asian
Jan-Mar;9(1):7-14.
5. Hsieh TC, Wang cation of glutathione g ferase-pi protein (RTP)
Z, Deng sulfotrans-
H, new
Wu
JM.,
Identifi targetin affinity
(GSTP1) as a and studies of
resveratrol resveratrol
resveratrol-responsive chromatography., Anticancer
protein changes by Res. 2008
Jan-Feb;28(1A):29-36.
6. Inui
H,
Harada
N, Nakano Y., the level
Murata Y, Resveratrol
Yamaji R, down-
Miura at (Tokyo).
T, the
regulates post-translational 2007
androgen receptor in prostate Nutr Sci Vitaminol
cancer cells. J Dec;53(6):556-60.
7. Khan N, Afaq through dietary antioxi-
F,
Mukhtar H.,
Cancer chemoprevention
dants: Signal. 2008
progress and Mar;10(3):475-510.
promise.,
Antioxid
Redox
8. Zahid M, Inhibition of Chem
Gaikwad NW, depurinating
Rogan es-
EG, by
Cavalieri
EL.,
trogen-DNA adduct formation Res Toxicol. 2007 Dec;20(12):1947-53.
natural compounds.,
9. Zhou Mol
J,
Sallman Wei
DA, S,
Chen Djeu
X, JY., in
Zhong B, Clusterin prostate
Gilvary DL, tumor cells.,
mediates TRAIL Cancer Ther.
resistance 2007
Nov;6(11):2938-47.
10. Horvath Grusch M, Ozsy N, Djavan B, cycle
Z, M,
Marihart-Fazekas S, Harik M, Handler Jaeger W, T., Novel Fritzer-Szekeres resveraand
Saiko
P, M,
Erker T, Szekeres
trol derivatives induce apoptosis arrest in prostate cancer cell lines., Anticancer Res. 2007
cause
cell
Sep-Oct;27(5A):3459-64.
11. JM, cells
Gill C, Watson RW.,
Walsh SE, Resveratrol
Morrissey independent
C, prostate
Fitzpatrick cancer mechanis
sensitizes androgen to death-receptor mediated
apoptosis
through multiple
ms.,
Prostate. 1;67(15):1641-53.
2007
Nov
12. Wang
Hudson TS, TT, Young
Hartle DK, HA, Arany
Hursting of
SD, prostate
Nunez
NP, cancer
P, growth by
Green JE., muscadine
Inhibition grape skin
extract and Cancer Res. 2007
resveratrol Sep
through distinct
mechanisms.,
1;67(17):8396-405.
13. K, 5
Shankar Srivastava
S, RK.,
Chen Q, Sensitization cells by molecular
Siddiqui I, of TRAILresveratrol potential. (3, J
Sarva 4 , Mol
resistant LNCaP tri-hydroxystilbene):
mechanisms Signal. 2007 Aug
and therapeutic 24;2:7.
14. Djavan B, Marihart Partin A, Schalken J, in [Resveratrol therapy of carcinoma], and newly prostate Urologe A.
S, Kuehhas F, Sekeres T., synthetized 2007
Rom
M, analogs [German]
resveratrol
Sep;46(9):1101-3.
15. Harper CE, Patel Eltoum IA, Lamartiniere in Resveratrol transgenic
BB, CA.,
Wang prostate
J,
Arabshahi
A,
suppresses mice.,
cancer progression
Carcinogenesis. 2007
Sep;28(9):1946-53.
16. Shankar S, Molecular mechanisms with
Siddiqui I, of resveratrol and
Srivastava its
RK.,
(3,4,5-trihydroxy-trans-stilbene) TNF-related apopto-
interaction
sis prostate
inducing ligand (TRAIL) in cancer cells., Mol
androgen-insensitive
Jul
Cell 17.
Biochem.
2007
Oct;304(1-2):273-85.
Epub
2007
17. Cardile V, Sciuto S, Spatafora s Antiproliferative of Eand Naturforsch [C].
Chillemi R, C, Tringali activity of Z-resveratrol., Z 2007
Lombardo C., methylated
L, analogue
Mar-Apr;62(3-4):189-95.
18. on
Wietrzyk J., the antitumor
[The influence activity of Med Dosw
of
isoflavonoids 2007;61:
vitamin D3] 253-60. [Polish]
Postepy Hig
(Online).
19. Benitez Castelln E, and Non-genomic oestrogen
DA, Pozo-Guisado Fernandez-Salguero action of receptors
E, PM.,
Clementi on androgen
M,
resveratrol in of J the
prostate cancer: modulation 3-kinase pathway., Br Cancer. 2007 May
phosphoinositide
21;96(10):1595-604.
20. Von Review. Facts
Lw and
EC, Perabo FG, fiction of phyfor prostate preclinical and Vivo. 2007
Siener R, cancer: a clinical
Mller SC., critical
totherapy assessment of data., In
Mar-Apr;21(2):189-204.
21. Wang rol Ther.
Ahmad KA, G, Ahmed kinase and
Harris NH, Johnson AD, K., Protein apoptosis
Lindvall induced by
HC, resverat Cancer
CK2 modulates epigallocatechin-
3-gallate in prostate 2007 Mar;6(3):1006-12.
cancer cells., Mol
22. Scarlatti F, Milani F, Minella M, cells Lett.
Sala G, Botturi M,
Ricci C, Ghidoni R., DU145 prostate
Maioli C, cancer Cancer
Resveratrol sensitization of to ionizing radiation is 2007 Epub
associated to ceramide Aug 8;253(1):124-30. 2007 Feb 26.
increase.,
23. Zhao for
Landis-Piwowar KR, Y, Chan TH, QP., novel
Milacic V, Yan B, as and
Chen Dou a che-
D,
Yang
H, target
The proteasome anticancer drugs Drug
potential Dec;9(6):263-73.
mosensitizers.
Resist Updat. 2006
24. Narayanan BA., expression pattern: Curr predicting Cancer Drug Dec;6(8):711-27.
Chemoprotective agents alters global gene of 2006 action and targets.,
their mode Targets.
25. Nonn lammatory
L, Duong activities other
D, of
Peehl
DM.,
Chemoprotective anti-inf by MAP
curcumin and kinase phosphatase-5 6. in prostate
phytochemicals mediated cells., Carcinogenesis. 2007
Jun;28(6):1188-9
26. A,
Benitez DA, Fernandez-Salguero PM, Castelln
Pozo-Guisado EA.,
E,
Alvarez-Barrientos involved in resverat
Mechanisms
rol-induced cell
apoptosis cycle arrest in Androl. 2007 prostate cancer-derived
and cell lines., J
Mar-Apr;28(2):282-93.
27. of Opin
Bemis DL, Katz natural products moprotective Investig
AE, as
Buttyan R., cheprostate
Clinical cancer.,
trials Expert
agents for Drugs. 2006
Oct;15(10):1191-200.
28. N.,
Aziz MH, Nihal Resveratrol-caused human via
M, Fu apoptosis
VX,
Jarrard DF, LNCaP Bcl-2 cells
Ahmad is
of mediated .,
prostate modulation
carcinoma of phospathway and
phatidylinositol 3 -kinase/Akt Mol Cancer Ther. 2006
family proteins
May;5(5):1335-41.
29. KT, of
Yoo Kim
KM, SY,
Kim Choi
S, SY.,
Moon BK, Kim Potent inhibitory on
SS,
Kim
effects of prostate Pharm
resveratrol derivatives cancer cells., Arch 2006
progression
(Weinheim).
May;339(5):238-41.
30. Renis
Scifo C, Milasi A, M., Resveratrol and extract: an insight into
Guarnera propolis the
A, morphological
Sinatra F, and molecula
changes induced in DU145 cells., Oncol Res. 2006;15(9):409-21.
31. K, and d
Kotha A, Khaled A,
containing
Mar;5(3):621-9.
32. Jones SB, Resveratrol-induced
DePrimo SE, gene
Whitfield in human
ML, prostate
Brooks JD., cancer
expression profiles cells., Cancer Epidemiol Biomarkers Prev. 2005
Mar;14(3):596-604.
33. Cardile Tringali C., rol
V, Lombardo L, Chemo-enzymatic synthesis activity
Spatafora of
C, resverat
and cell-growth inhibition analogues., Bioorg Chem. 2005 Feb;33(1):22-33.
34. rol
Awad and
AB, Burr AT, beta-sitosterol in reactive cells.,
Fink com-
CS.,
Effect of
resverat
bination on release by PC-3 . Prostaglandins
oxygen species and Acids. 2005
prostaglandin Mar;72(3):219-26
Leukot Essent Fatty
35. ve
Manson MM, agents in prevention.,
Farmer PB, cancer
Gescher A,
Steward WP., 2005;166:257-75.
Innovati
Recent Results Cancer Res.
36. Narayanan rol-induced cell inhibition modulation of
NK, Narayanan growth and apoptosis phosphoglycerate human gel prostate
BA, is
Nixon
DW.,
Resverat with
associated
mutase B in nsional sodium dodecyl etry sulfate-polyacrylamide evaluation.,
cancer cells: two-dime mass spectrom
electrophoresis and 2004;28(6):443-52.
Cancer Detect Prev.
37. YH, l is
Shih Tang
A, HY,
Zhang S, Lennartz
Cao MR,
HJ, Davis
Boswell S, FB, effect of
Wu epiderma
Davis PJ, Lin growth factor on trol-induced mediated C-alpha.,
HY., Inhibitory resvera-
apoptosis in prostate by protein kinase Mol Cancer Ther. 2004
cancer cells Nov;3(11):1355-64.
38. Aggarwal BB, Seeram NP, Shishodia of
Bhardwaj A, S, Takada Y.,
Aggarwal and
RS, therapy
Role of resveratrol cancer: preclinical and studies. Anticancer Res.
in prevention clinical 2004
Sep-Oct;24(5A):2783-840.
39. C, or
Scifo C, Capasso F,
Cardile V, Vanella A,
Russo Renis
A,
Consoli R, as prosnecrosis
Vancheri
M., Resveratrol and apoptosis inducers tate carcinoma
propolis in human Res.
cells., Oncol
2004;14(9):415-26.
40. PJ,
Shenouda Sakla MS,
NS, Zhou Lubahn DB,
C,
Browning
JD,
Ansell regulate
Macdonald RS., prostate cancer cell growth in
Phytoestrogens in
common herbs
vitro., Nutr
Cancer. 2004;49(2):200-8.
41. JM.,
Wang Z, Hsieh Identification and
TC, Zhang purification
Z, of
Ma using
Y,
Wu
resveratrol targeting proteins resveratrol affinity chromatography., ):743-9. Biochem Biophys Res
immobilized Oct 22;323(3
Commun. 2004
42. c-Jun of
Yuan H, induced by resverol inhibits the androgen
Pan Y, quercetin
Young and
CY.,
Overexpression of and function 2004 Sep
the expression receptor in
human prostate 30;213(2):155-63.
cancer cells., Cancer Lett.
43. and
Simopoulos cancer., 2004
AP., Eur
The J
traditional Cancer Prev.
diet
of
Greece
Jun;13(3):219-30.
44. Sala Ghidoni R.,
G, Minutolo F, Resveratrol structure
Macchia M, and in
Sacchi N, prostate
ceramide-associated cancer cells., Drugs Exp Clin Res.
growth inhibition
2003;29(5-6):263-9.
45. Gao androgen
S, Liu GZ, receptor-dependent
Wang Z., transcripand May
Modulation in
of prostate
tion by resveratrol cancer cells., Prostate. 2004 1;59(2):214-25.
genistein
46. M,
Cardile Morgia G,
V, Motta
Scifo M,
C, Renis
Russo M,
A, Falsaperla Imbriani of HSP70 Res. in 2003
E, Silvestre G., resveratrol-induced apoptosis human prostate Nov-Dec;23(6C):4921-6. cancer.,
Involvement of
Anticancer
47. Kim iferative 2003
YA, Rhee effect of
SH, Park resveratrol carcinoma
KY, in
Choi
YH., Med
Antiprol Food.
human prostate Winter;6(4):273-80.
cells., J
48. s Cell
Ho of nogenesis Biochem.
SM., Estrogens and prostate carciand 2004 new Feb
anti-estrogens: key candidates.,
mediator J
therapeutic
15;91(3):491-503.
49. Stewart JR, EGFR-dependent Erk1/2 activation cancer cells with New in as-
O Brian CA., human
Resveratrol
antagonizes prostate Invest
androgen-independent PKC alpha
sociated isozyme-selective Drugs. 2004 Apr;22(2):107-17.
inhibition.,
50.
Fulda S,
Debatin KM.,
Sensitization
for
tumor
necrosis
factor-related apoptosis-inducing ligand-induced apoptosis tective agent resveratrol., Cancer Res. 2004 Jan by the chemopro
1;64(1):337-46.
51. olic
Carraway antioxidants
RE, mimic
Hassan S, the
Cochrane on 2004
DE., neurotensin
Polyphen receptor
effects of function in J
1,4-dihydropyridines PC3 cells., Exp Ther.
Pharmacol
Apr;309(1):92-101.
52. a J
Stewart candidate tional Nutr.
JR, Artime MC, nutri-
O Brian CA.,
Resveratrol:
substance for 2003 Jul;133(7
prostate
cancer prevention.,
Suppl):2440S-2443S.
53. by ms D, in
Aziz MH, resveratrol: and in (review).,
Kumar in vivo Int
R, vitro
Ahmad
N.,
Cancer chemoprevention underlying Chun YJ, mechanis Kim
studies and the J Oncol. 2003 F,
Jul;23(1):17-28. Peter Guengerich Gillam EM, Shimada T., Cytochrome P450 anticarcinogenesis Mutat Res. 2003 1B1: a strategies.,
target for
inhibition
Feb-Mar;523-524:173-82.
54. DW., ated
Narayanan Differential
BA, Narayanan expression of
NK, in
Re LNCaP
GG,
Nixon
genes induced by resveratrol molecular targets., Int J Cancer. 2003 Mar
cells: P53-medi
20;104(2):204-12.
55. SM, in J
Kris-Etherton PM, Binkoski AE, Griel AE, foods: their tion Med. of 2002
Hecker KD, Hilpert KF, TD., the
Bonanome Bioactive prevencancer.,
A,
Coval
Etherton role in
compounds Am
cardiovascular disease and Dec 30;113 Suppl
9B:71S-88S.
56. man
Deeb N,
D, Xu Chapman RA,
YX, Jiang Gautam SC., enhances
H,
Gao tumor in
X, necrosis LNCaP
Janakira
Curcumin (diferuloyl-methane) factor-related apoptosis-inducing cancer cells., Mol Cancer Ther.
ligand-induced apoptosis 2003 Jan;2(1):95-103.
prostate
57. Ratan HL, rol--a prostate
Steward WP, cancer
Gescher AJ, Oncol. 2002
Mellon JK.,
Resverat
chemoprotective agent?, Urol
Nov-Dec;7(6):223-7.
58. ation
Ding and
XZ, Adrian TE., induces apoptosis pancreatic
Resveratrol
inhibits
prolifer 2002
in human Nov;25(4):e71-6.
cancer cells., Pancreas.
59. Culig Z, receptors in
Klocker H, prostate
Bartsch G,
Hobisch A.,
Androgen
cancer. Endocr Relat
Cancer. 2002
Sep;9(3):155-70.
60.
Morris GZ,
Williams
RL,
Elliott MS,
Beebe
SJ.,
Resveratrol LNCaP decrease DU
induces apoptosis cells and viability 145
in hydroxyl and 2002 Sep groups to 1;52(4):319-29.
requires in LNCaP
cells., Prostate.
61. LJ, in 5.
Lin HY, Bennett JA,
Shih Davis
A, PJ.,
Davis FB, Resveratrol p53 Urol.
Tang
HY,
Martino
induced serine phosphorylation of a mutant p53 prostate cancer cell line., J
causes apoptosis 2002 Aug;168(2):748-5
62. BP.,
Narayanan Interactive
BA, gene
Narayanan expres-
NK,
Stoner GD,
Bullock
sion phenolic 2002
pattern in prostate antioxidants., Life Sci. Mar 1;70(15):1821-39.
cancer cells
exposed to
63. M, s
Kuwajerwala Barrack ER, Resveratrol phase and synthesis.,
N, Reddy
Cifuentes GP.,
E,
Gautam S, entry
Menon into
induces prostate inhibits DNA Cancer Res. 2002
cancer cell May
1;62(9):2488-92.
64. na
Sgambato A, Wolf Resveratrol,
A, FI, a
Ardito R, Cittadini natural phenolic
Faraglia A.,
B, compound,
Boninseg inhibits
cell Sep
proliferation
and
preDNA damage., Mutat Res. 2001
vents oxidative 20;496(1-2):171-80.
65. Cuendet M, genase and lipoxygenase
Pezzuto JM., in Drug
The
role
of
cyclooxy
cancer chemoprevention., 2000;17(1-4):109-57.
Metabol Drug
Interact.
66. A, Wine cell
Kampa M, Bakogeorgou
Hatzoglou A, E, Gemetzi
Notas
G, Castanas
Damianaki E., cancer
C, Kouroumalis E, antioxidant polyphenols inhibit the lines., Nutr proliferation Cancer.
Martin PM, of human
prostate
2000;37(2):223-33.
67. G, E., J
Damianaki Hatzoglou
A, A,
Bakogeorgou Panagiotou
E, S,
Kampa
M, Castanas
Notas
Gemetzi C, Kouroumalis E, Potent inhibitory action of red Cell wine polyphenols Biochem. 2000 on Jun
Martin PM, human
breast cancer cells.,
6;78(3):429-41.
68. Hsieh TC, resveratrol deLNCaP er
Wu
JM.,
Grape-derived antigen (PSA)
chemoprotective agent expression mechanism., in Anticanc
creases prostate-specific cells by an androgen receptor Res. 2000 Jan-Feb;20(1A):225-8.
(AR)-independent
69. Mitchell inhibits the
SH, Zhu expression
W, and receptor
Young CY., function in
Resveratrol LNCaP prostate
of the androgen cancer cells., Cancer Res. 1999
of tea.,
Dec 1;59(23):5892-5. action of antioxidants as Food exemplified in Chem Toxicol.
Weisburger vegetables, 1999
JH., tomatoes
Mechanisms and
Sep-Oct;37(9-10):943-8.
70. ner
Ulsperger G, Hejna
E, M,
Hamilton Hoffmann Resveratrol
G, O,
Raderer M,
Baumgart
Mallinger R., AHTO-7 human osteoblasts carcinoma Oncol. to cell 1999
pretreatment in J response
desensitizes to
growth stimulation supernatants., Int Nov;15(5):955-9.
71. cell
Hsieh TC, Wu cycle arrest, and
JM., Differential induc-
effects on in
growth, human
tion prostate Res.
of apoptosis by cancer cell lines., Exp 1999 May
resveratrol Cell
25;249(1):109-15.
Protein Activation
1. YM., r male
Ma HJ, Cao Microinjection of rostral ventrolateral tone through nitric oxide rats., Acta
YK, Liu resveratrol
YX, into
Wang
R,
Wu vasomoto
medulla decreases Ca2+
sympathetic in
and intracellular Pharmacol
anesthetized
Sin.
2008
Aug;29(8):906-12.
2. athan
Venkatesan L, Kamat
B, A,
Ghosh-Choudhury N, Choudhury in Jun
Das GG.,
F,
Mahimain
Kasinath BS, inhibits PDGF of mitogenic PTP1B., FASEB
Abboud HE, receptor signaling J. 2008
Resveratrol cells: role
mesangial 20.
3. M,
Chakraborty Raha S.,
PK, Mustafi SB, Resveratrol in tarsurvival 2008 K562
Ganguly S, (chronic protein,
Chatterjee myelogenous heat shock
induces apoptosis leukemia) cells by geting protein 70., a key Cancer Sci.
Jun;99(6):1109-16.
4. y
Klinge CM, SM., Resveratrol
Wickramasinghe NS,
Ivanova MM, by
Doughert
stimulates nitric oxide production estrogen receptor alpha-Srccaveolin-1 umbilical vein lial interaction endotheJ. and 2008
increasing human
phosphorylation in Jul;22(7):2185-97.
cells., FASEB
5. A,
Lee Hwang
KW, MK,
Kang NJ, Bowden GT,
Heo
YS, Z.,
Rogozin EA, Raf and
Pugliese MEK
Bode AM, protein kinases are a
Lee HJ, Dong direct molecular
targets for the major flavonol wine., Cancer Res.
chemoprotective effect of in red 2008 Feb 1;68(3):946-55.
quercetin,
6. Zhou Mol
J,
Sallman Wei
DA, S,
Chen Djeu
X, JY., in
Zhong B, Clusterin prostate
Gilvary DL, tumor cells.,
mediates TRAIL Cancer Ther.
resistance 2007
Nov;6(11):2938-47.
7. R.,
Ohshiro Delivery to
K, of
Rayala SK, cytoplasmic
El-Naggar proAutophagy.
AK, 2008
Kumar Jan-Feb;
teins 4(1):104-6.
autophagosomes.,
8. Ohshiro Vadlamudi RK, tor R., PELP1 Cancer
K, Rayala SK, El-Naggar AK,
Kondo Kumar
S, receptor
Gaur
A, coactiva
Identifying the estrogen in autophagosomes., Res. 2007 Sep
1;67(17):8164-71.
9. YY,
Lee Bode
KW, AM,
Kang Lee Dong of and
NJ, HJ,
Rogozin EA, Surh YJ,
Kim is
HG, a
Cho novel
Bowden GT, natural inhibitor 7. transformation
Z., Myricetin neoplastic cell
MEK1., Carcinogenesis. 2007
Sep;28(9):1918-2
10. Wu CC, concentrations of Med. the 2007
Wu CI, resveratrol
Wang WY, potentiate
Wu
YC.,
Low Planta
antiplatelet effect of May;73(5):439-43.
prostaglandins.,
11. ML., or
Su JL, Forkhead
Yang CY, proteins
Zhao are
M, Kuo critical regulation
ML, for and
Yen anti-tum
bone morphogenetic activity of
protein-2 resvera-
trol.,
Biol
Chem.
2007
Jul
6;282(27):19385-98.
12. Kutuk O, 4-hydroxynonenal: c-Jun/AP-1
Basaga H., a role pathway.,
Apoptosis for JNKRedox Rep.
signalling 2007;12(1):30-4.
by
13. in m
Faber AC, transformed
Chiles TC., follicular
Resveratrol for Int J
induces apoptosis a novel mechanis Dec;29(6
lymphoma OCI-LY8 cells: evidence involving inhibition BCL6 signaling.,
of ):1561-6.
Oncol. 2006
14. Fulda S, signal transduction tosis Detect Prev.
Debatin KM., in apop-
Resveratrol a
modulation mini-review.,
of Cancer
and cell survival: 2006;30(3):217-23.
15. N, and Rep.
Ovesn Z, Erker T,
Kozics K, Szekeres
Bader T., of
Y,
Saiko
P,
Handler
Antioxidant activity 3,3 ,4,4 ,5,5 -hexahydroxytrans-stilbene in three 2006 Sep;16(3):617-24.
resveratrol, cell
piceatannol lines., Oncol
leukemia
16. ch A431
Kim L,
AL, Zhu Bickers DR,
Y, Athar
Zhu M., human
H, Han Resveratrol epidermoid
L,
Kopelovi
inhibits proliferation of cells by modulatMEK1 2006
carcinoma Exp
ing Dermatol.
and AP-1 signalling Jul;15(7):538-46.
pathways.,
17. KM.,
Koo N, Effects of
Cho D, resveratrol
Kim on
Y, mast
Choi cell
HJ, de-
Kim the
granulation and signaling components
tyrosine of the
phosphorylation of
IgE
receptor.,
Planta Med.
2006
Jun;72(7):659-61.
18. K, and d
Kotha A, Khaled A,
containing
Mar;5(3):621-9.
19. of Lett.
Choi HK, resveratrol pression of 2006 Oct
Yang on ErbB2
JW, the in
Kang exhuman
KW.,
Bifunctional
effect
breast cancer cell., Cancer
28;242(2):198-206.
20. DK,
Fukuda S, Bertelli
Kaga A,
S, Zhan Maulik N.,
L, Bagchi D, Resveratrol inducing kinase receptor
Das vascular
ameliorates myocardial endothelial growth factor-angiogenesis and Flk-1., Cell Biochem Biophys. 2006;44(1):43-9.
damage by tyrosine
21. Li X, kinase pathways estradiol
Zhang in and
S, MCF-7
Safe cells
S., by
Activation 17beta-
of compound
structurally
diverse estrogenic
s.,
J Mol
Steroid Biochem Biol. 2006 Feb;98(2-3):122-32.
22. QS, Acta
Zhang LP, Zhao J.,
Yin JX, Effect of
Liu Z, resveratrol rat
Zhang on
Y, L-
Wang
type calcium current in Pharmacol Sin. 2006 Feb;27(2):179-83.
ventricular
myocytes.,
23. WS.,
Juan SH, Lee Antiproliferative
JL, and
Ho PY, Lee antiangiogenic an
YH,
Lee
effects of 3-methylcholanthrene, receptor agonist, Eur in J human umbilical Pharmacol. 2006 vascular Jan
aryl-hydrocarbon endothelial cells.,
13;530(1-2):1-8.
24. Kutuk O, Poli against 4-hydroxynonenalinduced apoptosis -1signaling., Toxicol Sci. Mar;90(1):120-32.
G, by 2006
Basaga H., blocking
Resveratrol JNK and
protects c-JUN/AP
25. nol C
Wung BS, upregulates heme and
Hsu MC, endothelial
Wu
CC, via 2006
Hsieh novel
CW.,
Piceatan
oxygenase-1 tyrosine
expression kinase Res.
protein kinase
pathways.,
Pharmacol
Feb;53(2):113-22.
26. M,
Liu Wang
Z, QS., free Sheng Oct
Zhang LP, Resveratrol
Ma HJ, Wang reduces intracelluin rat
C,
Li
lar myocytes., 2005
calcium concentration Li Xue Bao. 25;57(5):599-604.
ventricular
27. on 2006
Chan WH, Chang ethanol-induced cell death Feb in the 8;161(1):1-9.
YJ., human
Dosage effects of K562 cell
resveratrol
line., Toxicol Lett.
28. Tyagi A, Sclafani RA, Resveratrol Chk1/2-Cdc25C pathway as arrest in human noma
Singh RP, Agarwal R.,
Agarwal C,
Siriwardana
S, ATM/ATRphase
causes Cdc2-tyr15
phosphorylation via for S
a central mechanism ovarian carci-
Ovcar-3 cells., Carcinogenesis. 2005
Nov;26(11):1978-87.
in of
to
becomes clearer.,
Hypertens.
Jul;23(7):1285-3
30. Das Maulik N,
S, Das
Alagappan VK, DK., Coordinated
Bagchi D, after
Sharma HS, resveratrol the
induction consumption: a
of iNOS-VEGF-KDR-eNOS potential resveratrol
mechanism for heart., Vascul Pharmacol. 2005
preconditioning of
Apr-May;42(5-6):281-9.
31. Haider UG, Roos Sorescu D, Griendling
TU, KK,
Kontaridis Vollmar
MI,
Neel
BG,
II-
AM, and
Dirsch VM., epidermal
Resveratrol growth activation: 2005
inhibits role of
angiotensin Gab1 and
factor-mediated Akt Shp2., Mol Pharmacol. Jul;68(1):41-8.
32. l es, a.
Azios NG, Dharmawardhane SF., exert disparate effects on and focal assembly in 2005 Feb;7(2):128-40. cell migration, adhesion MDA-MB-231 human
Resveratrol cell
and
estradio structur
surface actin
breast cancer cells., Neoplasi
33. Chan WH., induced stress in kemia K562 15;94(6):1267-79.
Effect of human leucells., J
resveratrol Cell Biochem.
on
high 2005
glucoseApr
M, Di
Re F, Stasio G, on
Orlando F, A., of
development J
mice., Int
Cancer. 2005
35. r
Klinge CM, Blankenship S, Noisin EL, Sumanasekera WK, Zhao
KA, L,
Risinger Brey DM,
KE,
Bhatnaga
Keynton RS.,
Resveratrol
and
estradiol MAPK beta signaling in Biol Chem. through estrogen 2005 Mar 4;280(9)
rapidly activate receptors alpha and endothelial :7460-8.
cells., J
36. ES., ion
Evers DL, Wang X, 3,4 ,5-Trihydroxy-transstilbene (resveratrol) and virus-
Huong
SM, human
Huang
DY,
Huang
inhibits signaling.,
cytomegalovirus replicat Res. 2004
induced cellular Aug;63(2):85-95.
Antiviral
37. Guastalla [Cyclooxygenase 2 Bull
JP, and
Bachelot T, breast cancer. to
Ray-Coquard therapeutic
I., trials],
From biological concepts Cancer. 2004 May;91 Spec No:S99-108. [French]
38. Storz P, Dppler H, Toker phosphorylation controls protein Mol kinase D-dependent Pharmacol. 2004 Oct;66(4):870-9. Epub activation 2004 Jun
A., of 29.
Activation
loop
nuclear factor kappaB.,
39. of tic -55.
Conte A, resveratrol
Pellegrini S, and catechin
Tagliazucchi on and Res.
D., their
Effect synergis
PC12 tyrosine protection from amyloid toxicity.,
kinase activities betaDrugs Exp Clin
2003;29(5-6):243
40. Reagan-Shaw Modulations of regulatory B-mediated responses by skin., Oncogene.
S, Afaq critical
F, cell
Aziz cycle
MH,
Ahmad
N.,
events during chemoprevention of resveratrol 2004 Jul in SKH-1
ultraviolet mouse
hairless
1;23(30):5151-60.
41. Andrieux L, Krauser JA, Savouret FP, receptor d Baffet G, activation
Langout S, JF, Guengerich Guillouzo and cytoA., by
Fautrel A, Aryl the
Ezan
F,
hydrocarbon mitogen-activate 2004 Apr;65(4
chrome P450 1A induction protein kinase inhibitor in hepatocytes., Mol
U0126 ):934-43.
Pharmacol.
42. Stewart JR, EGFR-dependent Erk1/2 activation cancer cells with New in as-
O Brian CA., human
Resveratrol
antagonizes prostate Invest
androgen-independent PKC alpha
sociated isozyme-selective Drugs. 2004 Apr;22(2):107-17.
inhibition.,
43. Kubota T, Uemura Y, Combined effects of reser veratrol and Res. 2003 paclitaxel
Kobayashi on lung
M,
Taguchi H.,
cancer cells., Anticanc
Sep-Oct;23(5A):4039-46.
44. DS,
Woo Chang
JH, JS,
Lim Lee inhibits
JH, YH,
Kim Park
YH, JW,
Suh Kwon
SI, TK.,
Min
Resveratrol
phorbol myristate
acetate-induced
matrix metalloproPKC teinase-9 expression by delta signal transduction., Oncogene. 2004 Mar inhibiting JNK and
11;23(10):1845-53.
45. A, of ation
Arakaki Tanaka H,
N, Nagao Kuramoto
T, Y,
Niki Emoto
R, Y, Possible
Toyofuku role and prolifer
Shibata H, Magota K, cell surface H+ -ATP in of the human extracellular umbilical cells., Mol
Higuti T., synthase ATP vein
synthesis 2003
endothelial
Cancer Res.
Nov;1(13):931-9.
46. on tion
Lin of
MT, Yen vascular
ML, Lin endothelial by
CY, Kuo growth resveratrol cadherin
ML.,
Inhibiti
factor-induced angiogenesis of Src-depen-
through interrup tyrosine
dent vascular phosphorylation., Mol 2003
endothelial Pharmacol.
Nov;64(5):1029-36.
47. a J
Stewart candidate tional Nutr.
JR, Artime MC, nutri-
O Brian CA.,
Resveratrol:
substance for 2003 Jul;133(7
prostate
cancer prevention.,
Suppl):2440S-2443S.
48. tial
Maccaglia effects of
A, Mallozzi quercetin and on red Band blood
C,
Minetti M.,
Differen
resveratrol signalling of
3 tyrosine cells., Jun
phosphorylation 6;305(3):541-7.
Biochem Biophys Res
Commun. 2003
49. Lin
Liang YC, Tsai SH, JK., Resveratrol-induced through the inhibition
Chen G2 of
L, Lin-Shiau arrest CDK7 and
SY,
p34CDC2 kinases
in
colon
carcinoma
HT29 2003 Apr 1;65(7):1053-60.
cells., Biochem Pharmacol.
50. S,
Della Ragione F, Borriello A,
Cucciolla Zappia V.,
V,
Criniti V, by
Indaco a
Antioxidants induce different phenotypes distinct modulation of signal transduction., FEBS Lett. 2002 Dec
18;532(3):289-94.
51. Ashikawa K, Bharti AC, Shishodia on lpha Piceatannol inhibits and NF-kappaB-mediated gene kinase and
Majumdar S, S, Aggarwal TNF-induced
Banerjee BB., NF-kappaB of Dec
S, activati IkappaBa 1;169(11
expression p65 J
through suppression Immunol. 2002
phosphorylation., ):6490-7.
52. SF,
Brownson Mabry TJ.,
DM, Azios Flavonoid
NG, cancer.,
Fuqua
BK, J
Dharmawardhane Nutr. 2002
effects relevant to Nov;132(11 Suppl):3482S-3489S.
53. Tou phospholipase
JS., d
Differential activity
regulation and
of
neutrophil Apr 12;292(4
degranulation., Biochem Biophys Res ):951-6.
Commun. 2002
54. MJ,
Sekhar KR, Holt JT,
Spitz Gius
DR, D,
Harris S, Marnett
Nguyen TT,
Meredith
LJ, Summar ML, between KIAA0132 of and Nrf2 mediates gamma-glutamyl-
Freeman ML.,
Redox-sensitive interaction expression 2002 Apr
indomethacin-induced Radic Med Gius Biol 2002 Med. Jul
cysteine synthetase., 1;32(7):650-62. Erratum Guis in: David David]. Free Radic [corrected
Free Biol to
31;33(1):149.
55. E,
Kong Hu
AN, R,
Yu Ee
R, R,
Hebbar V, Mandlekar by
Chen S.,
C, Owuor Signal
transduction compounds., Mutat 2001 Sep
events elicited Res. 1;480-481:231-41.
cancer prevention
56. S,
De Ldinghen Payrastre B, A, a
V, Bedin
Monvoisin C, P,
A,
Neaud
V, J.,
Krisa
Desmoulire Trans-resveratrol,
Bioulac-Sage grapevine-
Rosenbaum
derived polyphenol, invasion of hepatocellular Jul;19(1):83-8.
blocks hepatocyte cells., Int
growth factor-induced J Oncol. 2001
carcinoma
57. Yu Pezzuto JM, 1 Mol
R, Kong
Hebbar V, Kim AN., Resveratrol
DW, in-
Mandlekar activator
S, protein
hibits phorbol ester activation by ing with Pharmacol. Jul;60(1):217-24.
and UV-induced interfer-
mitogen-activated 2001
protein kinase pathways.,
58. Shih A, hormone promotes
Lin HY, serine phos-
Davis
FB,
Davis
PJ.,
Thyroid
phorylation of kinase., Biochemistry. Mar 6;40(9):2870-8.
p53 2001
by
mitogen-activated
protein
59. Z.,
She QB, Bode Resveratrol-induced
AM, Ma activation
WY, is
Chen mediated
NY,
Dong by
of p53 and apoptosis extracellular-signal-regulated protein kinases and 15;61(4):1604-10. p38 kinase.,
Cancer Res.
2001
Feb
60. JM.,
Bruder JL, Hsieh Induced cytoskeletal
T, Lerea changes
KM,
Olson
SC, cells
Wu by shear
in resveratrol nying stress.,
bovine pulmonary artery endothelial and the accompamodified BMC Cell responses to Biol. 2001;2:1.
arterial
61. F.,
Saijonmaa Upregulation
O, of
Nyman T, angiotensin-
Kosonen R,
Fyhrquist growth
converting factor., Am Circ Physiol.
enzyme by vascular J Physiol Heart 2001
endothelial
Feb;280(2):H885-91.
62. Lin JK, Tsai cardiovascular disease by 1999 resveratrol., Proc Jul;23(3):99-106.
SH., Natl
Chemoprevention of Sci Counc Repub
cancer and China B.
63. Palmieri resveratrol and on compounds cytolysis.,
L, some on Drugs
Mameli M, Ronca other natural tyrosine Exp Clin
G.,
Effect of and
kinase activity Res.
1999;25(2-3):79-85.
64. MAPK of ):63-7.
El-Mowafy activity translocation endothelin-1 stimulatory
AM, and in
White RE., nuclear coronary FEBS
Resveratrol
inhibits
artery smooth muscle: reversal Lett. 1999 May 14;451(1
effects.,
65. Lu derived from of
R, Serrero G., grape, exhibits
Resveratrol, inhibits
natural product the growth
antiestrogenic activity and human breast cancer cells., J Cell Physiol. 1999
Jun;179(3):297-304.
66. Ferrero Pellegatta F, A., ium., F, De Activity granulocyte Am J
ME, Corsi
Bertelli AE, MM, Bonfrate R, of
Fulgenzi A, M, Ferrara L, on to Bertelli endothel
Caterina in vitro and Clin
Giovannini resveratrol adhesion
monocyte Nutr. 1998
Dec;68(6):1208-14.
67. of of 4.
Kawada N, antioxidants, cetin, and cultured cells and
Seki S, resveratrol,
Inoue quer-
M,
Kuroki T., the 1998
Effect
N-acetylcysteine, on rat hepatic stellate Kupffer cells., Hepatology.
functions May;27(5):1265-7
68. ok
Jayatilake GS, NM, Geahlen RL,
Jayasuriya Ashendel Chang J CJ.,
H, CL,
Lee
ES,
Koonchan from
McLaughlin JL, Polygonum cuspidatum., Nat Prod. 1993
Kinase inhibitors
Oct;56(10):1805-10.
Reducing
heart
attack and
stroke injury
1. Penumathsa Bagchi D, Yet on -1, Maulik by
SV, SF,
Koneru S, Menon VP,
Samuel SM,
Maulik G,
N., Strategic resveratrol in
targets to myocardium:
induce neovascularizati Role and of vascular caveolin
hypercholesterolemic rat endothelial nitric
oxide endothelial Free
synthase, hemeoxygenase-1, growth factor., Radic Biol Med. 2008 Jul
27.
2. HH, after
Hu
Lin
JF, BR,
Lin Huang
SM, SS, and
Chih Tsai improves Sci.
CL, SK.,
Nien MW, Resveratrol ventricular
Su function
reduces infarct size myocardial ischemia in
rats., Life
2008
Jun
27.
3. M,
Lekli I, Varga E, Bak of
Szabo G, Szendrei I, Das resveratrol
Juhasz B, Das L, Gesztelyi DK, Tosaki A., against damage in
S, R,
Das Varadi
J, mechanisms from
Protective
ischemia-reperfusion-induced Zucker obese
hearts obtained
rats: the Physiol Heart
role Circ
of GLUT-4 and Physiol. 2008
endothelin.,
Am
Feb;294(2):H859-66.
4. H,
Burstein Poulin F,
B, Maguy Ethier N,
A, Clment R, Tardif JC, A, on Exp Nattel S.,
Gosselin Effects of followin
Hbert resveratrol g 3.
TE, Calderone (trans-3,5,4 -trihytreatment infarcPharmacol
droxystilbene) myocardial tion., J
cardiac remodeling Ther. 2007
Dec;323(3):916-2
5. ene
Cruz MN, K., Acute
Agewall S, dilata-
Schenck-Gustafsson estrogen heart Mar 23.
K, receptor
Kublicki
tion subtypes
to phytoestrogens and expression in small women 2008 with Epub coronary 2007
arteries from Atherosclerosis. Jan;196(1):49-58.
disease.,
6. Das y
Das DK.,
S, Falchi M, Attenuation of injury in resveratrol.,
Bertelli ischemia/rerats by
A, the
Maulik N, anti-inflammator
perfusion action of
Arzneimittelforschung.
2006;56(10):700-6.
7.
Penumathsa
SV,
Thirunavukkarasu
M,
Koneru S,
Juhasz B, rol Menon in
Zhan
L,
Pant
R, Statin and in resverat hypercho
VP, Otani combination
H, Maulik N., induces
cardioprotection against myocardial lesterolemic rat., J Mol Cell Cardiol. 2007
infarction
Mar;42(3):508-16.
8. s
Vigne P, Frelin C., the hypoxic tolerance Drosophila., PLoS ONE.
A in 2006
low Dec
protein diet 20;1:e56.,
increase
9. Bezstarosti K, Differential proteomic study tioning by trol.,
Das S, profiling of Med.
Lamers JM, to
Das
DK.,
the mechanism resveraJ Cell Mol
cardiac pharmacological precondi 2006 Oct-Dec;10(4):896-907.
10. Maulik N., Reactive angiogenesis?, Antioxid Redox Signal. 2006
oxygen species drives myocardial Nov-Dec;8(11-12):2161-8.
11. Das effect of ase 75.
S, Fraga resveratrol
CG, via
Das HO-1 p38 not Radic
DK., map Res.
Cardioprotective kinase and 2006 PI-3-kin
expression signaling,
involves but does Free
involve NFkappaB.,
Oct;40(10):1066-
12. of Epub
Baur JA, resveratrol: dence., Nat 2006 May
Sinclair the in Rev 26. Drug
DA., vivo
Therapeutic evi-
potential
Discov. 2006
Jun;5(6):493-506.
13. E,
Bak I, Varadi J,
Lekli I, Gesztelyi
Juhasz B, R, Szabo
Nagy G,
N, Varga Szendrei
L, seed rat Das
L, Bacskay I, Boucher F, de
Vecsernyes Leiris J, of
M, Antal Tosaki A.,
M,
Fesus cherry)
Cardioprotective mechanisms extract
Prunus cerasus (sour damage in 2006 isolated
against ischemia-reperfusion-induced hearts., Am J Physiol Heart Circ S, Tosaki A, Maulik N, signal in Physiol. Bagchi Das the
Sep;291(3):H1329-36. of a protein
D, survival
DK., Potentiation ischemic heart
by resveratrol kinase/mitogen- and protein
through p38
mitogen-activated
stress-activated protein kinase 1/cAMP response J Pharmacol Exp Ther.
element-binding 2006 Jun;317(
signaling., 3):980-8.
14. DK,
Fukuda S, Bertelli
Kaga A,
S, Zhan Maulik N.,
L, Bagchi D, Resveratrol inducing kinase receptor
Das vascular
ameliorates myocardial endothelial growth factor-angiogenesis and Flk-1., Cell Biochem Biophys. 2006;44(1):43-9.
damage by tyrosine
15. S, from
Cruz MN, Kublickiene responses men with disease.,
Luksha L, K., Acute
Logman H,
Poston L, small Circ arteries Physiol.
Agewall
to phytoestrogens in coronary heart Am J Physiol Heart
2006
May;290(5):H1969-75.
16. R, the 2006
Morelli R, Lo Scalzo R, duction of the natural antiradical of Lycopersicon Jan;282(1-2):65-73.
Das Das stilbene activity
S, DK,
Bertelli Falchi M., synthase mill., Mol
A, The gene Cell
Bollini introenhances Biochem.
esculentum
17. Kaga Resveratrol
S, Zhan enhances
L, Matsumoto neovascuthe of infarcted thioreand Cell vascular
M, rat
Maulik N., myocardium endothelial
larization in through the induction doxin-1, heme growth factor., Cardiol. 2005
oxygenase-1 J Mol
Nov;39(5):813-22.
18. Das Maulik N,
S, Das
Alagappan VK, DK., Coordinated
Bagchi D, after
Sharma HS, resveratrol the
induction consumption: a
of iNOS-VEGF-KDR-eNOS potential resveratrol
mechanism for heart., Vascul Pharmacol. 2005
preconditioning of
Apr-May;42(5-6):281-9.
19. DK., e
Das S, Tosaki A, Bagchi D, Resveratrol-mediated activation of A3 cAMP response receptor Akt-dependent Exp Ther. and 2005
Maulik N,
Das
element-binding protein through adenosin -independent pathways., J
by Pharmacol
Aug;314(2):762-9.
20. Red
Szmitko wine and Circulation.
PE, your 2005
Verma S., heart., Jan
Cardiology
patient pages.
18;111(2):e10-1.
21. Das S, Cordis GA, logical preconditioning with via 2005 resveratrol: adenosine role A3
Maulik N,
Das
DK.,
Pharmaco
of CREB-dependent Bcl-2 receptor J Physiol Heart Circ
signaling Physiol.
activation., Am Jan;288(1):H328-35.
22. Hung myocardial sion mechanisms., Free
LM, Su MJ, ischemia-reperfuinjury through both Radic Biol Med.
Chen
JK.,
Resveratrol and
protects
NO-dependent 2004 Mar
NO-independent
15;36(6):774-81.
23. with Sci.
Sato M, alcohol: and 2002
Maulik N, role of
Das both
DK., Cardioprotection alcohol N Y Acad
polyphenolic antioxidants., Ann May;957:122-35.
24. A,
Cui J, Maulik N, white
Tosaki A, Das DK., Exp
Bertelli AA, Cardioprotection Clin Res.
Bertelli with
wine., Drugs
2002;28(1):1-10.
25. Otani
Imamura G, H, Maulik N,
Bertelli Das DK., resveratrol: J Physiol.
AA, Bertelli Pharmacological an 2002 insight with
A, iNOS
preconditioning with knockout mice., Am Physiol Heart Circ
Jun;282(6):H1996-2003.
26. Hattori R, Otani Pharmacological preconditioning with Physiol Heart resveratrol: role Circ Physiol.
H, of 2002
Maulik N,
Das
DK., J
nitric oxide., Am
Jun;282(6):H1988-95.
27. Hale flavinoid
SL, found
Kloner RA., in red in Stud
Effects of wine, on
resveratrol, model of
a ischemia
infarct size /reperfusion., J 2001
an experimental Alcohol.
Nov;62(6):730-5.
28. A, s
Russo P, Cicala C.,
Russo phenolic
GL,
Venezia fraction
Feb;11(1):25-9.
29. MJ.,
Hung LM, Beneficial
Chen JK, effects of
Lee RS, astringinin, on the heart., 2001 Apr
Liang a ischemia
HC,
Su and
resveratrol analogue, reperfusion damage in rat Free Radic Biol Med.
15;30(8):877-83.
30. Bradamante Bertelli AA, De Jong preconditioning?, Tissue
S, De JW., Int
Piccinini Jonge R, Does J
F, Barenghi Beemster P,
L,
resveratrol
induce pharmacological
React. 2000;22(1):1-4.
31. and
Ballmer PE., still delicious], Umsch. 2000
[The Ther
Mediterranean [German]
diet--healthy
but
Mar;57(3):167-72.
32. RM, ,
Sato M, Bertelli DK., J 2000
Ray AA,
PS, Maulik G, Bertelli A, protection Pharmacol. with
Maulik N, Das red wine
Engelman extract.
Myocardial Cardiovasc Feb;35(2):263-8.
33. al Free
Sato M, protection a Radic novel Res.
Maulik G, Bagchi D, by protykin, extract of 2000
Das
DK., and
Myocardi emodin.,
trans-resveratrol
Feb;32(2):135-44.
34. Ray Bertelli
PS, A,
Maulik G, Das DK.,
Cordis GA, The red
Bertelli wine isolated
AA, rat
antioxidant resveratrol protects hearts from ischemia reperfusion injury., Free Radic Biol Med. 1999
Jul;27(1-2):160-9.
35. and
Constant J., Alcohol, the French paradox., Coron Artery Dis. 1997 Oct;8(10):645-9.
ischemic
heart
disease,
36. X,
Dong Li
W, F.,
Li N, Resveratrol the
Gao D, attenuates delayed phase
Zhen H, ischemic after
Zhang
brain damage in induces messenger RNA
stroke and
Vasc
and Surg.
protein express for 2008 Jun 21.
angiogenic
factors.,
37. JY,
Ban Bae
JY, K,
Cho Song
SO, KS,
Choi Seong Smilacis and Sci.
SH, YH.,
Ju
HS,
Kim
Neuroprotective effect of NMDA-induced neuin rotoxicity vivo., J Jan;106(1):68-77. in vitro Pharmacol
chinae rhizome on focal 2008 cerebral ischemia
38. N, the
Dong Li
W, F.,
Gao New
D, Lin insights
H, into
Zhang X, mechanism
Li for
effect ischemic
of resveratrol stroke: Possible
preconditioning against cerebral Med Hypotheses.
role of 2008;70(1):52-5.
matrix metalloprotease-9.,
39. MW,
Tsai Liu
SK, HY,
Hung Zhang
LM, FB,
Fu Huang
YT, SS.,
Cheng
H, cerebral Vasc
Nien
Resveratrol neuroprotective effects during focal ischemia injury via 2007 nitric oxide mechanism Aug;46(2):346-53. in rats., J
Surg.
40. is
Dong W, induced by
Gao D, resveratrol ischemic
Zhang stroke.,
X.,
Mitochondria Med
biogenes
against brain 2007;69(3):700-1.
Hypotheses.
41. Mokni M, Limam F, Elkahoui Aouani E., Strong cardioprotective on Jan effect of isolated resveratrol, a rat hearts after Arch red isch-
S, wine
Amri
M,
polyphenol, 2007
emia/reperfusion injury., 1;457(1):1-6.
Biochem Biophys.
42. W,
Gao Cheng
D, G,
Zhang Song
X, L.,
Jiang X, Resveratrol level 2006 of Apr
Peng MMP-9
Y,
Huang
reduces the elevated cerebral ischemia-reperfusion in mice., Life Sci.
induced by
25;78(22):2564-70.
43. l
Zhuang H, mechanism
Kim by a N
YS, which red Y
Koehler RC, reswine Acad 287-8.
Dor
S., protects
Potentia
veratrol, neurons., Ann
constituent, Sci. 2003
May;993:276-86; discussion
44. s
keda K, Negishi H, and hypoxia/ischemia
Yamori Y.,
Antioxidant 2003
nutrient Jul
brain injury in 15;189(1-2):55-61.
rodents.,
Toxicology.
45. Sinha K, Chaudhary G, Gupta effect of resveratrol against oxidamodel tive of 2002 stress in stroke in Jun middle cerebral rats., Life Sci.
YK.,
Protective
artery occlusion
28;71(6):655-65.
46. SC., -48.
agchi D, Benefits
Das of
DK, Tosaki A, resveratrol in Drugs Exp Clin
Bagchi M, Res.
Kothari
women s health.,
2001;27(5-6):233
47. SK.,
Huang SS, Resveratrol
Tsai MC, reduction
Chih of rats Sci.
CL, Hung infarct subjected 2001 Jul
LM, to
Tsai focal
size cerebral
in Long-Evans ischemia., Life
20;69(9):1057-65.
48. JS., under
Wang MJ, Resveratrol
Huang HM, inhibits in
Hsieh SJ, interleucortical
Jeng mixed
KC, glial 2001
Kuo cells Jan
kin-6 production hypoxia/hypoglycemia
followed by 1;112(1-2):28-34.
reoxygenation., J
Neuroimmunol.
Reducing LDL
levels
1. TY,
Do Park
GM, T,
Kwon Choi
EY, MS.,
Kim HJ, Long-term
Ha of E-defici
of atherogenic ent
tion and cholesterol mice., Biochem Biophys Res Commun. 2008 Sep
12;374(1):55-9.
2. A,
Zang M, Hou X,
Xu Jiang
S, B,
Maitland-Toolan KA, Wierzbicki M, RA., Polyphenols
Zuccollo stimulate
Verbeuren TJ, Cohen AMP-activated protein kinase, lower diabetic deficient
lipids, and inhibit accelerated LDL receptormice. Diabetes. 2006
atherosclerosis in Aug;55(8):2180-91.
3. Y,
Zern TL, Aggarwal
Wood D,
RJ, Greene C, Shachter NS, Grape preby 2005 polyphenols and lowering
West exert
KL, a
Liu cardiopr
Fernandez ML., otective effect in postmenopausal women reducing oxidative stress., J Nutr.
plasma lipids and
Aug;135(8):1911-7.
4. W.,
Rimando AM, Pterostilbene, a the
Nagmani R, new peroxisome and Chem.
Feller DR,
Yokoyama
agonist for alpha-isoform, lowers lesterolemic
proliferator-activated receptor cholesterol 2005 May in hypercho
plasma lipoproteins hamAgric Food
sters., J
4;53(9):3403-7.
5. ols of
Zern TL, decrease
West KL, Fernandez plasma triglycaccumulation
ML., in
Grape the
polyphen aorta
erides and cholesterol ovariectomized guinea pigs., J Nutr. 2003
Jul;133(7):2268-72.
6. J,
Pal Croft
S, K,
Ho N, Allister
Santos C, E., Red
Dubois P, Mamo wine polypheand Nutr.
nolics activity 2003
increase LDL and suppress
receptor expression the secrehuman HepG2 cells., J
tion of ApoB100 from Mar;133(3):700-6.
7. ants 1999
as
Weisburger JH., exemplified
Mechanisms in vegtea.,
of Food
action of Chem
antioxid
etables, tomatoes and Sep-Oct;37(9-10):943-8.
Toxicol.
8. Frmont activity of n
L, Belguendouz resveratrol and
L,
Delpal S., LDL
Antioxidant oxidatio
alcohol-free wine polyphenols and polyunsaturated fatty acids. Life Sci.
related to
1999;64(26):2511-21.
Triglyceride
levels and
resveratrol
1. J, on
Shan T, Feng J,
Wang Xu
Y, Z.,
Wu T, Guo J, Porcine adipose triglyceride acid J Anim
Liu
lipase complementary pattern, and by
deoxyribonucleic resveratrol.,
clone, expressi Sci. 2008
regulation Aug;86(8):1781-8.
2. TY., Res
Cho IJ, Resveratrol
Ahn JY, attenuates mRNA
Kim the in
S, Choi expression hamsters.,
MS, of
Ha
HMG-CoA reductase Commun. 2008 Feb 29;367(1):190-4.
Biochem Biophys
3. Y,
Wu
Wang Z, JM.,
Zou J, Dealcoholized
Cao red
K, wine
Hsieh con-
TC,
Huang atherosc levels.,
taining known amounts of lerosis in hyperInt
resveratrol
suppresses plasma lipid
cholesterolemic rabbits without affecting J Mol Med.
2005
Oct;16(4):533-40.
4. Ilan E, Tirosh O, oxidative stress inhibits hepatocytes., nitric oxide J Nutr.
Madar
Z., in
Triacylglycerol-mediated rat isolated
production 2005
Sep;135(9):2090-5.
5. Y,
Zern TL, Aggarwal
Wood D,
RJ, Greene C, Shachter NS, Grape preby 2005 polyphenols and lowering
West exert
KL, a
Liu cardiopr
Fernandez ML., otective effect in postmenopausal women reducing oxidative stress., J Nutr.
plasma lipids and
Aug;135(8):1911-7.
6. Aronis A, underlying oxidative to ated lipotoxicity: triacylglycerols
Madar Z, stress-mediexposure facilitates
Tirosh O., of
Mechanism
J774.2 macrophages and
mitochondrial reactive cellular necrosis., Free Radic Biol Med. 2005
oxygen species production May 1;38(9):1221-30.
7. Miura D, Miura Y, action of dietary resveratrol, phytoalexin in -bearing rats., Life Aug
Yagasaki a red
K., wine,
Hypolipidemic in hepatoma
grapes and Sci. 2003
1;73(11):1393-400.
Vasodilation
and
lowering
heart
disease
1. F.,
The
Soylemez effect of on and
S, Gurdal H, Sepici A, long-term resveratrol relaxation female rats: to Role estrogen
Akar in
treatment aortae from male
2008
of Jul
nitric oxide 4.
and
superoxide.,
Vascul Pharmacol.
2. T, ant Feb
Zambl Staels B, P, and
A, Martin-Nizard F, Bordet R, Duriez Bailleul properties F., of
Sahpaz S, Vasoactivity,
Hennebelle antioxid
Brunet C, aphrodisiac
Caesalpinia benthamiana 28;116(1):112-9.
roots., J
3. ti
E,
Calderone V, Breschi MC., of the effect of
Martelli Functional endothelial resveratrol activators potassium
A, Testai L, contricomponent of Arch the to
Martinot the
bution vasorelaxing e
and NS 1619, calcium-activated
large-conductanc 2007
channels., Mar;375(1):73-80.
Naunyn Schmiedebergs
Pharmacol.
4. GH,
Yoo Kwon
MY, DY,
Oh Kim
KS, YS,
Lee Ryu
JW, SY,
Seo Lee
HW, from of
Yon rhizome rat
BH., extract of
Vasorelaxant rhubarb
effect of on 2007 the
stilbenes contractility
(Rheum undulatum) aorta., Phytother Res. Feb;21(2):186-9.
5. Drug
Granados-Soto V., News Perspect.
Pleiotropic 2003
effects of
resveratrol.,
Jun;16(5):299-307.
6. Gmez
Orallo F, E, Fernndez
Alvarez E, P., The
Camia M, possible in
Leiro the 2002
JM, cardiopr Feb;61(2
implication of otective effects of moderate wine ):294-302.
trans-Resveratrol long-term Mol
consumption.,
Pharmacol.
7. Mizutani Extract of wine ously 1999
K, Ikeda phenolics
K, Kawai improves in Sci
Y,
Yamori Y., spontane (Tokyo).
aortic biomechanical hypertensive rats (SHRSP)., Jan;45(1):95-106.
properties J Nutr
stroke-prone Vitaminol
8. of
Chen CK, resveratrol isolated rat
Pace-Asciak CR., and quercetin aorta., Gen
Vasorelaxing in 1996
activity Mar;27(2):363-6.
Pharmacol.
9. Fitzpatrick DF, ium-dependent vasorelax., ing Am Pt
Hirschfield wine 1993
SL,
Coffey RG., grape
Endothel products
activity of J Physiol. 2):H774-8.
and other Aug;265(2
Use in repair
Cosmetic
to DNA
prevent photo
aging
and
1. Y.,
Mizutani, Resveratrol
K., Ikeda, K., Stimulates the and
Kawai, Y.,
and
Yamori, MC3T3
Proliferation Cells., Biochem Biophys Res
Differentiation of
Osteoblastic
Commun 253
(1998): 859 863.
2. A,
Rucinski Macchi C,
M, Ziolkowska Belloni AS, Malendowicz effect but not rat 2006
A, LK.,
Hochol A, Estradiol and
Pucher and collagen
Nussdorfer GG, resveratrol stimulating on -1alpha gene in cells., Int osteocalcin, expression
osteonectin calvarial
primary culture of J Mol Med.
osteoblast-like
Oct;18(4):565-70.
3. la rat
C,
Ziolkowska A, Nussdorfer
Rucinski M, GG, Malendowicz
Pucher A, marker genes disrupters Biol
Tortorel in diphenyl
LK., Expression of osteoblast calvarial osteoblast-like cells, effects of the benzophenone-3, endocrine Chem
and olpropane, 2006
resveratrol and silymarin., Dec 15;164(3):147-56.
Interact.
4. Sun, in
A.
Chanvitayapongs, S., Y., Amelioration
Draczynska-Lusiak, of Antioxidants 8 and
B.,
and
Oxidative Stress by PCI2 Cells., Neuroreport (1997): 1499 1502.
Resveratrol
5. of
Leung, Polydatin, Polygonum
A., an
and Mo, Z., Active Compound on
Protective from Ischemia
Effects
cuspidatum,
Cerebral
Damage in Bull
Rats., Chin 12
Pharm
(1996): 128-129.
6. B.
Nigdikar, A., and
S. V., Howard, A.
Williams, N. N., Consumption Reduces the Vivo., Amer
R., of
Griffin,
Red Low-Density 68
Wine Polyphenols Lipoproteins in
Susceptibility of I Clin Nutr
to Oxidation (1998): 258 265.
7. K., and
Sato, M., Myocardial Protykin, Emodin., Research 32
Maulik, C., Protection a Free
Bagchi, D., by
and
Das,
D.
Novel Extract of Radical
trans-Resveratrol
(2000): 135 144.
8. ,
J.
Frankel, F.,
F., Waterhouse, Inhibition of by Resveratrol.,
A. Human The
L., LDL
and
Kinsella (1993):
Oxidation 1103 1104.
Lancet 341
9. H., ry
Han, Y. Antioxidant Correlates Activity., 13
N., Ryu, Activity with Arch its Pharm
S. of
Y., and Resveratrol
Han, B. Closely Inhibito
Monoamine Res
Oxidase-A
(1990): 132 135.
Cerebral
blood
flow
and
cognition
David L
O Reay,
Kennedy, Emma L Georg Lietz, Edward J and Crystal F Haskell
Wightman, Okello,
Jonathon
AntheaWilde
From ria
the Brain University
PerformanceNutrition Tyne
Research ELW
Centre Northumb JLR AWCFH)th
Newcastle upon e School of Agriculture Newcastle
United Kingdom (DOK Development
FoodRural upon Tyne
Newcastle
University
United Kingdom (GLEJO).
----------------------- Page 146----------------------Read NaturalNews.com daily for breaking news on food,
nutrition, natural cures, health freedom & much more!
Join month
over to
two find
million readers who on the Articles to read, food are and
visit and no
NaturalNews.com each health related topics registration is
breaking news that matter most! completely required. FREE
here.
Our Just
news is intelligent, news and
100%
independent.
No
corporate
spin
independent
opinion pieces.
and
See much
fascinating more as
videos, cartoons, they
animations,
music
videos
are
released
on
NaturalNews!
at
Listen to
our
24/7
streaming
internet
radio
programs
www.NaturalNewsRadio.com
Watch healing at
unlimited
FREE
videos on
nutrition,
food
and
www.NaturalNews.TV
at
Learn
amazing information
on
self
improvement
and
healing
www.WebSeed.com
GMOs,
Get the vaccines,
inside scoop pharmaceu-
on
what s really happening
with
tical pollution, and many other
electropollution, important
pesticides,
herbal cures
topics.
Enjoy exclusive Suzanne Sommers, Jesse
interviews
with
famous guests such
as
Ventura,
Ron
Paul
and
many
more!
See :
it
all
at
the
NaturalNews
network of
websites
www.NaturalNews.com
(daily news
and
commentary)
www.NaturalNews.TV
(free
video
community)
www.NaturalNewsRadio.com
(free
streaming
radio)
www.WebSeed.com (streaming ent programs)
seminars,
how-to and
self
improvem
www.ConsumerWelllness.org
(non-profit
organization)
Enjoy!
Mike
Adams, Editor of
NaturalNews.com
----------------------- Page 147----------------------Copyright 2011 by Truth Publishing International, Ltd. All rights reserved, including the right of reproduction in whole or in part in any form. $%
h y
OJQJ^J hh CJOJQJ^JaJh
h OJQJ^J % x Y W 4
&
B d f *
M gd%QB ()VXmo') >@ UWgd%QBln&(
UW _]
EG !lB @ JL gd%QB$l )sT /!v!! "!"#"n""#H# ##"$n$$%I%gd%QBI% %%%%%/&0& & &&&'`'''@(v @9@:@q@r@@@ AASAtAvAAAA2B|BB CKCMCgd%QBMC CC/DyDDE[EEE%F'FpFFFDG GGHiHkH H HHH*I,ImI KTK KK/LzLL
M[MMM(N*NuNN OQO OOOOEP PPgd%QBPPP-Q.QeQfQQQRRIR RR TTT TTU!UjUUVHV VV Wgd%QB WjWWWW<XqXsXXQYYY2Z~Z ZZZZ Y
U V
m o D
gd%QB Y ;
a c ;
gd%QB c ; \E
V+-\] 02 ]
T 3gd%QB3 WY0v_9 +, E{} M LM4 /1gd%QB1|W 24a "q(*n,-dgd%QBdeK *q
MO ,|G gd%QBf%HJ -r S $&t R /v ;gd%QB;= i; ^` "bdI{} * s 2 4 b d =
gd%QB
A C
hO 'nL (sLN gd%QB &tMN5{ V *t4}gd%QB U +u V S MN0|gd%QB W 4! !!"X" " """"A# ##$g$$$$$%n% Kgd%QB KSK K KKLLVL LL/M{MM NSN NNNNN4O~OOOOO0P1P P Pgd%QB PPPQdQQQ9R;RgRiR R R X
XMXOX XX/YMYOY YY3Z ZZ[`[[[["\k\gd%QBk\\\P] ]]^^H^J^ ^ hhNhPh h hhiìii6jTjVj jjjjAk kk!llllllmmgd%QBmimmm=
rTr rr3stsgd%QBtsvssss+twttRu uu1v?vAv vvw]w w wwwxx\x^ u |V||||||+}s}}~N~ ~~. G I gd%QB $ & U V + - q 02 O Lmgd%QBmo%'[\ 35 Z v m o
j 6hgd%QBhjkm*, \
`z|)MO
2 UrtrZz|+FHgd%QBH G /CEyz
QSQSGI! # gd%QB# u $! !!!!L" " ""##b##$!$#$n$$%]
))_))*Y****S++++8,{,},gd%QB},,-g- - --4.u.w.....=/? S%S'S[S\S S SSS3T5T TTTTQUUUUOV Vgd%QB V VV/W_WaWW \>\?\gd%QB?\v\w\\\]]j]]^3^5^ ^^ _ _[____E` ` ``?a aaabNbgd%QBNbPbbbUcvcxcc)dZd\ddè e e e q
q_qqqqCr rrssnsssgd%QBs t^ttttPu u uuSv v vv&w(w}wwwxx:x;x x xxx6y yygd%QByzz _ W V gd%QB 3 ' ( r _ G / gd%QB * F 8 ` a C = g @ 78opgd%QBph _{}CE Aegd%QBegui+ce57 _ | ~ * M O 1 3
gd%QB )+w ]_< kS./fggd%QB ^"gi24 ]2 Oxz -_-----..h.j.....@/ ///040gd%QB4060 0000G1 1 11?2 4a4}4 44#5@5B5v5w555gd%QB5 6 6N6P666M7 7778k889v999$:w::*;,; ;;;<Y<<<gd%QB<<F=
FcF F FF.G GGGGHHgd%QBHLHMH H HHH%I'I}IIJJVJJJJKpK K K
WWWYWWWPXmXoXXgd%QBXXXX6Y8Y|Y~YY'ZJZLZZZH[J[ [[H\J\ \ _ _b_d__`Q`S```àaKaLaaaaa6bWbYbbbbgd%QBb!cwcc&d\d^d mOmQmmm'n)n~nnnogd%QBosouoooo6p`pbppppFq qqqqq"r#r B C 9 U W gd%QB F d f 3 V X P
d f F
gd%QB
\ / 1 e f
> @
gd%QB o
d j l d + E G gd%QBG 5 B C 5 $ & w sggd%QBg ? Q `gd%QB`BD 8 Y'z$%]^
aIK AC C _|gd%QB|~+ 9: *y7 W
]B Y[ Igd%QBI & s L -
^l2 "y
gd%QBe
3fh13 +- 12 "gd%QB"wSUU A 3rtOQGI @ #c####%$&$^$_$gd%QB_$$$$%Q%%%%2& &&&&G' ''(!(v((( .a. . ..F/ / //:0<0gd%QB<0 00/1L1N1 11N2h2j22 3W3w3y33&4z4 QHQJQ~Q QQQRRWRYRR S.S0S SSSgd%QBS%TwTTUUmUUUVWVVV [c[e[[[[F\ \\\5] ]]]0^ ^^^_X_ _ __2`x`gd%QBx`z`àra a fgd%QB f`ffff6g gg*h,h hh-iOiQi ii jjbjjjjTkkkk=l llgd%QBll mAmBm m mmm5n nnooooooph m ')vPRW ;[] D gd%QBA g 3 gd%QB+y{mGI$&Z[ MOce#%wygd%QBy
9;np,-ef
gd%QB21 h:p/ =!"# $ %
666666666vvvvvvvvv666666>6666666666666666666666666666666666666666666666666hH666666
Normal
dCJ_HaJmH
sH
tH
DA D
Default Paragraph FontRiR
Table Normal4 l4a (k ( 0 No List
JZ@J
V"0 Plain Text
dCJOJQJaJFoF
V"0Plain Text CharCJOJQJaJPK ![Content_Types].xml N0EH -J @ | $ULTB %
_g -; Yl |6^N`? [ PK !6 _rels/.rels j0
}Q%v/ C/}( h"O = C?hv= %xp {_P<1H0 [
ORBdJE4b$ q_ 6LR7`
M @}w 7c(EbC A 7 K Y, e. |,H,lx IsQ}# +!,^$j= GW)E+& 8PK !0C)theme/theme/theme1.xmlYOo6w toc'v u -Mn i P@I} a m a[ 4:l
!)O^rC$y@ /yH* ) UDb `}"q W+ 7 `g Jj| h(KD- dXiJ (x$(
X^)I`nE p)liV[] 1M< OP
:;! I_TS
1 ?E ? ?ZBm U/? ~xY'y5g& / >GM Ge D 3Vq%'# x}rx wr:\TZaG* y8IjbRc|X I u3KGnD1NIBs Ru K>V.EL+M2#' f i
~ V
vl{ u8z H * : (W ~JTe\O*tHG HY }KNP* T 9/#A7qZ $*c? qUn wN% Oi 4 =3N )bJ uV4(Tn 7 _? m- {U B<w_ $# [8{( /$0h F{L)#7i%=A:s$), Qg20 w \}DU4 p M{DB %J +{lC ]= 5 2FhsF+ Y \ n :3E [69 `&45!* 5k8`Fmw- Z " d>zn "Z
x JZ p; {/<P; ,)''KQk5 qpN 8KGbe S d \17 pa>S R! 3 K4'+rzQ TTIIvt]KcK#v5+| D ~O@%\w R! y+ Un ;*&/H rT >>\ _nN[L9K qVh n g
t=.T S; Z~! P9gi C!# B, ; X=,I 2UWV9$lk=A j u"x A@T_ q 6 4)kuV7 t ' %; i9s9x , -45xd 8? d/Y|t
; { AP79|s*Y
&LIL J` & -Gt/PK! 'theme/theme/_rels/themeManager.xml.rels M 0 wo & 5 o 6?$Q ,. a i c21h q m @RN ;d` o7g K(M&$R(.1 r'J T 8 V"AHu} |$b{ P : 0_rels/.relsPK!ky theme/theme/themeManager.xmlPK!0C)theme/theme/theme1.xmlPK! ' theme/theme/_rels/themeManager.xml.relsPK] <?xml version="1.0" encoding="UTF-8" standalone="yes"?> <a:clrMap xmlns:a="http://schemas.openxmlformats.org/drawingml/2006/main" bg1="l t1" tx1="dk1" bg2="lt2" tx2="dk2" accent1="accent1" accent2="accent2" accent3="a ccent3" accent4="accent4" accent5="accent5" accent6="accent6" hlink="hlink" folH link="folHlink"/>
r I%(+c1`72>MCIP W\bhoto{q S
gQ3 1d 3 ;
&E,J2O8>D K PqVk\agmtsx y = K}m2) hH# %&},2 8 ?DRJP V?\NbLh?nsy a z$*405<_BH~M RX=^bio3tz
G g/dKY` |SIe
"@_$*<0 6 <BH NS Zx` flrox m d " y
stuvwxyz{|}~
!"#$%&'()*+,-./0123456789:;<=>?@ABCDE8@ 0( B S ?kpqu ,15=ny} w !$z lqjosw/@HL#$ $ $e$t$%-%%%%%''))))h+k+o+v+,,.%.;0C0G0L0z1~153?3 5555|6 6 6 6|: :<<NB]B C C C ^k^p^t^x^-_5_9_=_______aa bbbb\bfb]eceg#gGgIgbhdhhhohiiiinn"n-n nnPpUprrLtRt\u_unvsvwv}vw wU{\{ {{:~@~D~F~Y c R Z C L ' , ; D w
!*/37%,04=E} &/| ,4
v{ &+&.#(,2:CGJ#+\bfkCP
RZ èim*2 #',JOSWERW` a NRV\t|.04:sy} KQUY iqW\48 $*hjnw &!,! " " " "@#F#i#n###$$ ( ( ( ()) * *J*R***F5H5L5V55599 9 9(;/;3;7;;;;;;; < < < <k=t=x= =g?k?@@AA/B7BC C CCSCWCVD^D4G:GTGYG\J_J J JJJLLLLrL{L L LwM M MMMMMMMMYNbN Q Q Q QQQQ R RRRRZR`SiS"T*TVT_TTTwU U UUUUVVVV.Z7Z}Z Z Z Z[[~^ ^^^àUa\aàda7c=cAcDchh*k/k tt-y3ygymyqytyyz z z{{{|N W v x | ( 7 L W o s # & * - D N R [ j n $ ( , 1 ^ g r v W a g m M V a f
$ 2 ; ? K
p t u y A J U Y [ e f j
P T X Z g m r z ~ " , 0 7 ; @ D L w / 4 s 17 ;CR[r{
! & ms "t}%q
KS 4< =@AE -2FOTY]bfn} (/MOnw| (.QZ &.CLv~$+6<jx KQx NTU\ #dgrt
*2
MWm}w
7 5
_c]c5=}
!$lyBI @IG $)lq)1sw /@ T^ nqHL",npIP 9 `b@ G =!@! ! !!!"%"g"p"""##q#u### $ $R$_$ $$$$1%6% % %%%&&&"'i'p''''':(C( ( ())c)f))))*w* ***o+v+,,N,[, , ,,,@-E x777{8899S9Z9992:6:|: ::: ; ; ;;;;/<:<y<}<<<=[=]=====>>>?D?H? ? ???@#@@'AoAwAAAB BNB]B CCTCVC C CCC/D2DzD DDD
EE[EÊEEEEuF}FFF G
GQGTG G GGGEHGH H HHHoIIIJOJ J JJJ&K+KnKrKKKTLVL LL
NHNRN NNNN O$OjOoOOO<PDPPP Q QQQZQQQQQ2R;RR=S S SSS&T1TnTrTTTTIUPU U UUUBVGVuV}VVV3W5W{W}WWWWX^X XXXX3Y U a=a a aaabb\bfbbbeccccDdLdddee]eceeeee>fCf f fg#gaggggg h)hhhohhhiiii j'jl *sosysss tttu\u_uuuuuwv}vvvwwUwWw wwww6x<x{x xxxyy y yyy1z;zwzzzzzU{\{
R Z
C L
' , s x E H
( i p B F
' ) - 2 z
VZ ]bTW 37 .404vy_h PS 3:
\_
MV V4> | W[ 35} } "+qt npn KR q{48 OU /3 GJ fk%- 1:vz HP hk_c RZ &(ptR[ -0z|ltnJQ")im JR x 2 s v
&
W { V\ *0t|4:} UY +0uy V[ W07| W\48 XZAB &gr$*nwKP S 0 5 y { &!,!p!t!!!I"K" " """"#'#i# &Y& '"'f'l''''(H(S( ( (((,)3))))*=*C*J*R* * ***4+7+++$,+,o,u,,,- -I-O- - --0O0P0 0 000*1;11122f2g22223C3G3334"4i4l444L5V555:6<6 6 6@7 7778"8 8 88899]9e < < <<<0=9=x= ===>>>"?%??.@u@z@@@A ALAUA A AAA/B7B{B~BBB CCSCWCCCVD^D DDDD/E5E{E EEE FFSFYF F F4G:G~G G:H HHHIIdIfIIIIIIIJJ7K?KKKLLLLMMZMbMMMMMqNvNN OO P ``àaàdaaaaa6b8b b bAcDc c ccc!d#dldnd eeiemeeeee f f gghh`hghhh9i<i}i iii
jjTj^j jjjj3k9kkkwlylll m mRmWm mmmm1n5n n nnnoo]oao pYppp2q?qxq~qqqrSr r 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 Y>%QB#fX
@ Unknown *Ax G Times New Roman5 Symbol3. *Cx Arial?= *Cx Courier New7 @ Cambria7. @ Calibri9= @ ConsolasA $B Cambria Math"1h qt !{ !{ ! 0 K HX Papa Cocoy Papa Cocoy Oh+'0`
( 4@HPX
Papa Cocoy
Normal.dotm
Papa Cocoy3Microsoft Office Word@ G@?@$) ! . +,0
hp
Project-OS.org {
Title
!"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_àbcdefghijklmnopqrstuvwxyz{|
!"#$%&'()*+,-./0123456789:;<=>?@ABCDEFHIJKLMNOPQRSTUVWXYZ[\]^_àbcdefghijklmnopqrstuvwxy
1TableGpWordDocument4 SummaryInformation( DocumentSummaryInformation F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q

Resveratrol and Its Effects On Human Health and Longevity

Caricato da

Informazioni sul documento

Descrizione originale:

Titolo originale

Copyright

Formati disponibili

Condividi questo documento

Condividi o incorpora il documento

Opzioni di condivisione

Hai trovato utile questo documento?

Questo contenuto è inappropriato?

Copyright:

Formati disponibili

Resveratrol and Its Effects On Human Health and Longevity

Caricato da

Copyright:

Formati disponibili

Resveratrol and its Effects on Human Health and Longevity - Myth or Miracle?

JaMEs BETz Founder and CEO of Biotivia Bioceuticals, LLC

Five essential provider

greater contribution age-related

promise which the an

taking scarce research of pharmaceuticals the

obesity, disease and

disease, levels in the

Alzheime develope and

disease prevention dismissed

without extensive scientists natural compound any effects.

barely heard and

handful of scientists real knowledge of the molecule s

physicians health and

The was on shown

first not the the

high-strength even consumers potential in

resveratrol radar. A life at span,

supplement, few and

animal studies had a in few hundred

for increases investigations primarily and

by researchers China elucidated

Japan, India with could that only respect be had to

resveratrol s to cancer and said for of at other one

chemoprotective properties, diabetes. hundreds However,

particularly the same drugs lab,

phytochemicals and time or

another shown promising be shuttled off

oblivion the same mammals,

when scientists effects in especially humans.

intriguing caught the

rather unique aspect of and the

resveratrol public was

attention of its ability to

both researchers extend

lifespan of for example, the

some lived same

percent longer than mice lived the mally

species without resveratrol. managed to and obesity. avoid all

31 percent longer and diseases norassociated with aging

The big however,

missing element in was a human Very

equation, major also what bioavail

trials by then known

little was in about about

resveratrol correct concerns questions Some

humans or the its low possible

dose; and ability of ratrol, as estrogenic

there were resvewell as effects.

scientists to avoid veratrol y the

speculated resfor this opposite has a and as this

be know a agent are life

reason. We is been shown powerful chemotherapeutic

wealth of against breast devoted to applications

more resources potent quality of

the research critical

earlier studies were teams

around the factors, this

pharmacokinetic effects of resveratrol and there were increased over 4,000

interest Asia, the late resand only

exponentially published was developi

consensus and examined